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Abstract 
Hsp90 inhibition has been at the centre of attention in current research due to the possibility of 
“cracking down” on the entire process leading to the development of malignant cancers. Small 
underlying principles common in all types of cancers have been determined that govern the 
transformation of normal human cells into cancerous cells, with all relying on the ATPase 
activity of Hsp90 protein. Hsp90 protein is therefore an attractive drug target that if 
successfully inhibited can result in the remission of cancer tumours by one form of treatment. 
To date, no Hsp90 inhibitor has been sanctioned for cancer treatment as most are still in clinical 
development. 
Our research was therefore inspired by reports that indicated the potential of quinones / 
naphthoquinones to act as Hsp90 inhibitors. Preliminary results of a few selected marine 
natural product quinone systems i.e. sargaquinoic acid (SQA) (2.47) and lapachol (3.6) showed 
moderate cytotoxicity and weak interactions with the Hsp90 molecular chaperone, and 
evidence suggested C-terminal binding of these molecules. No correlation has been determined 
yet between cytotoxicity and Hsp90 inhibition, hence we aimed to develop natural product 
inspired molecules that exhibit both cytotoxic and Hsp90 inhibition properties. 
Due to limited amounts of the natural product that can be acquired from natural sources, 
synthetic analogues were opted for. Isolation of a few selected quinones was conducted to have 
material that could be used in biological assays. For structural modifications, a series of 
truncated naphthoquinone systems were prepared adopting the sarganaphthoquinoic acid (3.5) 
scaffold. The naphthoquinones were prepared via Diels-Alder reactions of relevant 
benzoquinones with myrcene, followed by aromatization reactions using MnO2. Various alkyl 
and aryl amines were then coupled to the C-2/3 position of the naphthoquinone using Michael’s 
addition reactions. Tricyclic naphthoquinones were also synthesized from reactions with 
hypotaurine and citral. Design of the analogues incorporated functionalities from known Hsp90 
inhibitors e.g. geldanamycin (2.28) and its analogues.  
Preliminary results obtained showed that coupling of naphthoquinones with aryl-amines 
resulted in the most cytotoxic compounds (4.14-4.19) with IC50 values as low as 0.3 µM against 
Hs578T breast cancer carcinoma (triple negative). Most of the alkyl amines (4.20-4.25) had 
IC50 values greater than 50 µM except for 4.20 and 4.21 that showed IC50 values of 7.6 µM and 
2.6 µM respectively. Tricyclic naphthoquinones (4.28-4.29) showed moderate cytotoxic 
activity of approximately 10 µM.  
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Hsp90 inhibition was assessed by client protein degradation assays, of which SQA (2.47), 
showed the best Hsp90 inhibition properties, followed by compound 4.20. The most cytotoxic 
arylamino-naphthoquinone (4.16) and tricyclic naphthoquinones (4.28-4.29) showed only 
moderate inhibition. None of the compounds led to Hsp70 induction, suggesting possible 
binding to the C-terminus of Hsp90.  
Interactions at the binding site were assessed by molecular docking studies and saturation 
transfer difference (STD) NMR. Docking studies were conducted on the N-terminus of Hsp90 
and better binding was observed for arylamino naphthoquinones (4.14-4.19) than for other 
series of compounds. Unfortunately, the co-crystal structure for the C-terminus of Hsp90 is 
unavailable, hence docking study comparisons on both domains could not be conducted. 
However, STD NMR offered a platform to assess binding interactions between the 
naphthoquinones and the N- or C-terminal domains of Hsp90. However no interactions were 
observed at both the N- and C- termini of Hsp90 due to either weak binding of ligands to the 
protein or poor water solubility of the ligands. 
From these preliminary results, naphthoquinones bind to Hsp90 protein but conclusive remarks 
to which terminal domain they bind to could not be made. The best candidate from amongst 
the series of naphthoquinones prepared that showed moderate cytotoxicity and promising 
Hsp90 inhibition was compound 4.20. We therefore succeeded in developing a new series of 
naphthoquinones that possess moderate cytotoxicity and show Hsp90 inhibition.  
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CHAPTER ONE 
 
Natural products in the treatment of cancer 
Abstract 
Numerous cytotoxic molecules have been isolated from natural sources in search of new anticancer 
drug leads. Halaven®, Yondelis® and Adcetris® are a few examples of successful drugs derived from 
marine origin that are discussed in this chapter. They highlight the process of drug design and 
development, and indicate the importance of the marine environment as a source of cytotoxic 
compounds.  
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1.1 Introduction 
The use of natural products as lead compounds in the discovery and design of new drugs has 
continued unabated over the past century (Cragg and Newman, 2013). They offer a rich and 
unexplored source of bioactive molecules (Corson and Crews, 2007) compared to 
combinatorial chemistry and high-through put screening methods (Molinari, 2009; Cragg and 
Newman, 2013). The key element responsible for the success of natural products in drug 
discovery is accredited to the vast structural diversity of these compounds. Advances in 
technology, including the ability to synthesize highly complex natural products in the 
laboratory, has aided the exploration of compounds from natural sources and allowed their 
potential to be realized (Lahlou, 2013). 
Until recently, the marine environment has been the least explored compared to terrestrial and 
microbial environments for potential lead compounds. The ocean was regarded as a hostile and 
inhospitable place, not fit for exploration. An advancement in technologies involving 
snorkelling, use of self-contained underwater breathing apparatus (SCUBA diving), manned 
submersibles, and use of remotely operated vehicles (ROVs) has enabled vast bodies of water 
to be explored in search of new drug molecules. To date, six marine drugs have been registered 
by the Food and Drug administration board (FDA), one by the European Union (EU) and 
approximately 25 natural products are in different stages of clinical trials (Mayer, 2014).  
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1.2 Eribulin mesylate (Halaven®) 
Halichondrin B (1.1) is a macrocyclic polyether first isolated from the sponge Halichondria 
okadai (Uemura, et al., 1985). It exhibited cytotoxic activity by inhibiting cell division of 
cancerous cells which led to its inclusion in pre-clinical studies by the National Cancer Institute 
(NCI) in 1992. Under these studies it demonstrated great potency against blood cancer cell 
lines i.e., leukaemia. However further developments were hindered by difficulties in collecting 
sufficient material and the lengthy processes in the synthesis of the natural compound. 
Discovery of the C1-C38 moiety as the pharmacophoric element in the macrocyclic lactone led 
to the development and synthesis of ER-086526 (1.2) (Towle, et al., 2001) which is also known 
as E7389, NSC 707389 (Perez, 2009) and ER-076349 (1.3). 
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Assessment of more than 180 macrocyclic ketones resulted in the development of the above 
mentioned analogues, their structural difference being the substituent at C-35 which is either 
an alcohol or amine functionality. The analogues differed in structure to halichondrin B (1.1) 
by replacing a lactone ester at C-1, a methyl functionality at C-31 and a tricyclic system C29-
C38 on halichondrin B (1.1) with a ketone, methoxy group and a five-membered ring 
respectively.  
These compounds (1.1-1.3) have been identified as tubulin-based antimitotic agents. They 
disrupt microtubule formation during mitosis of rapidly dividing cells i.e., cancer cells. 
However, their interaction with tubulin is somehow different and specific in comparison to 
other tubulin depolymerizers e.g., Vinca alkaloids, dolastatins etc. A different interaction to the 
known mechanism may aid in unique tumour specificities and other desirable clinical outcomes 
(Bai, et al., 1991), hence the interest in this natural product.  
ER-086526 (1.3), now known as Eribulin has been pursued further due to better efficacy in in-
vivo studies, and was approved by the FDA for the treatment of metastatic breast cancer in 
2010 (Scarpace, 2012). The drug is metabolized by cytochrome P450 and was shown not to 
influence metabolism of other drugs (McBride and Butler, 2012; Zhang, et al., 2008). Eribulin 
has promising drug outcomes when used as a single agent in patients with locally advanced 
disease and in those with metastatic breast cancer that has become resistant to taxanes and 
anthracyclines (Cortes, et al., 2011). 
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1.3 Trabectedin (Yondelis®) 
Trabectedin (1.4) is a novel marine antineoplastic alkaloid that was initially isolated from the 
marine ascidian Ecteinascidia turbinata (D'Incalci and Galmarini, 2010). It consists of three 
tetrahydroisoquinoline rings, two fused together and linked via a benzylic sulphide bond to a 
ten carbon lactone bridge, and the other connected via a spiro ring. 
NH
OH
H3CO
S
N
N
O
O
OH
OCH3
OH
OAc
O
O
H
1.4
c
a
b
21
 
Six ecteinascidins [(ET’s) 729, 743, 745, 759A, 759B, and 770] were first described and 
characterized from a tunicate found in the Caribbean Sea, of which ET 743 (Trabectedin (1.4) 
was the most abundant (Rinehart, et al., 1991). Preliminary structure activity relationships 
conducted showed that the carbinolamine of C-21 and the presence of the aromatic C subunit 
were crucial for potency in cytotoxicity assays done againstmurine leukaemia cells L1210 
(Cuevas and Francesch,  2009).  
Trabectedin (1.4) was selected for clinical development due to its large relative abundance in 
the crude extracts and novel chemical structure. In 2007, it was registered for use in the 
treatment of advanced soft tissue sarcoma in patients showing resistance to anthracyclines and 
ifosfamide treatments. Concomitant use with pegylated liposomal doxorubicin was approved 
in 2009 for treatment of platinum-sensitive ovarian cancer in patients that had a relapse of the 
disease (Monk, et al., 2012). Its mode of action was determined to be related to DNA alkylation 
but not in a similar way to traditional alkylating agents. It binds to exocyclic N2 amino 
group of guanines in the DNA minor groove compared to known guanine N7 or O6 positions 
in the major groove where other alkylating agents bind.  Such alkylation results in DNA 
damage, thus inhibiting cancer growth and division, and leading to death of cancer cells 
(D'Incalci and Galmarini, 2010).  
As with most natural products, supply of the active metabolite had to be addressed. Trabectedin 
(1.4), currently marketed as Yondelis®, was initially manufactured by total synthesis using a 
Chapter One Natural products in the treatment of cancer 
 
6 

multi-step enantio-controlled process developed by Corey and colleagues (1996). Improvement 
in synthetic strategies led to the preparation of trabectedin (1.4) via semi-synthesis from 
cyanosafracin B (1.5). Cyanosafracin B (1.5) is a derivative of safracin B, an antibiotic obtained 
by fermentation of Pseudomonas fluorescens. Optimization of the fermentation process yields 
kilogram quantities of cyanosafracin B (1.5) that is used as the starting material for the 
synthesis of trabectedin (1.4) (Cuevas, et al., 2000; Cuevas and Francesch, 2009).  
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Scheme 1.1: Scheme showing cyanosafracin B (1.5) as the starting material for the preparation 
of trabectedin (1.4) (Cuevas, et al., 2000) 
Trabectedin (1.4) is licensed by the Spanish pharmaceutical drug company PharmaMar, and 
was co-developed by Johnson & Johnson Pharmaceutical Research and Development group. 
Induced toxicities related to trabectedin (1.4) are mainly haematological and hepatic. Current 
efforts are focusing on the development of new trabectedin-based combinations. 
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1.4 Dolastatin-10 
Dolastatins are naturally occurring cytotoxic pseudo peptides that display antineoplastic, 
bactericidal and antifungal properties (Pettit, et al., 1998). They were first isolated from the 
marine shell-less mollusc Dolabella auricularia, and dolastatin-10 (1.6) and dolastatin-15 
stood out as the most promising anti-proliferative natural products (Pettit, et al., 1987). 
1.6
N
O
NH
N
O
O
N
O O O
NH
S
N
 
Their mode of action involves inhibition of microtubule assemblies and inducing apoptosis in 
several malignant cell lines (Gajula, et al., 2013). Activity has been noticed mainly in human 
prostate cancer models, both in in vitro and in vivo assays. Complete growth inhibition was 
determined at concentrations as low as 1 nM of dolastain-10 (1.6) in in vitro studies (Turner, 
et al., 1998). Cell cycle arrest in G2-M phase and -tubulin depolymerisation mechanisms are 
believed to be the main causes of inhibition. In vivo studies demonstrated a decrease in the 
number and size of tumours in the diaphragm of mice and prevented invasion of musculature 
(Vaishampayan, et al., 2000). Such promising results of dolastatin-10 (1.6) led to its 
introduction in Phase II clinical trials together with several of its synthetic analogues.  
Recently a dolastatin analogue, brentuximab vedotin was approved by the FDA for use in the 
treatment of relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. The 
drug is marketed as Adcetris® and contains a very potent auristatin derivative monomethyl 
auristatin E (MMAE) (1.7) which is highly toxic. 
1.7
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To circumvent its toxicity, an antibody-drug conjugate (ADC) of the drug was developed. 
MMAE is linked to a tumour-seeking monoclonal antibody that directs it to cancer cells, 
sparing normal cells.  Research is under way to extend the applications of brentuximab vedotin 
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and to advance the field by developing other ADCs with new linker and conjugation strategies 
(Senter and Sievers, 2012).  
1.5 Previous studies on cytotoxic marine prenylated quinones 
Successful stories of marine natural products mentioned above inspired us to explore this 
untapped source of the ocean for cytotoxic lead compounds. Our major focus was aimed at 
molecules that have the potential to disrupt the six Hallmarks of cancer via Hsp90 inhibition. 
There is some evidence that suggests marine quinones have the potential to inhibit Hsp90 
molecular chaperone (Hadden, et al., 2009), in addition to the cytotoxic properties they exert 
via generation of reactive oxygen species (ROS) and by DNA alkylation mechanisms (Castro, 
et al., 2008; Rahmoun, et al., 2013). We were determined to explore this aspect further and of 
interest were meroterpenoids isolated from marine brown algae collected along the south-
western coastlines of South Africa. Sargassum incisifolium is available in relative abundance 
on the South African sea shores and isolated meroterpenoids from this brown alga display 
cytotoxic and antiplasmodial activities (Afolayan, et al., 2008) while preliminary evidence also 
suggests that selected metabolites may inhibit Hsp90 (Moyo, 2013).  
The main aim of the research was thus to explore the cytotoxicity and Hsp90 inhibition of 
selected naturally occurring terpenyl quinones and their derivatives. 
Specific objectives included: 
• Exploring the cytotoxic properties of marine quinones (meroterpenoids, lapachol and 
derivatives) 
• Synthesizing natural product inspired analogues to improve cytotoxicity and Hsp90 
inhibition  
• Conducting client protein degradation assays related to Hsp90 inhibition 
• Assessing Hsp90 inhibition by use of computational methods, i.e., molecular modelling 
• Assessing binding to Hsp90 protein via Saturation Transfer Difference NMR studies 
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1.6 Thesis summary 
Chapter one provides a general introduction to marine natural product based anticancer drug 
discovery while chapter two reviews the potential of Hsp90 protein as a drug target for cancer 
treatment. Known natural product inhibitors of Hsp90 are also reviewed in chapter two, with 
chapter three describing the isolation and characterization of selected natural product quinones 
that have the potential to inhibit Hsp90. Chapter four focuses on the synthesis of natural product 
analogues to enhance cytotoxicity and Hsp90 inhibition properties, and these activities are 
assessed in chapter five in in vitro assays.  Possible binding interactions to the active site of 
Hsp90 by test compounds is presented in chapter six using molecular docking and saturation 
transfer difference (STD) NMR, and chapter seven contains the summary of set goals, results 
obtained and conclusions drawn with regards to the development of cytotoxic Hsp90 inhibitors.  
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CHAPTER TWO 
 
The hallmarks of cancer 
Abstract 
Six hallmarks of cancer have been identified as essential for the propagation of tumours to malignant 
cancers, and are related to regulatory mechanisms that deal with cell proliferation and homeostasis. The 
engine that drives these aspects of cancer has been discovered to be the Hsp90 molecular chaperone. 
Drug leads that target this chaperone are being designed and developed so as to combat all stages of 
cancer with one form of treatment. This chapter gives a general overview of the hallmarks of cancer, 
the structural features of Hsp90 protein and examples of known Hsp90 inhibitors.  
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2.1 Introduction 
Advances in cancer knowledge over the last century have indicated the disease to comprise of 
dynamic changes in the genome (Bishop and Weinberg, 1996). Several research studies are 
focused on discovering mutations that lead to activation of oncogenes, with the aim of a more 
targeted approach to drug design. Despite the complexity of the disease, small underlying 
principles have been identified that govern the transformation of normal human cells into 
cancerous ones. Such principles involving molecular, biochemical and cellular traits are 
common in all types of cancer, providing a potential drug target that can cripple the entire 
process leading to the development of malignant cancers (Hanahan and Weinberg, 2000; 
Hanahan and Weinberg, 2011).  
Six essential alterations in cell physiology are responsible for malignant cancer growth, related 
to regulatory mechanisms that deal with cell proliferation and homeostasis. These six 
alterations are commonly known as the hallmarks of cancer (Figure 2.1) and include: self-
sufficiency in growth signals, insensitivity to growth-inhibitory signals, evasion of 
programmed cell death (apoptosis), limitless replicative potential, sustained angiogenesis, and 
tissue invasion and metastasis (Hanahan and Weinberg, 2000). 
 
Figure 2.1: The six hallmarks of cancer (Hanahan and Weinberg, 2000; Hanahan and 
Weinberg, 2011). 
Two additional hallmarks of cancer have been identified. One involves the capability to modify 
cellular metabolism such that neoplastic proliferation is adequately supported and the second 
allows cancer cells to evade immunological destruction, mainly by T and B lymphocytes. 
(Hanahan and Weinberg, 2011). These hallmarks have not been fully validated and are 
considered as emerging hallmarks. The first six hallmarks will be discussed in this chapter.  
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2.1.1 Self-sufficiency in growth signals 
One of the trademark signatures of cancer cells is the ability to proliferate uncontrollably. 
Normal cells are regulated by mitogenic growth promoting signals that are transmitted into the 
cell by transmembrane receptors containing intracellular tyrosine kinase domains. Cell 
proliferation is conducted via diffusible growth factors, extracellular matrix components and 
cell adhesion molecules bound to surface receptors that activate the cell to enter cell cycle. 
With mutated cells, such signals are deregulated and cell cycles are uncontrolled leading to 
massive aggregations of cell growths (Hanahan and Weinberg, 2011). Certain oncogenes in 
tumour cells mimic growth signalling pathways of normal cells by producing their own growth 
factor ligands or by stimulating neighbouring normal cells within the supporting tumour-
associated stroma to provide them with various growth factors (Cheng, et al., 2008).  
Other ways in which deregulation of growth signals can occur in malignant cells is by 
overexpression of oncogenic growth factor receptor proteins on the cell surface of cancer cells. 
This renders such cells hyper-responsive to an otherwise limiting amount of growth factor 
ligand resulting in excessive growth. Structural alterations to the receptor proteins can also 
occur which allows growth stimulation of cells without the ligand bound to it (Hanahan and 
Weinberg, 2011). Such independence from normal signal factors disrupts important 
homeostatic functions played by a particular tissue, resulting in loss of control of a set of cells 
embedded in the tissue.   
2.1.2 Insensitivity to growth-inhibitory signals 
Under normal circumstances, the extracellular matrix and nearby cells contain growth 
inhibitors (soluble and immobilized inhibitors) that associate with transmembrane receptor 
proteins and intracellular signalling circuits to initiate the end of the proliferation cycle. Anti-
proliferative signals are channelled through one of the most important factors, retinoblastoma 
protein (pRb), which alters the function of E2F transcription factors responsible for cell 
proliferation. Disruption of pRb in malignant cells allows the function of E2F transcription 
factors to continue, and thereby making such cells insensitive to antigrowth signals (Weinberg, 
1995). pRb is inactivated by phosphorylation reactions and is therefore protected by TGF in 
normal cells to allow its function. In tumour cells, TGF receptors are down regulated or lose 
responsiveness, promoting pRb inactivation and E2F function (Fynan and Reiss, 1993). In 
other cases, pRb function may be lost due to mutation of its gene, hence a mutated protein is 
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produced which cannot inhibit cell proliferation.  This is one strategy that is used by tumour 
cells for continuous cell division, although other mechanisms do exist.  
2.1.3 Evasion of programmed cell death (apoptosis) 
Apoptosis is a complex process that involves a series of events in tissue homeostasis. Once 
triggered, cell membranes are disrupted, and cytoplasmic and nuclear components are broken 
down within 30-120 min. All broken down components are engulfed by neighbouring cells in 
the tissue (Wyllie, et al., 1980). This process is governed by sensors and effectors. Sensors 
monitor extracellular and intracellular environments of cells for any abnormalities, and the 
effectors are responsible for the actual apoptotic death process when triggered to act by sensors. 
Cell death signals are channelled by FAS ligand binding to FAS receptor and by TNF binding 
to TNF-R1 (Ashkenazi and Dixit, 1999). The signals may emanate from the extracellular 
environment via cell surface receptors (extrinsic), primarily leading to activation of caspases 
or via the intrinsic pathway which initiates in the mitochondria and involves the BCL family 
of proteins, which in turn activate the caspase effectors (Green and Reed, 1998). Caspase 
enzymes are responsible for the destruction of cells (Thornberry and Lazebnik, 1998; Fulda 
and Debatin, 2006).  
Tumour cells upregulate bcl-2 and myc oncogenes that possess anti-apoptotic properties. Such 
a phenomenon was observed in follicular lymphomas via chromosomal translocation 
(Korsmeyer, 1992). In addition, the p53 tumour suppression gene loses its function via 
mutation in malignant cells, resulting in a defective p53 protein that cannot initiate apoptosis.  
2.1.4 Limitless replicative potential 
Disruption mechanisms described above do not necessarily result in the growth of cancer cells 
into tumours. All mammalian cells contain programs that limit cell replication and are 
independent of cell-to-cell signalling (Hayflick, 1997). These programs are distorted in cancer 
cells which results in life threatening masses emerging. Immortalization, as it is called, is an 
acquired phenomenon after several replications of cancer cells. Initially, the fast growing cells 
enter into a crisis state that is characterized by massive cell death and from it a variant cell (1 
in 107 cells) emerges with the ability to multiply without limit (Wright, et al., 1989). Under 
normal circumstance, rapid growth results in the loss of DNA telomere ends, and unprotected 
chromosomal ends fuse together yielding a karyotypic disarray associated with cell death.  
Immortalization is obtained by maintenance of telomere ends of chromosomes via upregulation 
of telomerase enzymes that add hexanucleotide ends, inhibiting chromosomal fusion (Shay and 
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Bacchetti,, 1997; Bryan and Cech, 1999). Such enzymes are almost non-existent in normal 
cells but are expressed in levels as high as 90 % in malignant cells. They are the main cause 
for cell survival in tumours, giving them limitless replicative potentials (Hanahan and 
Weinberg, 2011). 
2.1.5 Sustained angiogenesis 
All cells in a tissue are located within 100 µm of a capillary blood vessel so as to receive oxygen 
and nutrients for its survival. Angiogenesis is carefully regulated once a tissue is formed and 
cancer cells in their initial stages lack angiogenic ability. They only acquire this ability prior to 
appearance of a full blown tumour (Hanahan and Folkman, 1996). Angiogenesis is initiated by 
overexpression of vascular endothelial growth factor (VEGF), and acidic and basic fibroblast 
growth factors (FGF1/2), with the down regulation of angiogenesis inhibiting factors, 
thrombospondin-1 or -interferon (Volpert, et al., 1997).  
2.1.6 Tissue invasion and metastasis 
Human cancer deaths are mainly as a result of cancer cells breaking off from the parent tumour 
and invading new tissues in a process known as metastasis (Sporn, 1996). They inhabit new 
tissues or organs where space and nutrients are not a limiting factor for their growth. As with 
the primary tumour, invading cancer cells also need to acquire the five mechanisms discussed 
above for them to survive in a new territory. Though the process is complex and more 
understanding is required, there is no question that several classes of proteins that are involved 
in tethering cells to their environment in a tissue are altered (Hanahan and Weinberg, 2000). 
One important protein whose function is eliminated to allow tissue invasion and metastasis is 
E-cadherin (Christofor and Semb, 1999). Changes to cell-to-cell adhesion molecules in 
addition to E-cadherin are also noticed which are believed to play a role in tissue invasion and 
metastasis. 
It should be noted that the discussed aspects are common within most cancer types and other 
alternative pathways are being discovered that assist in propagation of this disease. It is no 
surprise that a lot of research is being conducted in this area, with new drug molecules being 
sought to combat the different complexity stages of cancer. Marine natural sources offer great 
diversity in chemical structures that can be explored for anticancer activity. Of particular 
interest are cytotoxic prenylated quinones and related compounds, of which a few will be 
discussed in the next section. 
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2.2 Cytotoxic marine natural products 
2.2.1 Sesquiterpene quinones and hydroquinones 
Marine natural products with a 1, 4-benzoquinone moiety have received a fair amount of 
attention due to their cytotoxic and anti-proliferative properties (Gordaliza, 2010). Promising 
opportunities for the development of new drug molecules are offered by quinones, 
naphthoquinones and hydroquinones of marine origin, and have been used to understand 
chemically induced toxicity in cellular mechanisms (Sunassee and Davies-Coleman, 2012). Of 
interest are the sesquiterpene quinones and hydroquinones isolated from sponges. The order 
Dictyoceratida is well-known for producing cytotoxic quinones that include avarone (2.1), 
avarol (2.2), bolinaquinone (2.3), nakijiquinone (2.4) and illimaquinone (2.5). They have been 
shown to be cytotoxic against several tumour cell lines, hence offer the promise of new 
structures that can be used in drug development (Gordaliza, 2010).  
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Avarone (2.1) and its hydroquinone avarol (2.2) are isolated from marine sponge Dysidea 
avara and have shown cytotoxic activity against leukaemia in both in vitro and in vivo studies, 
though they were determined to be more cytostatic rather than cytotoxic (Cozzolino, et al., 
1990). Bolinaquinone (2.3), on the other hand causes DNA damage and its cytotoxic activity 
has been noticed in HCT-116 human colon carcinoma cell line with an IC50 value of 1.9 g/mL 
(Guzmán, et al., 1998). As for the nakijiquinones (2.4), cytotoxic activity has been observed 
against L-1210 and KB cell lines, with IC50 values ranging between 2.8 - 8.1 µg/mL and 1.2 - 
7.6 µg/mL, respectively (Gordaliza, 2010), whilst illimaquinone (2.5) exhibited cytotoxicity 
against P-388 leukaemia cells and in several solid tumours A-549, HT-29 and B16/F10 with 
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IC50 values of 0.9 µg/mL, 3.4 µg/mL and 1.1 µg/mL, respectively (Rodriguez, et al., 1992). 
Further developments are underway to improve these molecules as drug candidates as potency 
for some of these metabolites has only been three times less than that of doxorubicin (Laube, 
et al., 2009).  
2.2.2 Isoquinoline quinones and iminoquinones 
Several isoquinoline quinones have been isolated from marine sponges Cribrochalina and 
Petrosia (Hawas, et al., 2009) and from sponge related microbes such as Streptomyces and 
Calothrix (Milanowski, et al., 2004). Antimicrobial and antitumour activities have been 
demonstrated with this class of compounds and a few are displayed below: 
N
O
O
R1
R2
R3
NH
2.9 R1 = H, R2 = CH3, R
3
 = CH3
2.8 R1 = H, R2 = H, R3 = CH3
2.7 R
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 = H, R
3
 = CH3
2.6 R
1
 = H, R
2
 = H, R
3
 = COOCH3
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2.10 R
1
 = H, R
2
 = H, R
3
 = 
 
In monolayer cell proliferation assays conducted with these metabolites, mansouramycin C 
(2.6) was the most active with an overall potency of 0.1 µM across a panel of 36 human tumour 
cells, of which 14 were different solid tumour types. It showed great selectivity towards 10 of 
these tumours i.e., bladder cancer (T-24), glioblastoma (SF-268), lung cancer (LXFA 629L), 
mammary cancer (MCF-7), melanoma (MEXF 276L, MEXF 514L, MEXF 520L), ovarian 
cancer (OVCAR-3), renal cancer (RXF 944L), and uterus cancer (UXF 1138L (Hawas, et al., 
2009). With regards to the other isoquinolines, mansouramycin B (2.7) and 3-methyl-7-(methyl 
amino)-5, 8-isoquinolinedione (2.8) had second highest activities with average cytotoxic IC50 
values of 2.7 µM and 3.5 µM, respectively. They also showed some degree of selective 
cytotoxicity to some cancers but to a lesser extent than 2.6.  
Different substitution patterns on mansouramycins mapped some SARs with chlorination (R1) 
influencing cytotoxic activity. R2 and R3 substitution also influenced cytotoxicity as observed 
in compounds 2.9 and 2.6 (Hawas, et al., 2009). Related compounds to mansouramycins, 
caulibugulones A-F (2.11-2.16), also possess cytotoxic properties. They have been isolated 
from extracts of the marine bryozoan Caulibugula intermis and tested by the U.S. National 
Cancer Institute (NCI) on their 60 tumour cell lines (Milanowski, et al., 2004).  
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2.11 R1 = H, R2 = CH3
2.12 R1 = Br, R2 = CH3
2.13 R1 = Cl, R2 = CH3
2.14 R1 = H, R2 = CH2CH2OH
N
O
O
R1
NH
R2
   
2.15 R = H
2.16 R = CH2CH2OHN
N
O
R
NH
 
The biological data for caulibugulones A-F (2.11-2.16) encompasses cytotoxic activities 
obtained against a murine IC-2WT cell line. Halogenation at R1 was determined to be 
unimportant for cytotoxicity as compounds 2.11-2.13 had similar IC50 values. However the 
iminoquinone 2.15 was more potent than its counterpart 2.11 and substitutions with the ethyl 
alcohol at R2 and R on both compound classes resulted in the more active metabolites 
(Milanowski, et al., 2004). Comparable activities were noticed for caulibugulones, 
cribrostatins and related isoquinoline quinones (Pettit, et al., 2000). 
2.2.3 Prenylated quinones and hydroquinones 
Over 600 prenylated quinone-type metabolites have been isolated from marine organisms, and 
approximately a third of these metabolites have demonstrated cytotoxic behaviours, with some 
possessing antioxidant properties (Sunassee and Davies-Coleman, 2012). Brown algae and 
sponges account for 60 % of prenylated systems produced by marine species. Their chemical 
structures usually contain a benzoquinone or hydroquinone moiety with a prenyl side chain 
attached to the C-2 position relative to the ketone. The length of the side chain and substitution 
patterns along this chain vary from species to species, which results in different metabolites 
being produced.  
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Plastoquinones 2.17-2.19 were obtained from crude extracts of Sargassum micracanthum and 
have been shown to be cytotoxic against a colon 26–L5 cancer cell line. In vitro assays 
indicated 2.17 and 2.18 as strongly cytotoxic with 2.19 showing moderate cytotoxicity (Mori, 
et al., 2005). The sargachromanol 2.20 induces apoptosis in human leukaemia HL-60 cells via 
caspase-3 signalling activation (Heo, et al., 2011), a phenomenon essential in one of the 
hallmarks of cancer described above. Smaller prenylated quinones, 2.21 and 2.22 isolated from 
the brown alga Perithalia capillaris found in New Zealand also exhibited cytotoxicity against 
human leukaemia HL-60 cell lines. Compound 2.21 was more cytotoxic with an IC50 of 0.3 
µM compared to compound 2.22 that had an IC50 value of 5.6 µM (Sansom, et al., 2007). An 
addition to these unusual smaller prenylated systems are the naphthoquinones 2.23-2.27. These 
metabolites are isolated from the brown algae Landsburgia quercifolia. They are quite similar 
to those found in higher plants and exhibit cytotoxic activity against P-388 leukaemia cells, 
compound 2.26 showing the greatest activity (Perry, et al., 1991) 
Cytotoxic activities of marine quinones from sponges and brown algae discussed above have 
sparked interest in the chemical composition and cytotoxicity of a large number of marine 
species that contain metabolites with hybrid structures related to quinones / hydroquinones / 
naphthoquinones. More selective drug candidates are needed, that exert their action with little 
to no side effect profiles. An ideal anticancer drug should result in the disruption of all six 
hallmarks of cancer, and Hsp90 inhibition has been linked to such a disruption (Miyata, et al., 
2013). Detailed mechanistic analysis have suggested that Hsp90 is a promising target for 
anticancer therapy. 
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2.3 Heat shock proteins (Hsp90) 
Molecular chaperones are a diverse set of enzymes that are responsible for proper folding and 
assembly of proteins in eukaryotic cells. Three major molecular chaperone systems have been 
reported in literature which include Hsp70, Hsp90 and TRiC/CCT (Frydman, 2001). Although 
their roles in biological systems are thought not to overlap, they function in a coordinated way 
that brings about survival of that particular cellular system ( Li, et al., 2012).  
The 90 kDa heat shock proteins (Hsp90) have been intensely studied and are involved in 
fundamental processes related to cell cycle control, cell survival, hormone signalling and 
response to cellular stress (Donnelly and Blagg, 2008; Li, et al., 2012). Four human Hsp90 
isoforms have been identified with the 2 major cytosolic forms being Hsp90 and Hsp90 
(Donnelly and Blagg, 2008). Hsp90 interacts as part of a multiprotein complex with other sets 
of proteins known as co-chaperones that assist it in its function (Pratt and Toft, 2003). Cancer 
cells are exposed to numerous cellular stresses, including nutrient deprivation, oxidative stress 
and high growth rates, hence such chaperones play an important role in maintaining multiple 
mutated and over-expressed signalling proteins that promote cancer cell growth and survival. 
In normal cells, Hsp90 accounts for 1-2% of all cellular proteins (Csermely, et al., 1998). In 
stressed cells the concentrations of certain Hso90 isoforms are upregulated in an effort to 
preserve protein homeostasis. In so doing, they provide tumour cells with the means to survive 
in harsh conditions by stabilizing oncogenic proteins that would otherwise be degraded 
(Sreedhar, et al., 2004). 
The main goal for Hsp90 inhibition is centred on prohibiting proper functioning of several 
“client proteins” that are key regulators of cellular growth, differentiation, stress-response and 
apoptotic pathways in cancer cells. These include mutated signalling proteins (p53, Bcr-Abl, 
Raf-1, Akt), HER2/Neu (ErbB2), nNos, HIF-1, epidermal growth factor receptors (EGFRs) 
and growth factor receptors (IGF-1Rs), Cdk4 (Kamal, et al., 2004). Hsp90 inhibition results in 
client protein degradation and subsequently leads to cell death. To effectively synthesize 
molecules that inhibit such a big chaperone, an understanding of its crystal structure and 
function is essential. 
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2.3.1 Hsp90 crystal structure 
Hsp90 is a homodimeric protein, with each protomer consisting of three main structural 
domains i.e., N-terminal domain, middle domain and C-terminal domain (Figure 2.2) ( Li, et 
al., 2012). The N-terminal domain contains an ATP binding site and most inhibitors that have 
been designed thus far bind to this pocket of Hsp90 e.g., analogues of the natural occurring 
Hsp90 inhibitor, geldanamycin (Kamal, et al., 2003). The middle domain is connected to the 
N-terminus by a charged linker and is a site for binding for most client proteins and co-
chaperones (Street, et al., 2011). Tetratricopeptide repeat (TPR) domain-containing co-
chaperones are anchored at the C-terminus with its C-terminal MEEVD motif (Scheufler, et 
al., 2000). A few molecules e.g., novobiocin have been demonstrated to bind to an alternative 
site in the C-terminus of Hsp90 (Hadden, et al., 2009).  
 
Figure 2.2: N-terminal, middle and C-terminal domains of Hsp90 protein (adapted from 
http://www.ucl.ac.uk/~zcbtfi4/domainm.html. accessed on 01.01 2015). 
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Hsp90 protein is a flexible macromolecule, and therefore can assume different conformations 
effected by ATP binding to the N-terminal domain, and interactions with co-chaperones. In its 
apo state, Hsp90 acquires the V-shaped open conformation due to constitutive dimerization at 
the C-terminus. This V shape closes up when bound to ATP, dimerizing the N-terminal 
domains and bringing them closer together to the middle domain. After ATP hydrolysis, ADP 
is released and an open conformation is restored (Figure 2.3). Progress through these different 
stages of the ATP cycle of Hsp90 also relies on interactions with a cohort of co-chaperones 
that influence ATP hydrolysis, post-translational modifications or client protein interactions of 
Hsp90 (not shown) ( Li, et al., 2012). 
 
Figure 2.3: Hsp90 from E. coli (HtpG). 
Open conformation and nucleotide-bound yeast Hsp90 in the closed conformation. The N-domain is 
depicted in blue, the M-domain in green and the C-domain in orange ( Li, et al., 2012) 
 
Due to such flexibility of the Hsp90 chaperone system, it is most likely that it can conform to 
various molecules binding to its domains, therefore favouring design of several classes of lead 
molecules that can be used as inhibitors. 
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2.3.2 N-terminal Hsp90 inhibitors  
(Geldanamycin, resorcinol and purine related compounds) 
Hsp90 in tumour cells has been demonstrated to be in its highly active state and has a higher 
affinity for geldanamycin (2.28) and its analogues (2.29-2.30) (Kamal, et al., 2003).  
O
O
N
H
H3CO
OH
O
O
NH2
O
H3CO
R
2.28 R = OCH3 : Geldanamycin
2.29 R = NHCH2CH=CH2 : 17 AAG
2.30 R = NHCH2CH2N(CH3)2 : 17 DMAG
2.31 R = NH2: IPI-493
2.32 R = CH3CH2CH2NH2
+CI-: IPI-504
 
Differences in active states between tumour cells’ Hsp90 and normal cell Hsp90 favours 
selectivity for drug design and development. Such an observation has triggered enormous 
attention to Hsp90 as a potential target for cancer therapy. Client proteins require ATPase 
activity of Hsp90 for their activation and stabilization which is non-existent in the presence of 
Hsp90 inhibitors (Kamal, et al., 2003). Molecules such as benzoquinones, ansamycins, 
radicicols and purine analogues have been shown to compete for the N-terminal binding site 
of Hsp90, thereby inhibiting its activity. Loss of ATPase activity results in loss of signal 
transduction pathways that promote growth signals of cancerous cells, and eventual death. 
However, one negative aspect of many N-terminal Hsp90 inhibitors is that they also induce the 
stress response that leads to the upregulation of other stress related proteins, like Hsp70 and 
Hsp27, which can partially compensate for the loss of Hsp90 function. Several Hsp90 inhibitors 
are in clinical trial phases and are shown below:  
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Geldanamycin (2.28) and radicicol (2.33) were the first two natural products that were 
discovered to be Hsp90 inhibitors (Neckers and Workman, 2012). Although they were too toxic 
and unstable for clinical use, they paved the way for other derivatives that have entered clinical 
trials. 17-AAG (2.29), known as tanespimycin was the first geldanamycin (2.28) analogue to 
enter clinical studies, and it showed promising activity against several malignant cancers 
(Banerji, et al., 2005). However further studies were discontinued due to suboptimal inhibition 
of targeted client proteins by this drug. No tumour regression was observed but rather a form 
of cytostatic arrest of cancer cells was noticed (Neckers and Workman, 2012). Drug 
metabolism of tanespimycin also yielded products that resulted in liver toxicity and further 
advocated its discontinued use (Kelland, et al., 1999). 17-DMAG (2.30) (alvespimycin), was 
introduced which possessed better metabolism and pharmacokinetic profiles but its further 
development together with IPI-493 (2.31) was halted. IP1-504 (2.32) development was also 
discontinued due to hepatotoxicity when tested against gastrointestinal stromal tumour. Liver 
toxicity of geldanamycin (2.28) and its analogues (2.39-2.32) was linked to the presence of the 
quinone moiety and its metabolized products (Janin, 2010).  .  
With the assistance of virtual screening, new sets of compounds were discovered with 
resorcinol and purine scaffolds. BIIB021 (2.37) and PU-H71 (2.38) containing the purine 
skeleton are now in Phase 1 clinical trials, together with NVP-AUY922 (2.34), KW-2478 
(2.35) and AT13387 (2.36) of resorcinol origin which are going further development (Neckers 
and Workman, 2012). Other chemotypes being investigated are SNX-5422 (2.39) and NVP-
BEP800 (2.40), currently in clinical trials (Fadden, et al., 2010; Brough, et al., 2009). 
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2.3.3 C-terminal Hsp90 inhibitors 
A second ATP binding pocket has been located in the C-terminus of Hsp90 protein. Several 
compounds have been identified that bind to this active site, which results in Hsp90 inhibition 
(Donnelly and Blagg, 2008).  
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Cl Cl
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Novobiocin (2.41) weakly interacts with Hsp90 at a concentration of 700 µM in SkBr3 cells, 
consequently leading to client protein degradation and cell death. A form of competitive 
inhibition with ATP has been demonstrated on the C terminus which results in the association 
of Hsp90 and its co-chaperones Hsc70 and p23 being disrupted (Marcu, et al., 2000). Cisplatin 
(2.43) on the other hand has a higher binding affinity for Hsp90, with its binding site located 
close to the C-terminal ATP binding site. It affects nucleotide binding and Hsp90 chaperone 
activity. However resistance has been noticed with this drug which could be a limiting factor 
for it to act as a potential Hsp90 inhibitor. (Donnelly and Blagg, 2008).  Epigallocatechin-3-
gallate (EGCG) (2.42) inhibits telomerases and kinases enzymes that are related to client 
proteins. It has been shown to also bind to the C-terminus of Hsp90 protein but in a different 
way to novobiocin (2.41) (Palermo, et al., 2005). 
Unfortunately the co-crystal structure of the C-terminus is unknown, therefore there is limited 
knowledge about the nature of the binding pocket. However it has been proposed that the C 
terminus is only available for binding once the N-terminus is occupied (Csermely, et al., 1998). 
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Although this second ATP binding site does not possess ATPase activity, it is involved in the 
correct conformation of the entire Hsp90 protein upon ATP binding on the N-terminus. One of 
its functions is to trap the nucleotide in the ATPase cycle, which is altered when novobiocin 
(2.41) or any other inhibitor is bound to the C-terminus (Donnelly and Blagg, 2008).  Further 
studies are still underway using novobiocin (2.41) and its analogues to fully understand the 
structure and role played by the C-terminal domain in Hsp90 functions (Marcu, et al., 2000). 
2.3.4 Hsp90 inhibitors containing the naphthoquinone/quinone core 
Exploration of a quinone moiety as a pharmacophoric element in Hsp90 inhibition has been 
continued by investigating the effect of having a naphthoquinone functionality on drug lead 
molecules. High through-put screening of small molecules has identified naphthoquinone 
containing molecules as potential inhibitors of Hsp90 protein. 
HTS1-HTS3 scaffolds (2.44-2.46) were determined to possess Hsp90 inhibition properties. 
Preliminary studies indicated that they bind to the C-terminal domain in a similar way to 
novobiocin (2.41) though this is still to be fully ascertained. Anti-proliferative assays 
conducted for these compounds also showed their tendency to be effective in treating oestrogen 
dependent cancers, making them useful in breast cancer treatment (Hadden, et al., 2009). 
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From amongst the meroterpenoids, sargaquinonic acid (SQA) (2.47) has demonstrated some 
degree of interaction with Hsp90 protein (Moyo, 2013).  
O
O
COOH
2.47
 
The potential of SQA (2.47) acting as a potential Hsp90 inhibitor inspired our research on 
meroterpenoids. SQA (2.47) as indicated in the previous chapter, is isolated from S. 
incisifolium with several other meroterpenoids (Afolayan, et al., 2008). Since hepatoxicity 
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reports have been published with regards to benzoquinones, modifications of SQA (2.47) to 
sarganaphthoquinoic acid (SNQA) as a potential Hsp90 inhibitor were targeted and comparison 
made to lapachol derivatives and known inhibitors belonging to the ansamycin class of 
compounds e.g., geldanamycin (2.28). Isolation and characterization of these natural quinones 
is therefore discussed in the following chapter.  
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CHAPTER THREE 
 
Isolation and characterization of quinone natural products 
Abstract 
The isolation of cytotoxic prenylated quinones from Sargassum incisifolium was conducted in an effort 
to acquire starting material for further studies. We aimed to explore the potential of these metabolites 
to inhibit Hsp90 function in the treatment of cancer. Five metabolites were isolated and characterized 
from Sargassum incisfolium. Additional compounds were obtained from a natural product library that 
included lapachol and its semi-synthesized derivatives. Isolation and characterization of these natural 
products is discussed in this chapter.     
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3.1 Introduction 
Prenylated quinones are particularly abundant in the brown algal genera Sargassum and 
Cystoseria (Reddy and Urban, 2009). Various biological activities have been associated with 
these types of compounds, and we were particularly interested in meroterpenoids isolated from 
Sargassum incisifolium. Previous work conducted on this species has afforded five secondary 
metabolites shown below. Sargahydroquinoic acid (SHQA) (3.1), sargaquinoic acid (SQA) 
(2.47), sargaquinal (3.2), sargachromenol (3.3) and fucoxanthin (3.4) demonstrate 
antiplasmodial and cytotoxic activities against a chloroquine sensitive strain of Plasmodium 
falciparum (Afolayan, et al., 2008) and MDA-MB-231 breast cancer cell line, respectively (de 
la Mare, et al., 2012; Munedzimwe, 2012). 
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3.1.1 Aim of the study 
Sargaquinoic acid (SQA) (2.47) and related compounds have been shown to be cytotoxic and 
potentially inhibit Hsp90 function (de la Mare, et al., 2012; Moyo, 2013). The main aim of this 
part of the project was to isolate and fully characterize natural products from S. incisifolium 
(Figure 3.1) for further studies. Previous studies had also indicated the potential of lapachol 
and its synthetic analogues to inhibit Hsp90 protein (Moyo, 2013), therefore they were 
incorporated in our search for cytotoxic Hsp90 inhibitors. 
 
Figure 3.1: Photograph of S. incisifolium  
(Photographs adapted from: http://oceanexplorer.noaa.gov/explorations/04etta/logs/aug25/media/sargassum.html.  
Web accessed: 07 Dec 2014) 
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3.2 Results and discussion 
3.2.1 Extraction and isolation of secondary metabolites from S. incisifolium 
S. incisifolium (NDK100213-1) was collected from Noordhoek (Port Elizabeth, South Africa) 
and extracted in DCM: MeOH (2:1) after soaking in MeOH for an hour. The DCM crude 1H 
NMR spectrum obtained (Figure 3.2) showed the presence of one major metabolite, compound 
3.1. Further fractionation of the crude extract by column chromatography using solvents of 
increasing polarity (Hexane/EtOAc) gave eight fractions A-H (Scheme 3.1). Fraction B yielded 
compound 3.2. Compound 2.47 was obtained from fraction C and fraction D gave compound 
3.1 in great yields and in its pure form, together with compound 3.3 in minute quantities.  
Compound 3.4 was eluted in fraction E. The different metabolites were identified by comparing 
their 1H and 13C NMR spectra to those reported in literature. It is important to note how the 
presence of other metabolites was masked in the 1H NMR crude extract and appear with further 
fractionation of the extract with relative purity, demonstrating the efficiency of the increasing 
polarity approach.  
 
 
Figure 3.2: 1H NMR spectrum (600 MHz, CDCl3) of the crude extract of S. incisifolium 
collected from Noordhoek, Port Elizabeth (South Africa) 
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Scheme 3.1 Extraction and isolation of secondary metabolites from S.incisifolium1,2 
 
 
 

MeOH (aq) fractions were also pooled and extracted using EtOAc as shown above. 

Step gradient solvents systems are in the ratio of Hexane: EtOAc  

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3.2.2 Characterization of S. incisifolium metabolites 
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Figure 3.3: 1H NMR spectrum (600 MHz, CDCl3) of compound 3.1 
Compound 3.1 exists in abundance in DCM crude extracts of S. incisifolium. Characteristic 
features of its 1H NMR spectrum (Figure 3.3) include two aromatic singlets at  6.49 (H-3) 
and  6.46 (H-5), along with three sets of olefinic protons at  5.99 (t, J = 7.0 Hz, H-10’),  
5.27 (t, J = 7.2 Hz, H-2’) and  5.10 (m, H-6’ and H-14’). Three methylene signals for the 
prenyl chain are observed at  3.29 (d, J = 7.3 Hz, H-1’),  2.58 (q, J = 7.5 Hz, J = 7.7 Hz, H-
9’) and  2.26 (t, J = 7.2 Hz, H-12’). The other methylene signals appear as clusters at  2.13 
(m) and  2.08 (m). Signals at  2.18 (s),  1.75 (s),  1.67 (s) and  1.59 (s) clearly show the 
methyl groups on the molecule. All chemical shifts were consistent with previously reported 
values (Table 3.1) (Afolayan, et al., 2008). 
Compound 2.47 was obtained in minute quantities from S. incisifolium. The 1H NMR spectrum 
of compound 2.47 shown in Figure 3.4 showed two major differences to that of compound 3.1 
in Figure 3.3. The aromatic proton at  6.54 (H-3) appears slightly more deshielded compared 
to the  6.49 (H-3) shown for compound 3.1. The 13C NMR spectrum of compound 2.47 
(Figure 3.5) shows three carbonyl signals at  188.5 (C-1),  188.0 (C-4) and  172.8 (C-18’). 
The more deshielded signals correspond to the benzoquinone moiety, whilst in compound 3.1, 
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those signals are absent. All other spectroscopic data matched those published in literature 
(Table 3.1) (Afolayan, et al., 2008) 
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Figure 3.4: 1H NMR spectrum (600 MHz, CDCl3) of compound 2.47 
 
Figure 3.5: 13 C NMR spectrum (150 MHz, CDCl3) of compound 2.47 
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Compound 2.47 can also be prepared via semi-synthesis by oxidation of compound 3.1 using 
Ag2O or MnO2 in a mixture of solvents (CHCl3/MeOH), if needed in larger quantities. In the 
same reaction, cyclization of sargahydroquinoic acid (3.1) can occur to form very minute 
quantities of sarganaphthoquinoic acid (3.5). We hypothesize that the reaction follows some 
type of Diels-Alder reaction, whereby the quinone moiety acts as the dienophile and the C1’- 
C3’ portion of the prenyl chain system acts as the diene, or undergo a 6- electron electrocyclic 
ring closure with subsequent re-aromatization (Scheme 3.2). 
R
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R R
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Scheme 3.2: Semi-synthesis of sarganaphthoquinoic acid (3.5) from sargahydroquinoic acid 
(3.1) 
However, the reaction is unpredictable and yields vary with each attempt (Munedzimwe, 2012). 
Further research is underway to fully understand the dynamics of this reaction and to improve 
the yield of sarganaphthoquinoic acid (3.5) that is formed.  
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The 1H NMR spectrum of compound 3.2 (Figure 3.6) was very similar to that of compound 
2.47. However it comprised of a characteristic aldehyde signal at  9.55 (s, H-18’) indicative 
of sargaquinal (3.2), which was further confirmed by the carbonyl signal at  204.9 on the 13C 
NMR spectrum. All other signals matched perfectly with reported values and confirmed 
compound 3.2 to be sargaquinal (Table 3.1) (Afolayan, et al., 2008). 
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Figure 3.6: 1H NMR spectrum (600 MHz, CDCl3) of compound 3.2 
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Figure 3.7: 1H NMR spectrum (600 MHz, CDCl3) of compound 3.3 
The 1H NMR spectrum (Figure 3.7) for compound 3.3 also contained two aromatic protons as 
observed in other secondary metabolites, at  6.49 (s, H-5) and  6.31 (s, H-3). Of interest was 
the appearance of two new olefinic protons coupled to each other at  6.24 (d, J = 9.8 Hz, H-
1’) and  5.56 (d, J = 9.8 Hz, H-2’), and the disappearance of one of the olefinic triplets and 
benzylic methylene signal at  3.29 (d, J = 7.3 Hz). A comparison with published data of 
chromenols confirmed compound 3.3 to be sargachromenol, that was previously isolated from 
S. micracanthum (Ham, et al., 2010) (Table 3.1).  
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Figure 3.8: 1H NMR spectrum (600 MHz, CDCl3) of compound 3.4 
 
Figure 3.9: 13C NMR spectrum (150 MHz, CDCl3) of compound 3.4 
1H and 13C NMR spectra (Figure 3.8 and Figure 3.9) for compound 3.4 were completely 
different from the other isolated metabolites. Overlapping signals were observed in the region 
between  6.00 and  7.00 indicative of a highly conjugated double bond system. This was 
confirmed in the 13C NMR spectrum which showed a large number of resonances between 
110-150. In total, 42 resonances were noted and it was most likely that compound 3.4 
belonged to a class of carotenoids. With careful analysis of the 1H and 13C NMR data published 
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of similar compounds isolated from Sargassum, compound 3.4 was identified as fucoxanthin 
(Afolayan, et al., 2008) (Table 3.2). 
The 13C NMR spectra for isolated metabolites from S. incisifolium not shown in this chapter 
are present in the supplementary section (Figure S3.1 – S3.3)  
Table 3.1: 1H and 13C NMR chemical shifts of secondary metabolites from S. incisifolium 
 
 
 2.47 3.1 3.2 3.3 
Carbon 
no. 
  C  H, mult,  
J(Hz) 
  C  H, mult, 
J(Hz) 
  C  H, mult, 
J(Hz) 
  C  H, mult, 
J(Hz) 
1 188.1 - 146.5 - 188.0 - 145.7 - 
2 145.9 - 125.5 - 145.9 - 121.0 - 
3 133.1 6.54, br, s 115.3 6.49, br, s 132.3 6.53, s 110.3 6.31, m 
4 188.0 - 148.7 - 187.9 - 148.7 - 
5 131.0 6.45, s 114.0 6.46, br, s 132.2 6.44, s 117.2 6.49, m 
6 148.5 - 127.6 - 148.4 - 126.4 - 
7 17.7 2.04, m 16.1 2.18, s 16.1 1.66, s 15.8 2.12, s 
1’ 27.5 3.12, d, 7.3 29.9 3.29, d, 7.0 27.4 3.11, d, 7.3 123.0 6.24, d, 9.7 
2’ 118.0 5.11, m 121.6 5.27, t, 7.1 118.2 5.06, m 130.5 5.56, d, 9.8 
3’ 139.8 - 138.2 - 139.9 - 78.0 - 
4’ 39.5 2.07, m 39.5 2.08, m 39.6 2.05, m 40.5 1.99, m 
5’ 26.2 2.11, m 26.1 2.13, m 26.4 2.05, m 22.6 2.05, m 
6’ 124.4 5.11, m 124.4 5.10, m 125.2 5.06, m 125.0 5.13, m 
7’ 134.6 - 134.6 - 133.7 - 134.2 - 
8’ 39.0 2.07, m 39.1 2.08, m 39.0 2.23, m 40.0 2.05, m 
9’ 28.1 2.56, q, 7.3 28.3 2.58, q, 7.5 27.3 2.05, m 28.2 2.58, q, 7.3 
10’ 145.9 5.94, t, 7.2 145.5 5.99, t, 7.0 155.0 5.38, m 144.9 5.98, t, 7.0 
11’ 130.6 - 130.5 - 132.3 - 130.5 - 
12’ 34.6 2.24, t, 7.1 34.5 2.26, t, 7.2 27.5 2.05, m 34.6 2.25, t, 7.3 
13’ 28.1 2.11, m 27.8 2.13, m 25.6 2.09, m 27.8 2.12, s 
14’ 123.5 5.11, m 123.5 5.10, m 123.6 5.13, t, 7.7 123.4 5.13, m 
15’ 132.2 - 132.3 - 133.2 - 132.3 - 
16’ 25.6 1.66, s 25.7 1.67, s 25.0 1.66, s 25.6 1.67, m 
17’ 17.7 1.57, s 17.7 1.58, s 17.8 1.55, s 17.8 1.58, m 
18’ 172.6 - 172.3 - 204.9 9.55, d, 3.2 172.8 - 
19’ 15.9 1.59, s 16.0 1.59, br, s 16.0 1.60, s 15.6 1.58,  m 
20’ 16.0 1.61, s 16.1 1.75, s 16.1 1.60, s 26.0 1.67, m 
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Table 3.2: 1H and 13C NMR chemical shifts of compound 3.4 
Carbon no.   C   H Carbon no.   C  H 
1 35.8 - 11 123.4 6.54 
1’ 35.1 - 11’ 125.7 6.58 
2 47.0 - 12 145.1 6.67 
2’ 45.4 1.48 12’ 137.1 6.33 
3 64.3 3.80 13 135.4 - 
3’ 68.1 5.36 13’ 138.1 - 
4 41.6 1.76 14 136.7 6.39 
4’ 45.2 1.50 14’ 132.2 6.25 
5 66.2 - 15 129.4 6.63 
5’ 72.7 - 15’ 132.5 6.74 
6 67.1 - 16 25.0 1.02 
6’ 117.4 - 16’ 21.5 1.80 
7 40.8 2.57 17 28.1 0.95 
7’ 202.4 3.64 17’ 32.1 1.06 
8 197.9 - 18 21.2 1.21 
8’ 103.4 6.04 18’ 31.3 1.34 
9 134.5 - 19 11.8 1.93 
9’ 132.5 - 19’ 14.0 1.80 
10 139.2 7.13 20 12.8 1.98 
10’ 128.5 6.11 20’ 12.9 1.98 
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3.2.3 Lapachol and its derivatives 
Compounds 3.6-3.11 were a gift from Professor Davies-Coleman, University of the Western 
Cape, South Africa. The natural naphthoquinone, lapachol (3.6) has been isolated from many 
species of Bignoniaceae family, particularly from those of the genus Tabebuia (T. aurea, T. 
impetiginosa, T. ochracea and T. avellanedae) (Hussain, et al., 2007). It comprises of an 
amylene hydroxy-naphthoquinone moiety, with both substituents attached to the quinone ring. 
Compound 3.6 has been intensely studied for various biological properties including anti-
tumour properties, and was once registered by the NCI for clinical trials (de Almeida, 2009). 
Its antitumour properties led to the synthesis of a wide range of naphthoquinone (Sunassee, et 
al., 2013) derivatives and has been demonstrated to show Hsp90 inhibition, hence our interest 
in this molecule and its derivatives.  
             
O
O
OH
3.6
         
O
O
O
3.7
         
O
O
O
3.8
 
           
O
O
O
OH
3.9
                  
O
O
O
3.10
                
O
O
OH
3.11
 
 
3.2.4 Synthetic strategies for lapachol and related compounds  
Various methods have been employed to synthesize lapachol (3.6) in the laboratory, with 
relative success using silver salts, lithium salts and palladium as catalysts (Hussain, et al., 
2007). Attempts to increase its cytotoxic nature have yielded semi-synthetic derivatives (3.7-
3.11). -Lapachone (3.7) and -lapachone (3.8) are obtained by treating lapachol (3.6) with 
H2SO4 and HCl respectively (Salas, et al., 2008), which results in the cyclization of its 
isoprenyl chain by nucleophilic attack of the hydroxyl group (da Silva Junior, et al., 2008). -
OH-lapachone (3.9) is a hydroxylated analogue of -lapachone (3.8), effected by use of 
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MCPBA in CH2Cl2 (Salas, et al., 2008; Sun, et al., 1998). The synthesis of -nor-lapachone 
(3.10) requires an alternative precursor molecule and is conducted by C-allylation of lawsone 
and then cyclization by conc H2SO4 (Kongkathip, et al., 2003). C-allyl lawsone (3.11) is 
prepared by alkylation of lawsone with allyl bromide of the sodium salt (Silva, et al., 2006). 
All of these reactions are depicted in Scheme 3.3.  
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Scheme 3.3: Synthesis of lapachol (3.6) and derivatives 
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3.2.5 Characterization of lapachol and semi-synthetic derivatives 
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Figure 3.10:  1H NMR spectrum (600 MHz, CDCl3) of compound 3.6 
The 1H NMR spectrum of lapachol (3.6) depicted in Figure 3.10 shows four aromatic protons 
at  8.19 (d, J = 7.8 Hz, H-8) ,  8.06 (d, J = 7.8 Hz, H-5),  7.74 (t, J = 7.5 Hz, H-7) and  7.67 
(t, J = 7.5 Hz, H-6) indicative of the naphthoquinone system. The two C=O functionalities of 
the naphthoquinone are evident on the 13C NMR spectrum at  181.7 (C-4) and  184.6 (C-1). 
A methylene group at  3.30 (d, J = 7.6 Hz, H-1’) coupled to an olefinic methine proton at  
5.21 (t, J = 7.6 Hz, H-2) was also observed, with two terminal methyl signals at  1.78 (s, H-
4’) and  1.68 (s, H-5’). All other 1H and 13C spectral data were consistent with reported 
literature values (Table 3.3) (Oliveira, et al., 2002).  
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Figure 3.11:  1H NMR spectrum (600 MHz, CDCl3) of compound 3.7 
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Figure 3.12:  1H NMR spectrum (600 MHz, CDCl3) of compound 3.8 
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A distinguishing feature of the 1H NMR spectra for both -lapachone (3.7) and -lapachone 
(3.8) is the disappearance of the olefinic methine proton at  5.21 (t, J = 7.6 Hz,) noticeable in 
lapachol (3.6), which clearly indicates the absence of an alkene functionality. Cyclization is 
evident by the appearance of two sets of methylene protons at  1.81 (t, J = 6.7 Hz, H-2’) and 
 2.61 (t, J = 6.6 Hz, H-1’) for -lapachone (3.7), and at  1.84 (t, J = 6.7 Hz, H-2’) and  2.56 
(t, J = 6.5 Hz, H-1’) for -lapachone (3.8). The difference between the two natural products is 
noticeable in their aromatic regions of the 1H NMR spectra. The aromatic protons in -
lapachone (3.7) are somehow more clustered due to the manner in which the cyclization has 
occurred, where by in -lapachone (3.8), one sided cyclization occurs and results in aromatic 
protons (H-5 and H-6) being less deshielded due to absence of the carbonyl on C-4. Further 
confirmation of the structure was conducted by 13C NMR spectroscopy and by comparison to 
the published NMR data (Salas, et al., 2008). 
O
O
O
OH
3.9
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5
8 9
10 1'
3'
4'5'
 
Figure 3.13:  1H NMR spectrum (600 MHz, CDCl3) of compound 3.9 
The 1H NMR spectrum of -OH-lapachone (3.9) shares similarities to that of -lapachone (3.8) 
especially in the aromatic region. Differences are noted with the appearance of a single triplet 
signal of a methine proton at  3.91 (t, J = 5.2 Hz, H-2’) bonded to the hydroxyl functionality. 
The one set of methylene protons of the cyclized isoprenyl chain is observed at  2.63 (dd, J = 
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
2.72.8 ppm
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17.8 and J = 5.3 Hz, H-1a’) and  2.83 (dd, J = 17.8 Hz and J = 5.3 Hz, H-1b’). The C-OH 
signal was noted on the 13C NMR spectrum at  68.5 (C-2’). All other chemical shifts were 
consistent with literature values and are displayed in Table 3.4 (Salas, et al., 2008). 
O
O
O
3.10
1
5
8 9
10
1'
3'
4'
5'
 
 
Figure 3.14:  1H NMR spectrum (600 MHz, CDCl3) of compound 3.10 
-nor-lapachone (3.10) structural difference from -lapachone (3.8) is the presence of a 
tetrahydrofuran moiety rather than a tetrahydro-2H-pyran. Cyclized part of the molecule is one 
carbon short and the 1H NMR spectrum contains a characteristic methylene signal at  2.94 (s, 
H-2’) uncoupled to any other proton. All other chemical shifts are consistent with published 
spectroscopic data (Kongkathip, et al., 2003). 
A related compound to lapachol (3.6), C-allyl lawsone (3.11) consists of a similar 
hydroxynaphthoquinone system and a prenyl side chain that contains a terminal double bond.  
Its structure and spectroscopic data is depicted in Figure 3.15  
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O
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Figure 3.15:  1H NMR spectrum (600 MHz, CDCl3) ofcompound 3.11 
The 1H NMR spectrum of 3.11 displays two terminal methylene protons indicated by doublets 
at  5.05 (d, J = 10.6 Hz, H-3a’) and  5.17 (d, J = 17.2 Hz, H-3b’). These two protons are 
coupled to a methine proton at  5.91 (m, H-2’) giving a -CH=CH2 structural motif, and in turn 
the methine coupled to methylene protons at  3.37 (d, J = 6.9 Hz. H-1’), completing the prenyl 
system attached to the naphthoquinone. The 13C NMR spectrum of 3.11 displays the absence 
of methyl carbons normally observed at  17.9 and  22.7 in lapachol (3.6). All other chemical 
shifts were similar to those of lapachol (3.5) and are shown in Table 3.4 (Silva, et al., 2006). 
The 13C NMR spectra of lapachol and its related compounds have been compiled in the 
supplementary section (Figure S3.4 – S3.8)  
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Table 3.3: 1H and 13C NMR chemical shifts of compounds 3.6-3.8 
 
 
 
 
 
 
 
 
 
 
 
 
O
O
OH
3.6
1
45
8
9
10
1'
3' 4'
5'
 
O
O
O
3.7
1
45
8
9
10
1'
3'
4'
5'
 
O
O
O
3.8
1
5
8 9
10 1'
3'
4'5'
 
Carbon 
No. 
 C  H, mult, J(Hz)  C  H, mult, J(Hz)  C  H, mult, J(Hz) 
1 181.7 - 180.0 - 179.8 - 
2 152.6 - 154.6 - 178.5 - 
3 123.4 - 120.1 - 112.7 - 
4 184.5 - 184.4 - 162.1 - 
5 126.7 8.06, d, 7.8 126.3 8.07, m, 2H 124.1 7.80, d, 7.6 
6 134.8 7.67, t, 7.5 133.9 7.67. m, 2H 134.8 7.49, t, 7.8 
7 132.8 7.74, t, 7.5 132.9 7.67, m, 2H 130.9 7.63, t, 7.8 
8 126.0 8.19, d, 7.8 125.9 8.07, m, 2H 128.5 8.05, d, 7.6 
9 129.4 - 131.1 - 130.1 - 
10 132.9 - 132.0 - 132.6 - 
1’ 22.6 3.30, d, 7.6 16.7 2.61, t, 6.6  16.1 2.56, t, 6.5 
2’ 119.6 5.21, t, 7.6 31.4 1.81, t, 6.7 31.5 1,84, t, 6.7 
3’ 133.8 - 78.1 - 79.3 - 
4’ 25.7 1.68, s 26.5 1.43, s 26.7 1.46, s 
5’ 17.8 1.78, s 26.5 1.43, s 26.7 1.46, s 
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Table 3.4: 1H and 13C NMR chemical shifts of compounds 3.9-3.11 
 
 
 
 
 
 
 
 
O
O
O
OH
3.9
1
5
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10 1'
3'
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O
O
O
3.10
1
5
8 9
10 1'
2'
3'
4'
 
O
O
OH
3.11
1
45
8
9
10
1'
3'
 
Carbon 
No. 
   
 C             H, mult,  J(Hz)     C             H, mult,  J(Hz)     C             H, mult,  J(Hz) 
1 179.5 - 180.1 - 184.2 - 
2 178.5 - 176.2 - 153.1 - 
3 110.3 - 114.3 - 121.8 - 
4 161.5 - 168.8 - 181.5 - 
5 124.4 7.83, d, 7.6  124.1 7.57, m, 1H 126.9 8.08, d, 7.7  
6 134.9 7.51, t, 7.6  133.5 7.63, m, 2H 133.7 7.68, t, 7.6 
7 130.9 7.65, t, 7.8  129.2 7.63, m, 2H 133.0 7.76, t, 7.7 
8 128.8 8.06, d, 7.6  128.3 8.07, d, 7.6  126.1 8.13, d, 7.8  
9 130.0 - 131.1 - 129.3 - 
10 132.0 - 133.4 - 132.8 - 
1’ 22.1 1a’: 2.82, dd, 17.8  
and 5.3  
1b’ :2.62, dd, 17.8  
and 5.3  
40.1 2.94, s 27.5 3.36, d, 6.6  
2’ 68.2 3.91, t, 5.2 94.1 - 135.0 5.91, m, 1H 
3’ 81.4 - 29.5 1.60, s 116.4 3a’: 5.17, d, 17.3 
3b’: 5.05, d, 10.2 
4’ 25.0 1.45, s 29.5 1.60, s  N/A - 
5’ 25.4 1.51, s N/A N/A N/A - 
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3.3 Conclusion 
Five secondary metabolites (2.47, 3.1-3.4) were isolated from S. incisifolium. Six additional 
compounds i.e., lapachol and its related compounds (3.6-3.11), were added in the search for 
cytotoxic Hsp90 inhibitors.  Structural modifications of the natural product skeleton are limited 
by quantities obtained from natural sources, therefore synthetic analogues inspired by natural 
product structures were opted for.  
Our interest was in the natural product sarganaphthoquinoic acid (3.5) due to its 
naphthoquinone moiety that has been identified as a potential structural feature that imparts 
Hsp90 inhibition on lead molecules. Due to difficulties in preparing sarganaphthoquinoic acid 
(3.5) in sufficient amount for further research, truncated sarganaphthoquinoic acid derivatives 
were prepared in an attempt to modify its structure for improved cytotoxicity and Hsp90 
inhibition properties. The different analogues prepared are discussed in the next chapter.  
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3.4 Experimental 
3.4.1 General experimental 
Solvents  
All solvents used for extractions and chromatography were of HPLC grade (Chromasolv®) 
acquired from Merck, South Africa.  
Chromatography 
Column chromatography was conducted using silica gel 60 (0.040-0.063 mm), from ASTM 
Merck. Thin layer chromatography experiments were run on TLC silica gel 60F254 20 x 20 
aluminium sheets and visualized using a Syngene UV lamp 230 V, 50 Hz with dual 
wavelengths 365 nm and 254 nm.  
High Performance Liquid Chromatography 
HPLC separations were done on an instrument consisting of a Waters® 1515 isocratic HPLC 
pump connected to a Waters® 2414 refractive index detector. A Whatman Partisil® 10 (1 x 50 
cm) normal phase column was used for purification.  
Nuclear magnetic resonance (NMR) 
NMR data (1D and 2D experiments) were acquired on a Bruker Avance 600 MHz 
spectrometer. Chemical shifts are recorded in ppm and referenced to residual non-deuterated 
solvent (CDCl3 H 7.26, C 77.0). All coupling constants are reported in Hz.  
Plant material 
Specimens of S. incisifolium were collected at low tide at Kelly’s Beach, Port Alfred and from 
Noordhoek near Port Elizabeth. Identification of algae collected were done by Prof John J. 
Bolton of the department of Botany, University of Cape Town, South Africa. Voucher 
specimens are kept in our repository at Rhodes University, South Africa. Crude and pure 
extracts isolated were stored in vials at -20 ºC, covered with a thin film of hexane and flushed 
with argon/nitrogen.  
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3.4.2. Isolation and purification of secondary metabolites from S. incisifolium 
Protocols adopted for extraction, isolation and purification of metabolites are represented by 
the flow chart in Scheme 3.1.  
Extraction and Isolation 
Sufficient methanol was used to completely submerge the algae (45.7 g, dry weight) in a 1 L 
conical flask for 1 h. The solvent was decanted and the algae re-extracted three times with a 
2:1 DCM/MeOH mixture at 35 ºC for 30 min. Appropriate volumes of DCM and H2O were 
added to the decanted MeOH fraction, and H2O to the DCM/MeOH fraction to allow phase 
separation. The DCM layers were collected and concentrated in vacuo to give the DCM crude 
extract. 
The DCM
 
crude extract (~ 1 g) was chromatographed on a silica column (10 g) using a step 
gradient protocol of increasing polarity from 100% hexane to 100% EtOAc, and the column 
was finally washed with EtOAc-MeOH. Further column chromatography (silica, 10 g, hexane-
EtOAc, 95:5) of the hexane-EtOAc (9:1) fraction (120 mg) yielded compound 3.2 (23 mg). 
Compound 2.47 (9.8 mg) was obtained from fraction C (100 mg) of hexane-EtOAc (8:2) by 
column chromatography (silica-10 g, Hex/EtOAc 85:15). Fraction D of Hex/EtOAc (6:4) gave 
compound 3.1 in greatest yield (382 mg) and in its pure form, together with compound 3.3 (3 
mg) in minute quantities. Compound 3.3 was purified by column chromatography (Hex/EtOAc 
7:3).  Compound 3.4 (37 mg) was eluted in fraction E of Hex/EtOAc (4:6).  Dry weight of the 
algae after extraction was 45.7g. 
1H and 13C NMR spectroscopy was used to characterize extracts obtained at each stage of the 
procedure. Fractions to further purify were chosen according to the NMR data acquired. All 
relevant chemical shifts for the natural product metabolites are in Tables 3.1-3.4 and also 
complied below: 
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Isolated metabolites from S. incisifolium 
Compound 3.1 
7
3 5
1'
6' 10' 14' 16'
17'19'
20'
COOHOH
OH
18'
 
Orange-yellow oil; 1H NMR (CDCl3):  6.49 (br, s, H-3), 6.46 (br, s, H-5), 2.18 (s, H-7), 3.29 
(d, 7.0 Hz, H-1’), 5.24 (t, 7.1 Hz, H-2’), 2.08 (m, H-4’), 2.13 (m, H-5’), 5.10 (m, H-6’), 2.08 
(m, H-8’), 2.58 (q, 7.5 Hz, H-9’), 5.99 (t, 7.0 Hz, H-10’), 2.26 (t, 7.2 Hz, H-12’), 2.13(m, H-
13’), 5.10 (m, H-14’), 1.67 (s, H-16’), 1.58 (s, H-17’), 1.59 (br s, H-19’), 1.75 (s, H-20’) 
13C NMR (CDCl3):  146.5 (C-1), 125.5 (C-2), 115.3 (C-3), 148.7 (C-4), 114.0 (C-5), 127.6 
(C-6), 16.1 (C-7), 29.9 (C-1’), 121.6 (C-2’), 138.2 (C-3’), 39.5 (C-4’), 26.1 (C-5’), 124.4 (C-
6’), 134.6 (C-7’), 39.1 (C-8’), 28.3 (C-9’), 145.5 (C-10’), 130.5 (C-11’), 34.5 (C-12’), 27.8 (C-
13’), 123.5 (C-14’), 132.3 (C-15’), 25.7 (C-16’), 17.7 (C-17’), 173.2 (C-18’), 16.0 (C-19’), 
16.1 (C-20’) (Afolayan, et al., 2008).  
Compound 2.47 
COOHO
O
7
3 5
6'
1'
10' 14' 16'
17'19'20' 18'
 
Orange-yellow oil; 1H NMR (CDCl3):  6.54 (br, s, H-3), 6.45 (br, s, H-5), 2.04 (s, H-7), 3.12 
(d, 7.3 Hz, H-1’), 5.11 (m, H-2’), 2.07 (m, H-4’), 2.11 (m, H-5’), 5.11 (m, H-6’), 2.07 (m, H-
8’), 2.56 (q, 7.3 Hz, H-9’), 5.94 (t, 7.3 Hz, H-10’), 2.24 (t, 7.1 Hz, H-12’), 2.11 (m, H-13’), 
5.11 (m, H-14’), 1.66 (s, H-16’), 1.57 (s, H-17’), 1.59 (s, H-19’), 1.61 (s, H-20’) 
13C NMR (CDCl3):  188.1 (C-1), 145.9 (C-2), 133.1 (C-3), 188.0 (C-4), 131.0 (C-5), 148.5 
(C-6), 17.7 (C-7), 27.5 (C-1’), 118.0 (C-2’), 139.8 (C-3’), 39.5 (C-4’), 26.2 (C-5’), 124.4 (C-
6’), 134.6 (C-7’), 39.0 (C-8’), 28.1 (C-9’), 145.9 (C-10’), 130.6 (C-11’), 34.6 (C-12’), 28.1 (C-
13’), 123.5 (C-14’), 132.2 (C-15’), 25.6 (C-16’), 17.7 (C-17’), 172.6 (C-18’), 15.9 (C-19’), 
16.0 (C-20’) (Afolayan, et al., 2008).  
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Compound 3.2 
CHOO
O
7
35
1'
6' 10' 14' 16'
17'
20' 19' 18'
 
Orange-yellow oil; 1H NMR (CDCl3):  6.53 (br, s, H-3), 6.44 (s, H-5), 1.66 (s, H-7), 3.11 (d, 
7.3 Hz, H-1’), 5.06 (m, H-2’), 2.05 (m, H-4’), 2.05 (m, H-5’), 5.06 (m, H-6’), 2.23 (m, H-8’), 
2.05 (m, H-9’), 5.38 (m, H-10’), 2.05 (m, H-12’), 2.09 (m, H-13’), 5.13 (t, 7.7 Hz, H-14’), 1.66 
(s, H-16’), 1.55 (s, H-17’), 9.54 (d, 3.2 Hz, H-18’), 1.60 (s, H-19’), 1.60 (s, H-20’) 
13C NMR (CDCl3):  188.0 (C-1), 145.9 (C-2), 132.3 (C-3), 187.9 (C-4), 132.2 (C-5), 148.4 
(C-6), 16.1 (C-7), 27.4 (C-1’), 118.2 (C-2’), 139.9 (C-3’), 39.6 (C-4’), 26.4 (C-5’), 125.2 (C-
6’), 133.7 (C-7’), 39.0 (C-8’), 27.3 (C-9’), 155.0 (C-10’), 132.3 (C-11’), 27.5 (C-12’), 25.6 (C-
13’), 123.6 (C-14’), 133.2 (C-15’), 25.0 (C-16’), 17.8 (C-17’), 204.9 (C-18’), 16.0 (C-19’), 
16.1 (C-20’) (Afolayan, et al., 2008).  
Compound 3.3 
OH
O
COOH
3
5
7
1'
20' 6' 10'
14'
17'18'19'
 
Orange-yellow oil; 1H NMR (CDCl3):  6.31 (m, H-3), 6.49 (m, H-5), 2.12 (s, H-7), 6.24 (d, 
9.7 Hz, H-1’), 5.56 (d, 9.8 Hz, H-2’), 1.99 (m, H-4’), 2.05 (m, H-5’), 5.13 (m, H-6’), 2.05 (m, 
H-8’), 2.58 (q, 7.3 Hz, H-9’), 5.34 (t, 7.0 Hz, H-10’), 2.25 (t, 7.3 Hz, H-12’), 2.12 (s, H-13’), 
5.13 (m, H-14’), 1.67 (m, H-16’), 1.58 (m, H-17’), 1.58 (m, H-19’), 1.67 (m, H-20’) 
13C NMR (CDCl3):  145.7 (C-1), 121.0 (C-2), 110.3 (C-3), 148.7 (C-4), 117.2 (C-5), 126.4 
(C-6), 15.8 (C-7), 123.0 (C-1’), 130.5 (C-2’), 78.0 (C-3’), 40.5 (C-4’), 22.6 (C-5’), 125.0 (C-
6’), 134.2 (C-7’), 40.0 (C-8’), 28.2 (C-9’), 144.9 (C-10’), 130.5 (C-11’), 34.6 (C-12’), 27.8 (C-
13’), 123.4 (C-14’), 132.3 (C-15’), 25.6 (C-16’), 17.8 (C-17’), 172.8 (C-18’), 15.6 (C-19’), 
26.0 (C-20’) (Ham, et al., 2010).  
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Compound 3.4 
O
O
OH
O
O
OH
1
3
1617
19
11
20
15
15'
20'
11'
19'
17'
9'
1'
3'
 
Red-Orange oil: 1H NMR (CDCl3):  1.48 (H-2’), 3.80 (H-3), 5.36 (H-3’), 1.76 (H-4), 1.50 (H-
4’), 2.57 (H-7), 3.64 (H-7’), 6.04 (H-8’), 7.10 (H-10), 6.11 (H-10’), 6.54 (H-11), 6.58 (H-11’), 
6.67 (H-12), 6.33 (H-12’), 6.39 (H-14), 6.25 (H-14’), 6.63 (H-15), 6.74 (H-15’), 1.02 (H-16), 
1.80 (H-16’), 0.95 (H-17), 1.06 (H-17’), 1.21 (H-18), 1.34 (H-18’), 1.93 (H-19), 1.80 (H-19’), 
1.98 (H-20), 1.98 (H-20’) 
13C NMR (CDCl3):  35.7 (C-1), 35.1 (C-1’), 47.0 (C-2), 45.4 (C-2’), 64.3 (C-3), 68.0 (C-3’), 
41.6 (C-4), 45.2 (C-4’), 66.2 (C-5), 72.6 (C-5’), 67.1 (C-6), 117.4 (C-6’), 40.7 (C-7), 202.3 (C-
7’), 197.8 (C-8), 103.3 (C-8’), 134.4 (C-9), 132.5 (C-9’), 139.2 (C-10), 128.5 (C-10’), 123.3 
(C-11), 125.6 (C-11’), 145.0 (C-12), 137.1 (C-12’), 135.4 (C-13), 138.0 (C-13’), 136.6 (C-14), 
132.1 (C-14’), 129.4 (C-15), 132.5 (C-15’), 25.0 (C-16), 21.4 (C-16’), 28.1 (C-17), 32.0 (C-
17’), 21.5 (C-18), 31.6 (C-18’), 11.8 (C-19), 14.0 (C-19’), 12.7 (C-20), 12.9 (C-20’) (Afolayan, 
et al., 2008).  
Lapachol and its related compound 
Compound 3.6 
O
O
OH1
45
8
9
10
1'
3' 4'
5'
 
Yellow crystals; 1H NMR (CDCl3):  8.06 (d, 7.8 Hz, H-5), 7.67 (t, 7.5 Hz, H-6), 7.74 (t, 7.5 
Hz, H-7), 8.19 (d, 7.8 Hz, H-8), 3.30 (d, 7.6 Hz, H-1’), 5.21 (t, 7.6 Hz, H-2’), 1.68 (s, H-4’), 
1.78 (s, H-5’). 13C NMR (CDCl3):  181.7 (C-1), 152.6 (C-2), 123.4 (C-3), 184.5 (C-4), 126.7 
(C-5), 134.8 (C-6), 132.8 (C-7), 126.0 (C-8), 129.4 (C-9), 132.9 (C-10), 22.6 (C-1’), 119.6 (C-
2’), 133.8 (C-3’), 25.7 (C-4’), 17.8 (C-5’) (Oliveira, et al., 2002). 
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Compound 3.7 
O
O
O1
45
8
9
10
1'
3'
4'
5'
 
1H NMR (CDCl3):  8.07 (m, H-5), 7.67 (m, H-6), 7.67 (m, H-7), 8.07 (m, H-8), 2.61 (t, 6.6 
Hz, H-1’), 1.81 (t, 6.7 Hz, H-2’), 1.43 (s, H-4’), 1.43 (s, H-5’). 13C NMR (CDCl3):  180.0 (C-
1), 154.6 (C-2), 120.1 (C-3), 184.4 (C-4), 126.3 (C-5), 133. (C-6), 132.9 (C-7), 125.9 (C-8), 
131.1 (C-9), 132.0 (C-10), 16.7 (C-1’), 31.4 (C-2’), 78.1 (C-3’), 26.5 (C-4’), 26.5 (C-5’) (Salas, 
et al., 2008). 
Compound 3.8 
O
O
O
1
5
8 9
10 1'
3'
4'5'
 
1H NMR (CDCl3):  7.80 (d, 7.6 Hz, H-5), 7.49 (t, 7.8 Hz, H-6), 7.63 (t, 7.8 Hz, H-7), 8.05 (d, 
7.6 Hz, H-8), 2.56 (t, 6.5 Hz, H-1’), 1.82 (t, 6.7 Hz, H-2’), 1.46 (s, H-4’), 1.46 (s, H-5’). 13C 
NMR (CDCl3):  179.8 (C-1), 178.5 (C-2), 112.7 (C-3), 162.1 (C-4), 124.1 (C-5), 134.8 (C-6), 
130.9 (C-7), 128.5 (C-8), 130.1 (C-9), 132.6 (C-10), 16.1 (C-1’), 31.5 (C-2’), 79.3 (C-3’), 26.7 
(C-4’), 26.7 (C-5’) (Salas, et al., 2008). 
Compound 3.9 
O
O
O
OH
1
5
8 9
10 1'
3'
4'5'
 
1H NMR (CDCl3):  7.83 (d, 7.6 Hz, H-5), 7.51 (t, 7.6 Hz, H-6), 7.65 (t, 7.8 Hz, H-7), 8.06 (d, 
7.6 Hz, H-8), 2.82 (dd, 17.8 Hz, 5.3 Hz H-1a’), 2.62 (dd, 17.8 Hz, 5.6 Hz, H-1b’), 3.91 (t, 5.2 
Hz, H-2’), 1.45 (s, H-4’), 1.51 (s, H-5’). 13C NMR (CDCl3):  179.5 (C-1), 178.5 (C-2), 110.3 
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(C-3), 161.5 (C-4), 124.4 (C-5), 134.9 (C-6), 130.9 (C-7), 128.8 (C-8), 130.0 (C-9), 132.0 (C-
10), 22.1 (C-1’), 68.2 (C-2’), 81.4 (C-3’), 25.0 (C-4’), 25.4 (C-5’) (Salas, et al., 2008). 
Compound 3.10 
O
O
O
1
5
8 9
10
1'
3'
4'
5'
 
1H NMR (CDCl3):  7.57 (m, H-5), 7.63 (m, H-6), 7.63 (m, H-7), 8.07 (m, H-8), 2.94 (s, H-
1’), 1.60 (s, H-3’), 1.60 (s, H-4’). 13C NMR (CDCl3):  180.1 (C-1), 176.2 (C-2), 114.3 (C-3), 
168.8 (C-4), 124.1 (C-5), 133.5 (C-6), 129.2 (C-7), 128.3 (C-8), 131.1 (C-9), 133.4 (C-10), 
40.1 (C-1’), 94.1 (C-2’), 29.5 (C-3’), 29.5 (C-4’) (Kongkathip, et al., 2003). 
Compound 3.11 
O
O
OH
1
45
8
9
10
1'
3'
 
1H NMR (CDCl3):  8.08 (d, 7.7 Hz, H-5), 7.68 (t, 7.6 Hz, H-6), 7.76 (t, 7.7 Hz, H-7), 8.13 (d, 
7.8 Hz, H-8), 3.36 (d, 6.6 Hz, H-1’), 5.91 (m, H-2’), 5.91 (m, H-3a’), 5.05 (m, H-3b’). 13C 
NMR (CDCl3):  184.2 (C-1), 153.1 (C-2), 121.8 (C-3), 181.5 (C-4), 126.9 (C-5), 133.7 (C-6), 
133.0 (C-7), 126.1 (C-8), 129.3 (C-9), 132.8 (C-10), 27.5 (C-1’), 135.0 (C-2’), 116.4 (C-3’) 
(Silva, et al., 2006) 
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CHAPTER FOUR 
 
Synthesis of truncated sarganaphthoquinoic acid (SNQA) derivatives 
Abstract 
The quinone moiety was identified as the active component of secondary metabolites isolated from 
Sargassum incisifolium and Tabebuia avellanedae. Due to limited amounts of the natural products, 
prenylated naphthoquinone derivatives were designed and synthesized to improve the cytotoxicity of 
these compounds, and to develop them as potential Hsp90 inhibitors. The naphthoquinone moiety was 
constructed via Diels-Alder reactions of a range of benzoquinone analogues and myrcene, followed by 
MnO2 catalyzed aromatization. Various aryl and alkyl amines were then coupled to the quinone in the 
presence of Cu(OAc)2 to prepare a small library of compounds. The synthesized compounds were 
prepared in yields varying from 55-95% and characterized by Nuclear Magnetic Resonance (NMR) 
spectroscopy and mass spectrometry. 
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4.1 Introduction 
Naphthoquinones are a class of compounds that possess a wide spectrum of biological activities 
that include anti-bacterial, anti-inflammatory, anti-parasitic, anti-tumour and cytotoxic 
activities (Chung, et al., 2007). The quinone moiety is an essential component of these 
molecules and several drugs that are used in current treatments have the quinone nucleus as the 
core pharmacophoric element (Rahmoun, et al., 2013) e.g.  atovaquone (4.1) for the treatment 
and prevention of malaria (Ramirez, et al., 2014), mitomycin C (4.2) and doxorubicin (4.3) for 
treatment of cancer (Dubowchik, et al., 1998). In relation to cancer, quinones have been 
discovered to be effective inducers of apoptosis rather than the less preferred necrosis, which 
makes them ideal candidates for further investigation in cancer treatment (Ramirez, et al., 
2014).   
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4.1.1 Mechanism of action of cytotoxic naphthoquinones / quinones 
Two major mechanisms have been proposed for the cytotoxic action of quinones and 
naphthoquinones. Firstly, they possess the ability to undergo redox cycling effected by 
microsomal NADPH-cytochrome P-450 reductase or mitochondrial NADH ubiquinone 
oxidoreductase, thereby generating reactive oxygen species (ROS) that cause oxidative stress 
in cancer cells (Castro, et al., 2008). Secondly, quinones are susceptible to attack by 
nucleophiles e.g. thiol groups of proteins and reduced glutathione (GSH). Depletion of GSH 
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due to the formation of GS-conjugates catalysed by glutathione transferase isoforms has been 
the major cause of cytotoxicity and oxidative stress in cells (Seung, et al., 1998). Oxidative 
stress causes damage to proteins, cell membranes and DNA of cancer cells resulting in 
apoptosis. An example is presented below (Scheme 4.1) involving menadione and how ROS 
are generated and quenched in a biological system. 
O
O OH
O-
OH
OH
menadione
NAD(P)H NAD(P)+
1e[R]/H +
NAD(P)H
NAD(P)+
1e[R]/H+
NAD(P)H
NAD(P)+
2e[R]/2H+
O2
O2
detoxification
O2
-
   
 
.
O2
-
   
 
.
.
4.4
4.5
 
Scheme 4.1: Redox cycling reaction of menadione in cancer cells (Criddle, et al., 2006). 
Quinones undergo one electron reduction reactions to produce unstable semi-quinones (4.4). 
In the presence of molecular oxygen, semi-quinones enter into a redox cycle to regenerate the 
quinone but in the process generate ROS (Criddle, et al., 2006). NAD(P)H is used as the 
electron donor and its concentration in cells decrease as more ROS are formed. Another route 
that occurs concomitantly to the one described above involves transfer of two electrons in the 
reduction process by use of NAD(P)H:quinone oxidoreductase 1 to produce the more stable 
hydroquinone (4.5). This route is seen as a detoxifying mechanism and NAD(P)H:quinone 
oxidoreductase 1 concentrations have been observed to be elevated in cancer cells during 
chemotherapy (Dinkova-Kostova and Talalay, 2000).  
Other minor mechanisms highlighted for the quinones include DNA intercalation, alkylation, 
DNA strand breaks induction and inhibition of topoisomerase enzymes (Rahmoun, et al., 
2013). Their binding properties can occur in three different oxidation states, i.e. i) in the 
quinone form ii) semi-quinone form (one electron reduced form) and iii) catechol form (two 
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electron reduced form), allowing them to interact with biological systems at different levels 
(Pierpont, 2001).  
The following table (Table 4.1) gives examples of cytotoxic mechanisms of action of 
naphthoquinones as reported in literature. 
Table 4.1: Examples of naphthoquinones and their cytotoxic mode of action.  
Compound Structure Mode of Action Reference 
menadione O
O
 
 
Generates ROS and 
cause oxidative stress 
 
(Seung, et al., 1998) 
diospyrin O
O
O
O
OH
OH
 
Inhibits action of 
topoisomerase I 
enzymes. 
Inhibits electron 
transport chain 
 
(Sagar, et al., 2010) 
isodiospyrin 
O O
O
O OH
OH
 
 
Inhibits action of 
topoisomerase I 
enzymes 
 
(Ting, et al., 2003) 
juglone O
OOH
 
DNA damage and 
inhibition of 
transcription enzymes 
(Paulsen and Ljungman, 
2005) 
plumbagin O
O OH
 
 
Generates ROS and 
causes oxidative stress 
 
(Lee, et al., 2012) 
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4.1.2 Synthetic methodologies for the construction of naphthoquinones 
Due to naphthoquinone’s diversity in biological activity, vast attention has been given to 
develop methods that can be employed to synthesize these molecules. One of the most common 
methods used is the Diels-Alder reaction (Witayakran and Ragauskas, 2007). In this reaction, 
benzoquinones act as dienophiles that react with dienes to form a Diels-Alder adduct (Scheme 
4.2), followed by aromatization to the naphthoquinone. 
O
O
R
+
O
O
R
O
O
R
dienophile diene Diels-Alder adduct naphthoquinone
oxidantheat or catalyst
 
Scheme 4.2: General Diels-Alder and aromatization reactions 
Various catalysts have been used to improve the outcome of the Diels-Alder reaction i.e. 
BF3·Et2O, Lewis acids etc., together with ultrasonic or microwave irradiation (Miguel del 
Corral, et al., 2002). In older methods, only heat was employed to form the Diels-Alder adduct, 
followed by aromatization to the naphthoquinone. Use of oxidants such as Ag2O, CAN and 
DDQ have been investigated in aromatization reactions but they give rise to complex mixtures 
that are difficult to isolate and purify. Only MnO2 yields fairly distinct cyclized adducts and 
has been the most preferred in aromatizing Diels-Alders adducts (Miguel del Corral, et al., 
2002).  
Other methods that have been employed to synthesize naphthoquinones involve oxidation of 
naphthols from benzenoid precursors e.g. o-allyl-p-cresol (Achari, et al., 1985) and methoxy-
allylbenzamides, (Sibi, et al., 1986) or through rearrangement of hydroxycyclobutenones 
(Scheme 4.3). Presently, the Diels-Alder reaction is superior in preparing naphthoquinones and 
a similar method was adapted for the synthesis of our series of analogues discussed in this 
chapter.  
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Scheme 4.3: Summary of naphthoquinone syntheses 
4.1.3 Aim of this study 
Investigation into the cytotoxic properties and Hsp90 inhibition of sarganaphthoquinoic acid 
(SNQA) (3.5) was limited due to the quantities of natural product we obtained. Semi-synthetic 
routes developed by our group to prepare 3.5 from sargahydroquinoic acid (3.1) only yielded 
minute quantities and the reaction was unpredictable and fell short of reproducibility. 
Optimization of the reaction is essential and warrants further investigation. However for this 
part of the project, we resorted to truncated sarganaphthoquinoic acid derivatives, with 
modifications targeted at increasing cytotoxic nature of these molecules. Their Hsp90 
inhibition properties were then assessed.  
Therefore, the aim of the project was to design and synthesize prenylated naphthoquinone 
analogues with improved cytotoxic activity and Hsp90 binding properties. 
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4.2 Results and discussion 
4.2.1 Rationale for the design of prenylated naphthoquinone derivatives 
Our design strategy was centred on incorporating moieties from known Hsp90 inhibitors onto 
our naphthoquinone scaffold, with the anticipation of enhancing their properties towards Hsp90 
binding and also maintaining their cytotoxic properties. Scheme 4.4 briefly highlights targeted 
compounds that were synthesized for this project.
O
O
COOH
O
O
COOH
O
O
O
O
NH
N
O
O
NHO
O
NH
R
O
O
NH
allyl analogue (17-AAG)
dimethyl amino analogue (17-DMAG)arylamino analogues (novobiocin)
conversion of quinone 
SNQA
alkyne analogue
(access to probe binding)
easily accessible 
truncated naphthoquinone analogue
to naphthoquinone
SQA
O
O
S
N
H
O O
O
O
O
chromene-naphthoquinone hybridthiazinonaphthoquinone

Scheme 4.4:Analogue design strategy 
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4.2.2 Synthesis of the naphthoquinone scaffold by the Diels-Alder reaction 
The first series constituted simple naphthoquinone derivatives bearing H, CH3, OCH3 and Cl 
substituents at the C-2 or C-3 position of the quinone moiety. The aim was to evaluate the 
importance of position 2 and 3 in cytotoxicity and Hsp90 inhibition of naphthoquinones. 
Substituents were chosen based on their electron withdrawing and electron donating properties.  
Benzoquinones 4.7 and 4.9 are commercially available while 2-methoxybenzoquinone (4.8) 
was prepared via oxidation of 2-methoxyhydroquinone by MnO2. Reactions of p-
benzoquinones 4.7-4.9 with myrcene in refluxing EtOH gave isomeric mixtures of the 2- and 
3- substituted Diels-Alder products. This product was immediately oxidized to the 
naphthoquinone derivative with MnO2 under reflux for four hours in C6H6 (Scheme 4.5). Other 
aromatization reactions explored included reactions with KOH and DDQ. The former yielded 
mainly 2- and 3- hydroxylated products while the latter yielded complex mixtures (Miguel del 
Corral, et al., 2002). MnO2 was thus the preferred oxidant to use in all naphthoquinone 
syntheses conducted for this research. Final purification of naphthoquinones 4.11-4.13 was 
achieved by column chromatography and normal phase HPLC. 
O
O
R
+
O
O
O
O
R
R
O
O
R
MnO2EtOH
70-80 oC, 5h 80-85 
oC, 4h
+
4.6 R = H
4.7 R = Cl
4.8 R = OCH3
4.9 R = CH3
4.10 R = H
4.11 R = Cl
4.12 R = OCH3
4.13 R = CH3
 
 
Scheme 4.5: Preparation of naphthoquinones via Diels-Alder and aromatization reactions 
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The synthesized naphthoquinones were characterized by 1D and 2D NMR spectroscopy. 
Representative 1H and 13C NMR spectra for naphthoquinones (4.10-4.13) are presented in 
Figure 4.1 and Figure 4.2 respectively for compound 4.10. 
O
O
1
4 5
8
1' 6'
5'
4.10
 
Figure 4.1: 1H NMR spectrum (600 MHz, CDCl3) of compound 4.10 
 
Figure 4.2: 13C NMR spectrum (150 MHz, CDCl3) of compound 4.10 
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In the 1H NMR spectrum (Figure 4.1), the naphthoquinone moiety was characterized by a set 
of mutually coupled aromatic doublets at  7.98 (d, J = 7.8 Hz, H-8) and  7.55 (d, J = 7.8 Hz, 
H-7), a methine singlet at  7.88 (s, H-5) and a benzoquinone methine proton at  6.93 (s, H-2 
and H-3). The presence of C-1 and C-4 carbonyl carbons was observed in the 13C NMR 
spectrum at  185.4 and  184.9 respectively. The prenyl side chain was represented by a triplet 
at  2.76 (t, J = 7.8 Hz, H-1’) coupled to a quartet at  2.34 (q, J = 7.5 Hz, H-2’), which in turn 
was coupled to an olefinic methine at  5.11 (t, J = 7.1 Hz, H-3’). Two methyl signals observed 
at  1.66 (s, H-6’) and  1.52 (s, H-5’) completed the side chain. In total, the 13C NMR spectrum 
showed the presence of four methyl and methylene carbons in the region  16-40, four 
quaternary carbons and six methine carbons consistent with compound 4.10. The spectroscopic 
data matched literature values (Miguel del Corral, et al., 2002) and is shown in Table 4.3. 
 The 1H and 13C NMR spectra of compounds 4.11, 4.12, 4.13 were similar to that of compound 
4.10 apart from signals corresponding to the -OCH3 at  3.89 (s) and -CH3 at  2.18 (s) 
appearing for compounds 4.12 and 4.13, respectively. The integration of the aromatic protons 
to the benzoquinone signal reduced from two to one, indicative of a substituted molecule at 
position 2 or 3. Due to two possible substitution patterns that can occur on the molecule, the 
initial 1H NMR spectra for compounds 4.11- 4.13 had duplicated signals in the aromatic region. 
The regioisomers were separated by normal phase HPLC (Hex/EtOAc) and a representative 
chromatogram obtained for compound 4.11 is shown in Figure 4.3.   
      
Figure 4.3: Normal phase HPLC chromatogram showing separation of the two regioisomers, 
eluting at different retention times of 18 min and 20 min. 
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The ratios of the individual isomers in the mixture were calculated relative to peak heights on 
the HPLC chromatograms, and the retention times were noted (Table 4.2). Isomer A appeared 
to elute first from the HPLC, followed by isomer B.  
Table 4.2: Percentage yields and HPLC fractions obtained 
Compound % yield Ratio of isomers Retention times (mins) 
 
 A (%) B (%) A B 
4.11 83.3 49.8 50.2 18.6 20.0 
4.12 84.6 49.6 50.4 34.1 35.7 
4.13 98.4 50.0 50.0 23.9 25.0 
 
The two regioisomers were identified based on their HMBC correlations which are shown in 
Figure 4.4 and Figure 4.5 for compounds 4.11A and 4.11B respectively. Several aspects are 
essential to note with these correlations:  
i) The two carbonyl carbons were distinguished based on their HMBC correlations to H-5 and 
H-8 
ii) Aromatic protons mainly correlate to carbonyl carbons that are three bonds away; two bond 
correlations are often missing in these systems.  
 
Figure 4.4: HMBC corrections of compound 4.11A 
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Figure 4.5: HMBC corrections of compound 4.11B 
Based on these aspects, a correlation of H-8 to the same carbonyl (C-1) as the benzoquinone 
signal indicates substitution at C-2. Correlation of H-5 and the benzoquinone signal to the same 
carbonyl (C-4) suggests substitution at C-3. Isomers 4.11A and 4.11B were therefore 
determined as having the halogen at C-2 and C-3, respectively. Such analysis is consistent with 
work published by Miguel del Corral and colleagues (2006).  
Comparisons were also done between the acquired 1H NMR spectra, before and after separation 
of the regioisomers (Figure 4.6 and 4.7) and it was noticed that C-3 substitution resulted in a 
more deshielded H-5 signal compared to C-2 substitution, which potentially could be used to 
distinguish the isomers. Similar patterns were observed in other substituted naphthoquinone 
derivatives, 4.12 and 4.13. Table 4.3 contains a list of all 1H and 13 C chemical shifts of isomers 
belonging to compounds 4.10-4.13.  
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Figure 4.6: 1H NMR spectra (600 MHz, CDCl3) of compound 4.11 as a mixture and of the 
individual isomers after separation by normal phase HPLC. 
 
Figure 4.7: Expansion of the aromatic region of the 1H NMR spectra (600 MHz, CDCl3) of 
compound 4.11 regioisomers. 
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Table 4.3: 1H and 13C NMR chemical shifts of compounds 4.10-4.13 
 4.10 4.11A 4.11B 4.12A 4.12B 4.13A 4.13B 
C no.  H, mult,  
J(Hz) 
 C  H, mult,  
J(Hz) 
 C  H, mult,  
J(Hz) 
 C  H, mult,  
J(Hz) 
 C  H, mult,  
J(Hz) 
 C  H, mult,  
J(Hz) 
 C  H, mult,  
J(Hz) 
 C 
1 - 184.9 - 177.8 - 182.6 - 180.2 - 182.9 - 185.5 - 185.9 
2 6.93, s 138.5 - 146.4 7.18, s 135.9 - 155.3 6.13, s 113.2 - 148.2 6.80, s 133.9 
3 6.93, s 138.7 7.19, s 135.7 - 146.1 6.14, s 113.4 - 155.6 6.80, s 133.8 - 147.9 
4 - 185.4 - 183.0 - 178.3 - 183.1 - 181.1 - 185.6 - 185.0 
5 7.88, s 126.5 7.89, s 126.6 7.97, s 127.4 7.89, s 127.1 7.93, s 127.9 7.86, s 126.7 7.90, s 126.4 
6 - 149.4 - 150.2 - 149.8 - 149.5 - 149.9 - 149.2 - 149.0 
7 7.55, dd, 
7.8; 1.7 
134.1 7.56, d, 
7.9 
134.3 7.57, d, 
7.7 
134.7 7.51, d, 
7.8 
135.6 7.53, d,  
7.9 
135.8 7.52, dd, 
7.8, 1.7 
135.5 7.52, dd, 
7.8; 1.7 
135.7 
8 7.98, d, 
7.8 
126.2 8.07, d, 
7.8 
127.7 7.99, d, 
7.7 
126.8 8.03, d 
7.8 
126.7 7.98, d 
7.9 
126.8 8.00, d, 
7.8 
125.9 7.95, d,  
7.8 
126.2 
9 - 129.9 - 129.2 - 129.7 - 131.5 - 131.7 - 130.1 - 130.2 
10 - 133.1 - 133.3 - 133.3 - 133.8 - 132.0 - 133.1 - 133.1 
1’ 2.76, t, 7.8 36.2 2.78, t, 7.7 36.2 2.78, t, 7.7 36.1 2.76, t, 7.6 36.3 2.75, t, 7.6 36.2 2.75, t, 7.5 36.2 2.76, t, 7.6 36.2 
2’ 2.34, q, 
7.5 
29.3 2.34, q, 
7.6 
29.2 2.34, q, 
7.4 
29.2 2.34, q, 
7.4 
29.4 2.34, q, 
7.6 
29.5 2.34, q, 
7.2 
29.3 2.33, q, 
7.5  
29.4 
3’ 5.11, t, 7.1 122.5 5.11, t, 7.1 122.4 5.11, t, 7.0 122.4 5.12, t, 7.1 122.5 5.12, t, 7.2 122.6 5.12, t, 7.1 122.6 5.12, t, 7.3 122.6 
4’ - 131.8 - 131.7 - 131.2 - 132.0 - 131.9 - 132.2 - 132.0 
5’ 1.54, s 17.6 1.52, s 17.6 1.52 17.7 1.53, s 17.6 1.52, s 17.7 1.52, s 17.7 1.52, s 17.7 
6’ 1.66, s 25.6 1.66, s 25.6 1.67 25.6 1.67, s 25.6 1.66, s 25.6 1.66, s 25.6 1.66, s 25.7 
7’       3.89, s 58.8 3.89, s 58.9 2.18, s 16.5 2.18, s 16.5 
NB. C-2 substituted naphthoquinones are presented as isomer A and C-3 substituted ones as isomer B 
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4.2.3 Synthesis of arylamino-naphthoquinones (second series) 
2-Amino-1, 4-naphthoquinone moieties have been found to possess cytotoxic properties. They 
are known to take part in enzyme inhibition, DNA cross linking, as well as interfering with 
electron transport and oxidative phosphorylation systems (Miguel del Corral, et al., 2005; Ryu, 
et al., 2000). Two major methods have been developed to synthesize these molecules, and 
involve either oxidative coupling reactions of amines to unsubstituted naphthoquinones on C-
2/3 position or via nucleophilic substitution of 2-halonaphthoquinones (Lisboa, et al., 2011). 
For this part of the project, the former method was used to prepare our second series of 
naphthoquinones. 
Several anilines were coupled to compound 4.10. Under normal conditions the reaction can be 
carried out in EtOH at room temperature with no catalyst, but longer reaction times of 
approximately 72 hours are required. A quicker and more efficient method has been developed 
which requires use of Cu(OAc)2 as a catalyst in AcOH, at a temperature range of 60-70 °C. The 
reaction is complete within 30-40 min with stirring under atmospheric O2 (Lisboa, et al., 2011). 
4-Para substituted anilines were selected and a general reaction scheme is shown below for 
their preparation (Scheme 4.6).  
 
O
O
NH2
R
+
Cu(OAc)2 , AcOH
60-70 oC , 30-40 mins
4.10
4.14 R = H
4.15 R = CH3
4.16 R = OCH3
4.17 R = Cl
4.18 R = CF3
O
O
NH
R
O
O
NH
R
+
 
Scheme 4.6: Oxidative coupling of amines and naphthoquinones using Cu(OAc)2 as a 
catalyst 
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Choice of substituents was based on electron donating and electron withdrawing properties, on 
the para-position to the amine functionality. A general reaction mechanism proposed by 
Lisboa, et al. is shown in Scheme 4.7, indicating the role of Cu (II) in this reaction. 
O
O
NH
OH
O-Cu(II)
NH2
NH
O-Cu(II)
O-Cu(II)
AcOH AcOH
OH
NH
O
O
NH
O O
NH
O
Cu(II) salt
Cu(0)
Cu(I)
Cu(I) Cu(II)
ROS 1/2 O2 + AcOH
mechanism (i)
mechanism (ii)mechanism (iii) 2 Cu(1)
 
Scheme 4.7: Role of Cu(OAc)2 in oxidative coupling of anilines and 1, 4-naphthoquinone 
(Lisboa, et al., 2011) 
 
The addition-oxidation reaction to C-2 or C-3 position via nucleophilic attack by the amine is 
facilitated by formation of a complex between the quinone and Cu (II). Either one or both of 
the carbonyl groups can be involved in the complexation reaction, followed by direct 
interaction with atmospheric O2 to yield back the quinone functionality. Conversion to the 
quinone can occur by a one electron oxidation step that produces Cu (I) and is oxidized back 
to Cu (II) by O2, but in the process generating ROS. ROS in the presence of Cu(I) or Cu(0) and 
AcOH eventually take part in the regeneration of Cu(OAc)2 and H2O. Any copper salts at the 
end of the reaction are easily removed by solubilizing the product in CH2Cl2 and passing it 
through a plug of silica gel, eluting with CH2Cl2 (Lisboa, et al., 2011). High percentage yields 
have been reported by this method with the formation of fewer side products (Lisboa, et al., 
2011) 
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Regioisomers were also obtained with this series of naphthoquinones due to the amination of 
quinones occurring either at the C-2 or C-3 position. The two isomers were separated by normal 
phase HPLC and calculated ratios of the isomers in the mixtures showed an approximate ratio 
of 1:1. As was with the case with the first series of compounds, the A isomer was eluted first, 
followed by the B isomer (Table 4.4). 
Table 4.4: Percentage yields and HPLC fractions obtained 
Compound % yield Ratio of isomers Retention times (mins) 
 
 A (%) B (%) A B 
4.14 96.2 50.0 50.0 23.8 26.8 
4.15 79.5 50.6 49.4 23.5 27.1 
4.16 89.3 49.7 50.3 22.3 25.3 
4.17 84.3 49.9 50.1 23.5 23.9 
4.18 72.1 49.5 50.5 21.0 23.4 
4.19 81.9 50.3 49.7 19.6 21.3 
 
The separated isomers were characterized by 1D and 2D NMR spectroscopy. The 
naphthoquinone and prenyl side chain signals were clearly visible in the 1H and 13C NMR 
spectra as described above. Additional signals were noticed between  6.90 -  7.70, and 
between  120 -  140 in the 1H and 13C NMR spectra, representing the methine protons and 
methine carbons of the aniline moiety, respectively. Table 4.5 and Table 4.6 display the 1H 
and 13C NMR chemical shifts of compounds 4.14-4.19.  
The 1H NMR chemical shift for H-7 and the 13C NMR chemical shift for C-6 were used to 
distinguish between the isomers.  This was consistent with the analysis conducted in literature 
on similar types of compounds in which C-2 substitution resulted is a less deshielded H-7 signal 
but with a more deshielded C-6 signal compared to C-3 substituted compounds (Miguel del 
Corral, et al., 2005). 
For compounds 4.17, 4.18 and 4.19, high resolution mass spectroscopy data was also obtained 
to fully ascertain the presence of the Cl, CF3 and methylenedioxy moieties. Compounds 4.17, 
4.18 and 4.19 had adduct ions at 366.1249, 400.1592 and 376.1534, corresponding to molecular 
formulae of C22H21NO2Cl+H, C23H21NO2F3+H and C23H22NO4+H, respectively for the A 
isomer. The relevant spectroscopic data is displayed in the supplementary section (Figures 
S4.29-S4.57)  
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Table 4.5: 1H and 13C NMR chemical shifts of compound 4.14-4.16 
 4.14A 4.14B 4.15A 4.15B 4.16A 4.16B 
Carbon no.  H, mult, 
J(Hz) 
 C  H, mult, 
J(Hz) 
 C  H, mult, 
J(Hz) 
 C  H, mult, 
J(Hz) 
 C  H, mult, 
J(Hz) 
 C  H, mult, 
J(Hz) 
 C 
1 - 181.8 - 184.3 - 181.9 - 184.1 - 181.9 - 183.9 
2 - 144.8 6.39, s 103.4 - 145.1 6.32, s 102.9 - 145.8 6.19, s 102.7 
3 6.40, s 103.2 - 144.6 6.33, s 102.8 - 144.9 6.20. s 102.3 - 145.6 
4 - 184.4 - 182.5 - 184.3 - 182.5 - 184.1 - 182.4 
5 7.92, s 126.2 7.93, s 126.4 7.92, s 126.2 7.92, s 126.4 7.92, s 126.2 7.92, s 126.3 
6 - 150.7 - 147.6 - 150.7 - 147.5 - 150.6 - 147.4 
7 7.46, dd, 7.6; 
1.5 
132.5 7.56, dd, 7.8; 
1.8 
135.0 7.45, d, 7.9 132.4 7.55, d, 7.9 135.1 7.44, d, 7.8 132.3 7.55, d, 7.8 135.0 
8 8.03, d, 7.6 126.8 8.01, d, 7.8 126.1 8.02, d, 7.9 126.7 8.00, d, 7.9 126.2 8.01, d, 7.8 126.7 7.99, d, 7.8 126.2 
9 - 128.2 - 131.2 - 133.3 - 131.2 - 133.4 - 131.3 
10 - 133.2 - 130.4 - 128.3 - 128.8 - 128.3 - 130.3 
11 - 137.5 - 137.4 - 135.5 - 135.5 - 130.1 - 130.1 
12 7.27, d, 7.9  122.5 7.27, d, 7.7 122.5 7.21, d, 8.2 130.2 7.21, d, 8.3 130.2 7.19, d, 8.9 124.8 7.20, d, 8.9 124.7 
13 7.42, t, 7.6 129.6 7.42, t, 7.6 129.7 7.16, d, 8.2 122.7 7.16. d, 8.3 122.6 6.94, d, 8.9 114.9 6.94, d, 8.9 114.8 
14 7.21, t, 7.4 125.5 7.21, t, 7.5 125.6 - 134.8 - 134.8 - 157.7 - 157.7 
15 7.42, t, 7.6 129.6 7.42, t, 7.6 129.7 7.16, d, 8.2 122.7 7.16, d, 8.3 122.6 6.94, d, 8.9 114.9 6.94, d, 8.9 114.8 
16 7.27, d, 7.9 122.5 7.27, d, 7.7 122.5 7.21, d, 8.2 130.2 7.21, d, 8.3 130.2 7.19, d, 8.9 124.8 7.20, d, 8.9 124.7 
1’ 2.76, t, 7.6 36.5 2.76, t, 7.6 36.1 2.76, t, 7.5 36.5 2.76, t, 7.6 36.0 2.76, t, 7.5 36.5 2.76, t, 7.5 36.0 
2’ 2.34, q, 7.6 29.3 2.35, q, 7.6 29.4 2.34, q, 7.5 29.4 2.34, q, 7.4 29.4 2.34, q, 7.6 29.4 2.35, q, 7.6 29.4 
3’ 5.13, t, 7.1 122.6 5.14, t, 7.1 122.6 5.13, t, 7.1 122.7 5.13, t, 7.2 122.6 5.13, t, 7.2 122.7 5.14, t, 7.1 122.7 
4’ - 133.1 - 133.1 - 133.1 - 133.1 - 133.0 - 133.1 
5’ 1.53, s 17.7 1.54, s 17.6 1.53, s 17.7 1.53, s 17.7 1.54, s 17.6 1.54, s 17.7 
6’ 1.67, s 25.7 1.68. s 25.7 1.67, s 25.7 1.68, s 25.7 1.67, s 25.6 1.68, s 25.7 
7’ - - - - 2.36, s 21.0 2.36, s 21.0 3.83, s 55.6 3.83, s 55.6 
  NB. C-2 substituted naphthoquinones are presented as isomer A and C-3 substituted ones as isomer B 
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Table 4.6: 1H and 13C NMR chemical shifts of compound 4.17-4.19         
 4.17A 4.17B 4.18A 4.18B 4.19A 4.19B 
Carbon 
no. 
 H, mult, 
J(Hz) 
 C  H, mult, 
J(Hz) 
 C  H, mult, 
J(Hz) 
 C  H, mult, 
J(Hz) 
 C  H, mult, 
J(Hz) 
 C  H, mult, 
J(Hz) 
 C 
1 - 183.2 - 184.1 - 181.4 - 184.2 - 181.8 - 184.0 
2 - 144.5 6.33, s 103.7 - 143.7 6.50, s 104.9 - 133.3 6.20, s 102.7 
3 6.33, s 103.5 - 144.3 6.50, s 104.7 - 143.5 6.21, s 101.7 - 131.2 
4 - 184.3 - 182.1 - 184.4 - 182.0 - 184.1 - 182.3 
5 7.92, s 126.2 7.92, s 126.5 7.93, s 126.3 7.94, s 126.3 7.91, d, 1.7 126.2 7.91, d, 1.7 126.3 
6 - 150.9 - 147.7 - 151.0 - 148.0 - 150.6 - 148.4 
7 7.47, d, 7.8 132.6 7.56, d, 7.9 135.2 7.49, d, 7.9 132.9 7.58, d, 7.9 135.4 7.45, dd, 7.8; 
1.8 
132.6 7.55, dd, 7.9; 
1.8 
135.0 
8 8.03, d, 7.9 126.8 8.00, d, 7.8 126.3 8.04, d, 7.9 126.6 8.01, d, 7.9 126.4 8.01, d, 7.8 126.7 7.99, d, 7.9 126.2 
9 - 133.2 - 131.0 - 133.2 - 130.8 - 131.3 - 131.3 
10 - 128.2 - 130.7 - 128.1 - 130.1 - 128.7 - 130.3 
11 - 130.1 - 130.1 - 140.7 - 140.7 - 148.5 - 145.5 
12 7.21, d, 8.8 123.7 7.22, d, 8.7 123.7 7.38, d, 8.5 126.9 7.38, d, 8.4 126.9 6.77, d, 2.2 104.9 6.78, d, 2.2 104.8 
13 7.33, d, 8.8 129.8 7.38, d, 8.7  129.8 7.67, d, 8.5 121.5 7.67, d, 8.5 121.5 - 145.6 - 147.5 
14 - 136.1 - 136.1 - 141.0 - 141.0 - 145.7 - 147.7 
15 7.33, d, 8.8 129.8 7.38, d, 8.7 129.8 7.67,d, 8.5 121.5 7.67, d, 8.5 121.5 6.83, d, 8.2 108.7 6.83, d, 8.2 108.6 
16 7.21, d, 8.8 123.7 7.22, d, 8.7 123.7 7.38, d, 8.5 126.9 7.38, d, 8.4 126.9 6.71, dd, 8.2; 
2.7 
116.9 6.72, dd, 8.3; 
2.1 
116.1 
1’ 2.77, t, 7.5 36.5 2.76, t, 7.5 36.0 2.77, t, 7.5 36.5 2.77, t, 7.5 36.0 2.76, t, 7.5 36.5 2.76, t, 7.5 36.0 
2’ 2.35, q, 7.5 29.4 2.34, q, 7.5 29.4 2.35, q, 7.5 29.3 2.35, q, 7.5 29.4 2.34, q, 7.5 29.3 2.35, q, 7.5 29.4 
3’ 5.13, t, 7.2 122.6 5.13, t, 7.1 122.6 5.13, t, 7.1 122.6 5.13, t, 7.2 122.6 5.13, t, 7.2 122.7 5.13, t, 7.2 122.5 
4’ - 133.0 - 133.2 - 132.8 - 133.2 - 133.1 - 133.1 
5’ 1.54, s 17.6 1.53, s 17.6 1.53, s 17.6 1.53, s 17.6 1.53, s 17.7 1.54, s 17.7 
6’ 1.67, s 25.7 1.68, s 25.7 1.67, s 25.7 1.67, s 25.7 1.67, s 25.6 1.68, s 25.6 
7’ - - - - - 124.7 - 124.7 6.01, s 101.7 6.01, s 101.5 
NB. C-2 substituted naphthoquinones are presented as isomer A and C-3 substituted ones as isomer B 
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4.2.4 Synthesis of alkylamino-naphthoquinones (third series) 
The design of this series was centred on incorporating features of known Hsp90 inhibitors into 
the naphthoquinone scaffold. Firstly, allylamine and N, N-dimethylethyleneamine moieties, 
that are present on 17-AAG and 17-DMAG, were incorporated on the naphthoquinone scaffold 
to afford compounds 4.20 and 4.21 respectively. Additional functionalities were introduced to 
increase aqueous solubility and to allow for further manipulation of the alkyl amine side chain. 
Increasing reactivity by introducing epoxide functionalities (4.25-4.26) was also attempted and 
the synthesized derivatives are shown below1.  
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NB: 2-subsituted products are shown but both 2- and 3-substituted products were isolated 

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Preparation of alkylamino-naphthoquinones 4.20-4.23 was conducted without the use of a 
catalyst. The amine and naphthoquinone were stirred in MeOH at room temperature for 48 
hours under atmospheric O2, with a simple workup protocol that involved evaporating the 
solvent and purifying the product by column chromatography.  Published reports with regards 
to use of catalytic amounts of Cu(II)OAc for this reaction had shown that several side products 
may result in the presence of copper ions including cyclization reactions of alkylamines 
(Lisboa, et al., 2011). In order to avoid any side products forming, the catalyst was excluded 
with regards to alkylamines.   
O
O
+
O
O
NH
R
MeOH
stirring, r.t, 48h
4.10
NH2R
4.20 R =
4.21 R = N
4.22 R =
OH
4.23 R =
O
O
NH
R+
 
Scheme 4.8: General scheme for the preparation of alkyl amino-naphthoquinones 4.20-4.23 
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The desired products were acquired in fairly good yields as indicated below (Table 4.7). The 
regioisomers were also isolated by normal phase HPLC and the calculated ratio of isomers in 
the mixture also indicated a 1:1 proportion of each isomer.  
Table 4.7: Percentage yields and HPLC fractions obtained 
Compound % yield Ratio of isomers Retention times (mins) 
 
 A (%) B (%) A B 
4.20 71.8 50.3 49.7 24.0 27.2 
4.22 71.7 49.8 50.2 19.3 21.6 
4.23 73.5 50.0 50.0 25.7 28.1 
 
Characterization of the individual isomers by 1D NMR showed the presence of the described 
signals for the naphthoquinone and prenyl side chain in the 1H and 13C NMR spectra of 
compounds 4.20-4.23. Additional signals displayed belonged to the substituents attached to the 
C-2 or C-3 position of the quinone moiety. For compound 4.20, of importance was a methylene 
triplet observed at  3.83 (t, J = 5.7 Hz, H-11) coupled to an olefinic methine at  5.87 (m, H-
12), and two terminal methylene protons appearing as a multiplet at  5.28 (m, H-13) coupled 
to H-8’ giving a -CH=CH2 structural motif. The carbon shift values for the allylamine chain 
were observed at  44.8 (C-11),  131.5 (C-12) and  118.1 (C-13) on the 13C NMR spectrum.  
Compound 4.22A had additional signals at  2.90 (t, J = 7.2 Hz, H-12) and  3.39 (q, J = 7.0 
Hz, H-11) representing two mutually coupled methylene protons, and more deshielded 
doublets at  6.80 (d, J = 8.5 Hz, H-14) and  7.08 (d, J = 8.5 Hz, H-15) belonging to the aryl 
moiety. The 13C NMR spectrum had two additional methylene signals displayed at  43.8 (C-
11) and  33.4 (C-12), and two additional aromatic carbons at  115.7 (C-14, C-18) and  129.8 
(C-15, C-17).  
The substituent on compound 4.23A was represented by a methylene singlet at  3.99 (s, H-
11) and a methine signal overlapping with a quartet at  2.34 (m, H-2’). The terminal alkyne 
C-H signal was observed at  73.1 (C-13), its quaternary carbon at  88.0 (C-12) and the 
methylene carbon at  32.2 (C-11). The descriptions given were for the A isomers of 
compounds 4.20-4.23. The other 1H and 13C NMR chemical shifts are presented in Table 4.8.  
Compound 4.21 was successfully synthesized but separation of the respective isomers by the 
HPLC method used was unsuccessful. It showed characteristic signals at  3.20 (q, J = 5.8 Hz, 
H-11) and  2.62 (t, J = 5.8 Hz, H-12) representing two mutually coupled sets of methylene 
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protons, and two methyl groups observed as one signal at  2.29 (s, H-13a and H-13b). C-2 or 
C-3 substitution resulted in a less deshielded benzoquinone methine signal observed at  5.68 
or  5.67 (s, H-2 or H-3). Additional carbons were noticed on the 13C NMR spectrum at  39.5 
(C-11),  56.4 (C-12) and  45.0 (C-13a & 13b). The 1H and 13C NMR spectrum for compound 
4.21 are shown in the supplementary section (Figure S4.140-S4.141). 1H and 13C NMR data 
obtained for compounds 4.20-4.23 were as expected and matched the theoretically calculated 
values (Table 4.8) 
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Table 4.8: 1H and 13C NMR chemical shifts of compound 4.20 – 4.23        
NB. C-2 substituted naphthoquinones are presented as isomer A and C-3 substituted ones as isomer B 
 
 4.20A 4.20B 4.22A 4.22B 4.23A 4.23B 
Carbon 
no. 
 H, mult, 
J(Hz) 
 C  H, mult, 
J(Hz) 
 C  H, mult, 
J(Hz) 
 C  H, mult, 
J(Hz) 
 C  H, mult, 
J(Hz) 
 C  H, mult, 
J(Hz) 
 C 
1 - 181.6 - 183.3 - 181.5 - 183.2 - 181.3 - 183.3 
2 - 148.0 5.70, s 101.4 - 147.9 5.73, s 100.8 - 147.1 5.80, s 102.5 
3 5.71, s 101.3 - 147.7 5.74, s 101.1 - 147.7 5.81, s 102.4 - 147.4 
4 - 183.4 - 182.1 - 183.4 - 182.1 - 183.5 - 181.8 
5 7.91, s 126.5 7.86, s 126.3 7.93, s 126.5 7.83, s 126.3 7.92, s 126.5 7.86, s 126.4 
6 - 150.5 - 147.1 - 150.6 - 147.1 - 150.8 - 147.0 
7 7.41, d, 7.9 132.1 7.52, d, 7.9 135.0 7.40, d. 7.8 132.1 7.52, d, 7.8 135.0 7.43, d, 7.9 132.4 7.53, d, 7.8 135.0 
8 7.95, d, 7.9 126.2 7.99, d, 7.9 126.2 7.92, d, 7.8 126.2 7.99, d, 7.8 126.2 7.96, d, 7.9 126.3 8.00, d, 7.8  126.2 
9 - 128.3 - 131.6 - 128.4 - 130.4 - 128.3 - 130.3 
10 - 133.5 - 130.3 - 133.6 - 131.5 - 133.3 - 131.2 
11 3.83, t, 5.7 44.8 3.83, t, 5.7 44.9 3.40, q, 6.9 43.7 3.39, q, 7.0 43.8 3.98, s 32.3 3.98, s 32.2 
12 5.87, m 131.5 5.88, m 131.4 2.90, t, 7.2 33.7 2.90, t, 7.1 33.4 - 88.0 - 88.0 
13 5.29, m 118.1 5.29, m 118.2 - 129.9 - 129.9 2.34, m 73.1 2.33, m 73.3 
14 - - - - 6.80, d, 8.5 116.0 6.80, d, 8.5 115.7 - - - - 
15 - - - - 7.08, d, 8.5 129.8 7.08, d, 8.5 129.8 - - - - 
16 - - - - - 154.8 - 154.6 - - - - 
17 - - - - 7.08, d, 8.5 129.8 7.08, d, 8.5 129.8 - - - - 
18 - - - - 6.80, d, 8.5 116.0 6.80, d, 8.5 115.7 - - - - 
1’ 2.76, t, 7.6 36.4 2.73, t, 7.5 35.9 2.74, t, 7.5 36.5 2.72, t, 7.5 35.9 2.75, t, 7.6 36.4 2.74, t, 7.5 35.9 
2’ 2.33, q, 7.7 29.3 2.32, q, 7.6 29.4 2.33, q, 7.5 29.7 2.32, q, 7.5 29.4 2.34. m 29.3 2.33, m 29.4 
3’ 5.12, t, 7.2 122.7 5.12, t, 7.2 122.7 5.12, t, 7.2 122.9 5.12, t, 7.1 122.7 5.12, t, 7.1 122.7 5.12, t, 7.1 122.7 
4’ - 133.0 - 133.0 - 133.0 - 133.0 - 133.0 - 133.1 
5’ 1.53, s 17.6 1.52, s 17.7 1.53, s 17.9 1.52, s 17.6 1.53, s 17.7 1.52, s 17.7 
6’ 1.66, s 25.6 1.67, s 25.6 1.67, s 25.7 1.67, s 25.6 1.67, s 25.6 1.67, s 25.6 
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Solubility is an important aspect to consider when designing new therapeutic agents. Most of 
the naphthoquinone analogues considered here appear to be significantly lipophilic which 
could potentially impact on their activity. The next set of molecules was synthesized to improve 
water solubility of naphthoquinones (4.24-4.26). A morpholino functionality was coupled to 
naphthoquinone 4.10 as indicated in Scheme 4.9. 
O
O
+
N
H
O
O
O
N
O
Cu(OAc)
MeOH, rt, 1h
4.10
O
O
N
O
+
4.24A 4.24B
Scheme 4.9: Reaction scheme for the preparation of compound 4.24 
For this reaction, Cu(OAc)2 catalyst was used to facilitate the reaction. Naphthoquinone 4.10 
was reacted with morpholine in the presence of Cu(OAc)2 at room temperature under 
atmospheric O2 to give the morpholine-coupled naphthoquinone 4.24. The product obtained 
contained the usual regioisomers of the morpholine added to either the C-2 or C-3 position of 
the naphthoquinone. The important signals to consider in the 1H NMR spectra of 4.24 were 
two sets of methylene protons coupled to each other at  3.49 (t, J = 4.9 Hz, H-11 and H-14) 
and  3.86 (t, J = 4.9 Hz, H-12 and H-13) for isomer 4.24A and at  3.48 (t, J = 4.9 Hz, H-11 
and H-14) and  3.86 (t, J = 4.9 Hz, H-12 and H-13) for isomer 4.24B, indicative of the 
morpholino moiety. The 13C NMR spectrum showed additional signals at  49.2 (C-11, C-14) 
and  66.4 (C-12, C-13) belonging to the morpholino group. Identification of the isomers was 
also done by analysing H-7 and C-6, 1H and 13C NMR chemical shifts (Table 4.10). HRMS 
obtained for both isomers of 4.24 showed an adduct ion at 326.1746, consistent with the 
molecular formula of C20H24NO3+H 
Attempts to functionalize the terminal alkene on naphthoquinone 4.10 were conducted, initially 
by converting the alkene to an epoxide with the use of m-chloroperoxybenzoic acid (mCPBA). 
in the presence of NaHCO3 in CH2Cl2. Stirring was done at room temperature for an hour before 
quenching the reaction with Na2S2O3 (Scheme 4.10) 
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O
O
4.10 4.27
O
O
O
MCPBA, NaHCO3
CH2Cl2, r.t, 1h
 
Scheme 4.10: Epoxidation of 4.10 
Compound 4.27 was anticipated to provide an entry to a new series of  amino alcohols 
(Scheme 4.11). Reactions with tyramine and morpholine were attempted by stirring the 
epoxide 4.27 with the amine at room temperature for 18 hours in a mixture of EtOH and H2O. 
Two possible reactions were likely to occur due to the presence of two nucleophilic centres on 
compound 4.27. Coupling to the quinone moiety was favoured, probably because of steric 
hindrance at the epoxide region caused by the two methyl groups.  
4.27
O
O
O
O
O
O
R
O
O
OH
R
4.25 R =
4.26 R = 
OH
NH2
NH
O
Amine, EtOH/H 2O
r.t, 18h
X
 
Scheme 4.11: Reaction of amines with naphthoquinone epoxide 4.27 
For the reaction with tyramine, the 1H NMR data obtained showed changes in the region 
between  0.5 –  3.5 compared to compound 4.22. Multiplet signals were observed at  1.89 
and  2.89 corresponding to H-2’ and H-1’ respectively, and a triplet at  2.75 (t, J = 6.3 Hz) 
belonging to H-3’ confirmed by integral values relative to the benzoquinone methine signal. 
The methyl signals were less deshielded and were noted at  1.16 (s, H-5’) and  1.27 (s, H-
6’). From the 13C NMR spectra, C-3’ and C-4’ were observed at  63.5 and  58.6 respectively, 
indicative of an epoxide moiety and absence of an alkene functionality (Table 4.10). Further 
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evidence was acquired via mass spectrometry, with the adduct ion noted at 392.1850 
corresponding to a molecular formula C24H26NO4+H of compound 4.25.  
For compound 4.26, the multiplet signals were noticed at  1.90 (m, H-1’) and  2.90 (m, H-
2’), and two less deshielded terminal methyl groups at  1.17 (s, H-5’) and 1.28 (s, H-6’). The 
13C NMR spectrum showed a new set of signals at  63.6 (C-3’) and  58.6 (C-4’) indicative 
of an epoxide. Further confirmation of the chemical structure was ascertained by acquiring 
HRMS data that showed an adduct ion at 342.1697 corresponding to a molecular formula of 
C20H24NO4+H, compound 4.26. Identification of isomers was also based on similar trends 
observed in 1H and 13C NMR spectra for H-7 and C-6 chemical shifts, respectively (Table 
4.10). 
Percentage yields and calculated ratios for the isomers in the mixture after separation by HPLC 
are shown below in Table 4.9. The regioisomers existed in approximately 1:1 ratio.  
Table 4.9: Percentage yields and HPLC fractions obtained 
Compound % yield Ratio of isomers Retention times (mins) 
 
 A (%) B (%) A B 
4.24 80.4 50.0 50.0 35.4 38.1 
4.25 59.8 50.2 49.8 21.5 14.9 
4.26 55.7 50.0 50.0 22.0 21.1 
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Table 4.10: 1H and 13C NMR chemical shifts of compound 4.24 – 4.26        
NB. C-2 substituted naphthoquinones are presented as isomer A and C-3 substituted one as isomer B 
 
 4.24A 4.24B 4.25A 4.25B 4.26A 4.26B 
Carbon 
no. 
 H, mult, 
J(Hz) 
 C  H, mult, 
J(Hz) 
 C  H, mult, 
J(Hz) 
 C  H, mult, 
J(Hz) 
 C  H, mult, 
J(Hz) 
 C  H, mult, 
J(Hz) 
 C 
1 - 182.7 - 183.9 - 181.4 - 183.0 - 182.6 - 183.7 
2 - 153.9 5.98, s 112.2 - 148.0 5.74, s 101.0 - 153.7 5.99, s 112.2 
3 5.98, s 111.9 - 153.7 5.74, s 100.7 - 147.7 5.99. s 111.9 - 153.7 
4 - 184.1 - 183.2 - 183.2 - 182.0 - 183.9 - 183.0 
5 7.85, s 125.5 7.81, s 126.6 7.94, s 126.1 7.86, s 126.0 7.88, s 125.4 7.84, s 126.7 
6 - 149.6 - 147.9 - 149.5 - 146.2 - 148.5 - 147.2 
7 7.45, d, 7.9 132.8 7.50, d, 7.8 134.2 7.44, d, 7.8 132.2 7.56, d, 7.8 135.0 7.48, d, 7.9 132.9 7.54, d, 7.9 134.3 
8 7.90, d, 7.9 127.0 7.94, d, 7.8 125.8 7.95, d, 7.8 126.8 8.02, d, 7.8 126.5 7.94, d, 7.9 127.3 7.97, d, 7.9 126.0 
9 - 130.7 - 130.3 - 128.7 - 130.5 - 130.9 - 130.5 
10 - 132.2 - 132.6 - 130.5 - 131.8 - 132.4 - 132.8 
11 3.49, t, 4.9 49.2 3.48, t, 4.9 49.2 3.38, q, (t), 
6.8 
43.8 3.39, q (t), 
6.8 
43.9 3.50, t, 4.8 49.2 3.48, t, 4.7 49.3 
12 3.86, t, 4.9 66.4 3.86, t, 4.9 66.4 2.88, t, 7.1 33.4 2.90, t, 7.1 35.5 3.86, t, 4.8 66.5 3.86, t, 4.7 66.6 
13 3.86. t, 4.9 66.4 3.86, t, 4.9 66.4 - 129.6 - 129.9 3.86, t, 4.8 66.5 3.86, t, 4.7 66.6 
14 3.49, t, 4.9 49.2 3.48, t, 4.9 49.2 6.81, d, 8.4 115.8 6.80, d, 8.4 115.7 3.50, t, 4.8 49.2 3.48, t, 4.7 49.3 
15 - - - - 7.07, d, 8.4 129.7 7.08, d, 8.4 129.8 - - - - 
16 - - - - - 154.8 - 154.6 - - - - 
17 - - - - 7.07, d, 8.4 129.7 7.08, d, 8.4 129.8 - - - - 
18 - - - - 6.81, d, 8.4 115.8 6.80, d, 8.4 115.7 - - - - 
1’ 2.74, t, 7.5 36.3 2.74, t, 7.6 36.1 2.88, m 32.7 2.89, m 32.7 2.90, m 33.0 2.89, m 32.9 
2’ 2.33, q, 7.4 29.3 2.33, t, 7.5 29.4 1.89, m 30.1 1.89, m 30.2 1.90, m 30.2 1.90, m 30.3 
3’ 5.12, t, 7.2 122.3 5.13, t, 7.2 122.7 2.76, t, 6.2 63.5 2.75, t, 6.3 63.5 2.75, t, 6.2 63.7 2.75, t, 6.2 63.6 
4’ - 133.0 - 133.0 - 58.7 - 58.6 - 58.6 - 58.6 
5’ 1.53, s 17.8 1.53, s 17.7 1.16, s 18.6 1.16, s 18.6 1.16, s 18.8 1.17, s 19.1 
6’ 1.67 s 25.7 1.67, s 25.7 1.28, s 24.7 1.27, s 24.7 1.28, s 24.7 1.29, s 24.6 
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4.2.5 Tricyclic naphthoquinones (fourth series) 
Tricyclic naphthoquinones constituted the last series of our compounds. Thiazino-
naphthoquinone (4.28) and a chromene-naphthoquinone hybrid (4.29) molecules were 
synthesized to assess the influence of the thiazino and pyran moieties respectively on 
cytotoxicity and Hsp90 inhibition. It was anticipated that compound 4.29 would mimic 
novobiocin binding to the ATP binding site of Hsp90.   
S
N
H
O
O
O O
4.28
              
O
O
O
4.29
 
Synthesis and characterization of compound 4.28 
The synthesis of compound 4.28 was carried out by reacting naphthoquinone 4.10 with 
hypotaurine in a mixture of solvents, (CH3CN: EtOH: H2O, 5:5:1) at 70 °C for 2.5 hours 
(Scheme 4.12). Two isomers 4.28A and 4.28B were formed but 4.28A was obtained in greater 
yield (9:1) and purified by column chromatography. Only NMR data for 4.28A is presented. 
O
O
S
O
OH NH2
S
N
H
O
O
O O
4.28A
+
4.10
CH3CN / EtOH / H 2O
70 oC, 2.5h
N
H
S
O
OOO
4.28B
+
Scheme 4.12: Preparation of compound 4.28 from compound 4.10 
In the 1H NMR spectrum of 4.28, the important features to note were the disappearance of the 
benzoquinone methine signal and the appearance of two sets of methylene signals at  3.36 (m, 
H-11) and  4.13 (m, H-12). The 13C NMR spectrum indicated two additional methylene
 
signals
 
at  49.1 and  39.9 and the product was determined to be compound 4.28 (Table 4.11) 
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The correct orientation of the thiazine moiety fused to the naphthoquinone was assigned based 
on comparison to data published for this compound by Aiello and colleagues (2003). 
Table 4.11: 1H and 13C NMR chemical shifts for 4.28 
 
5
8
2
1'
4'
5'
6'
11 9
10
12
O
O
S
N
H
O O
 
Carbon no.  H, mult, J(Hz)  C 
1 - 178.6 
2 - 113.3 
3 - 145.4 
4 - 175.7 
5 8.01, s 127.2 
6 - 152.7 
7 7.47, d, 7.8 133.4 
8 7.96, d, 7.8 127.1 
9 - 127.2 
10 - 132.6 
11 3.36, m 49.1 
12 4.13, m 39.9 
1’ 2.77, t, 7.5 36.6 
2’ 2.33, q, 7.3 29.2 
3’ 5.09, t, 7.1 122.3 
4’ - 133.3 
5’ 1.51, s 17.6 
6’ 1.66, s 25.7 
 
. 
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Synthesis and characterization of compound 4.29 
Compound 4.29 was synthesized to integrate the naphthoquinone and chromene moieties in 
one molecule and determine whether a synergistic effect may arise from such a combination. 
This type of system is present in sargachromenol (3.3) that showed the most cytotoxic activity 
amongst the meroterpenoids isolated from S. incisifolium. Compound 4.29 was prepared from 
a mixture of reagents that included 2 hydroxynaphthoquinone, citral, -alanine and AcOH, 
dissolved in C6H6 and refluxed for 3 hours at 80- 85 °C (Scheme 4.13).  
O
O
OH
O
O
O
+
O
H β-alanine, AcOH
C6H6, reflux, 3h
4.29
Scheme 4.13: Reaction scheme demonstrating the synthesis of chromene-naphthoquinone 
hybrid (4.29) 
The 1H NMR spectrum (Figure 4.8) for compound 4.29 was characterized by four aromatic 
protons observed at  8.06 (dd, J = 7.5; J = 1.4 Hz, H-11, H-14) and  7.67 (m, H-12, H-13) 
belonging to the benzenoid ring, two methine doublets at  5.65 (d, J = 10.1 Hz, H-7) and  
6.68 (d, J = 10.1 Hz, H-8) of the pyran moiety, with no benzoquinone methine H-2 or H-3 
signal indicating three fused rings. The presence of the two carbonyl groups of the quinone 
could only be verified on the 13C NMR spectrum (Figure 4.9) and appeared at  181.8 and  
179.6 for C-1 and C-4 respectively. The prenyl side chain system had a different signal pattern 
comprising of multiplet signals at  1.93 (m, H-1’) and  2.11 (m, H-2’), and a less deshielded 
H-3’ proton at 5.03 (t, J = 7.1 Hz). Three sets of methyl signals were noticed at  1.53 (s, H-
5’),  1.60 (s, H-6’) and  1.50 (s, H-7’). The position of the methyl group displayed at  1.50 
(s, H-7’) could be verified by HMBC correlations to H-1’. HMBC correlations of C-6 relative 
to H-7, H-8 and H-1’, H-2’ indicated it to be a non-aromatic carbon and had a chemical shift 
of  83.1. All other chemical shifts are presented in Table 4.12. 
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82
1'
4'
5'
6'
11
9
1014
O
O
O
4.29

Figure 4.8: 1H NMR spectrum (600 MHz, CDCl3) of compound 4.29 
 
Figure 4.9: 13C NMR spectrum (150 MHz, CDCl3) of compound 4.29 
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Table 4.12: 1H and 13C NMR chemical shifts of compound 4.29 
 
82
1'
4'
5'
6'
11
9
1014
O
O
O
 
Carbon no.  H, mult, J(Hz)  C 
1 - 181.8 
2 - 131.5 
3 - 131.5 
4 - 179.6 
5 - - 
6 - 83.1 
7 5.69, d, 10.1 129.7 
8 6.68, d, 10.1 116.0 
9 - 117.4 
10 - 152.7 
11 8.06, dd, 7.5; 1.4 126.1 
12 7.67, m 133.9 
13 7.67, m 133.1 
14 8.06, dd, 7.5; 1.4 126.1 
1’ 1.93, m 41.2 
2’ 2.11, m 22.6 
3’ 5.03, t, 7.1 123.5 
4’ - 132.2 
5’ 1.53, s 17.7 
6’ 1.60, s 25.8 
7’ 1.50, s 27.6 
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4.3 Conclusion 
A series of naphthoquinone derivatives were successfully synthesized as a starting point for 
the design of cytotoxic Hsp90 protein inhibitors. This set of molecules present a new class of 
compounds that could be used to assess Hsp90 protein binding. Cytotoxicity of the synthesized 
molecules was determined, together with isolated metabolites discussed in chapter three.  
Hsp90 inhibition assays were then conducted and the results compared to establish if 
correlations exist between cytotoxicity and Hsp90 inhibition. The details of these assays are 
presented in the next chapter.  
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4.4 EXPERIMENTAL 
General experimental:  
See chapter three, section 3.4.1 
4.4.1 Synthesis of first series of naphthoquinone derivatives 
Preparation of naphthoquinone scaffold  
REPRESENTATIVE PROCEDURE 
Preparation of 6-(4-methylpent-3-en-1-yl) naphthalene-1, 4-dione (4.10) 
 
A mixture of myrcene (0.500 g; 3.6 mmoles) and benzoquinone (0.190 g; 1.8 mmoles) 
dissolved in absolute EtOH (10 ml) was placed in a 100 ml round bottomed flask and refluxed 
for 5 hours at 70 – 80 °C. The reaction mixture was allowed to cool to room temperature before 
concentrating under vacuum on a rotavap to yield 0.515 g of crude Diels-Alder product (4.32) 
(58.5 % yield).  
The crude mixture was used without further purification. It was dissolved in C6H6 in a 100 ml 
round bottomed flask and MnO2 (1.070 g, 12.3 mmoles) added with stirring. The mixture was 
heated to 80 – 85 °C and kept under reflux for 4 hours. After cooling to room temperature, the 
reaction mixture was filtered through celite x 2 and the solvent removed under reduced pressure 
to yield 0.3157 of crude product 4.10. The crude product (0.158 g) was purified by column 
chromatography eluting with Hex/EtOAc 9:1 to produce pure naphthoquinone 4.10 (0.462 g, 
96.2 % yield).  
The same method was used for the preparation of 4.11-4.13 from the respective benzoquinone 
derivatives with myrcene. See the supplementary data for details (Table S1-S2).  
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Compound 4.10  
O
O
1
4 5
8
1' 6'
5'
 
1H NMR (CDCl3):  6.93 (s, H-2; H-3), 7.88 (s, H-5), 7.55 (dd, 7.8 Hz; 1.6 Hz, H-7), 7.98 (d, 
7.8 Hz, H-8), 2.76 (t, 7.8 Hz, H-1’), 2.34 (q, 7.5 Hz, H-2’), 5.11 (t, 7.1 Hz, H-3’), 1.54 (s, H-
5’), 1.66 (s, H-6’). 13C NMR (CDCl3):  184.9 (C-1), 138.5 (C-2), 138.7 (C-3), 185.4 (C-4), 
126.5 (C-5), 149.4 (C-6), 134.1 (C-7), 126.2 (C-8), 129.9 (C-9), 133.1 (C-10), 36.2 (C-1’), 29.3 
(C-2’), 122.5 (C-3’), 131.8 (C-4’), 17.6 (C-5’), 25.6 (C-6’) (Miguel del Corral, et al., 2002). 
Compound 4.11A 
O
O
Cl 1
4 5
8
1' 6'
5'
 
1H NMR (CDCl3):  7.19 (s, H-3), 7.89 (s, H-5), 7.56 (d, 7.9 Hz, H-7), 8.07 (d, 7.8 Hz, H-8), 
2.78 (t, 7.7 Hz, H-1’), 2.34 (q, 7.6 Hz, H-2’), 5.11 (t, 7.1 Hz, H-3’), 1.52 (s, H-5’), 1.66 (s, H-
6’). 13C NMR (CDCl3):  177.8 (C-1), 146.4 (C-2), 135.7 (C-3), 183.0 (C-4), 126.6 (C-5), 150.2 
(C-6), 134.3 (C-7), 127.7 (C-8), 129.2 (C-9), 133.3 (C-10), 36.2 (C-1’), 29.2 (C-2’), 122.4 (C-
3’), 131.7 (C-4’), 17.6 (C-5’), 25.6 (C-6’) (Miguel del Corral, et al., 2006). 
Compound 4.11B 
O
O
Cl
1
4 5
8
1' 6'
5'
 
1H NMR (CDCl3):  7.18 (s, H-2), 7.97 (s, H-5), 7.57 (d, 7.7 Hz, H-7), 7.99 (d, 7.7 Hz, H-8), 
2.78 (t, 7.7 Hz, H-1’), 2.34 (q, 7.4 Hz, H-2’), 5.11 (t, 7.0 Hz, H-3’), 1.52 (s, H-5’), 1.67 (s, H-
6’). 13C NMR (CDCl3):  182.6 (C-1), 135.9 (C-2), 146.1 (C-3), 178.3 (C-4), 127.4 (C-5), 149.8 
(C-6), 134.7 (C-7), 126.8 (C-8), 129.7 (C-9), 133.3 (C-10), 36.1 (C-1’), 29.2 (C-2’), 122.4 (C-
3’), 131.2 (C-4’), 17.7 (C-5’), 25.6 (C-6’) (Miguel del Corral, et al., 2006). 
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Compound 4.12A 
O
O
H3CO
1
4 5
8
1' 6'
5'
 
1H NMR (CDCl3):  6.14 (s, H-3), 7.89 (s, H-5), 7.51 (d, 7.8 Hz, H-7), 8.03 (d, 7.8 Hz, H-8), 
3.89 (s, H-11), 2.76 (t, 7.6 Hz, H-1’), 2.34 (q, 7.4 Hz, H-2’), 5.12 (t, 7.1 Hz, H-3’), 1.53 (s, H-
5’), 1.67 (s, H-6’). 13C NMR (CDCl3):  180.2 (C-1), 155.3 (C-2), 113.4 (C-3), 183.1 (C-4), 
127.1 (C-5), 149.5 (C-6), 136.6 (C-7), 126.7 (C-8), 131.5 (C-9), 133.8 (C-10), 58.8 (C-11), 
36.3 (C-1’), 29.4 (C-2’), 122.5 (C-3’), 132.0 (C-4’), 17.6 (C-5’), 25.6 (C-6’) (Miguel del 
Corral, et al., 1998). 
Compound 4.12B 
O
O
H3CO
1
4 5
8
1' 6'
5'
 
1H NMR (CDCl3):  6.13 (s, H-2), 7.93 (s, H-5), 7.53 (d, 7.9 Hz, H-7), 7.98 (d, 7.9 Hz, H-8), 
3.89 (s, H-11), 2.75 (t, 7.6 Hz, H-1’), 2.34 (q, 7.6 Hz, H-2’), 5.12 (t, 7.2 Hz, H-3’), 1.52 (s, H-
5’), 1.66 (s, H-6’). 13C NMR (CDCl3):  182.9 (C-1), 113.2 (C-2), 155.6 (C-3), 181.1 (C-4), 
127.9 (C-5), 149.5 (C-6), 135.8 (C-7), 126.8 (C-8), 131.7 (C-9), 132.0 (C-10), 58.9 (C-11), 
36.2 (C-1’), 29.5 (C-2’), 122.6 (C-3’), 131.9 (C-4’), 17.7 (C-5’), 25.6 (C-6’) (Miguel del 
Corral, et al., 1998). 
Compound 4.13A 
O
O
1
4 5
8
1' 6'
5'
 
1H NMR (CDCl3):  6.80 (s, H-3), 7.86 (s, H-5), 7.52 (dd, 7.9 Hz; 1.7 Hz, H-7), 8.00 (d, 7.9 
Hz, H-8), 2.18 (s, H-11), 2.75 (t, 7.5 Hz, H-1’), 2.34 (q, 7.2 Hz, H-2’), 5.12 (t, 7.1 Hz, H-3’), 
1.52 (s, H-5’), 1.66 (s, H-6’). 13C NMR (CDCl3):  185.5 (C-1), 148.2 (C-2), 133.8 (C-3), 185.6 
(C-4), 126.7 (C-5), 149.2 (C-6), 135.5 (C-7), 125.9 (C-8), 130.1 (C-9), 133.1 (C-10), 16.5 (C-
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11), 36.2 (C-1’), 29.3 (C-2’), 122.6 (C-3’), 132.2 (C-4’), 17.7 (C-5’), 25.6 (C-6’) (Miguel del 
Corral, et al., 1998). 
Compound 4.13B 
O
O
1
4 5
8
1' 6'
5'
 
1H NMR (CDCl3):  6.80 (s, H-2), 7.90 (s, H-5), 7.52 (dd, 7.8 Hz; 1.65 Hz, H-7), 7.95 (d, 7.8 
Hz, H-8), 2.18 (s, H-11), 2.76 (t, 7.6 Hz, H-1’), 2.33 (q, 7.2 Hz, H-2’), 5.12 (t, 7.3 Hz, H-3’), 
1.52 (s, H-5’), 1.66 (s, H-6’).13C NMR (CDCl3):  185.9 (C-1), 133.9 (C-2), 147.9 (C-3), 185.0 
(C-4), 126.4 (C-5), 149.0 (C-6), 135.7 (C-7), 126.2 (C-8), 130.2 (C-9), 133.1 (C-10), 16.5 (C-
11), 36.2 (C-1’), 29.4 (C-2’), 122.6 (C-3’), 132.0 (C-4’), 17.7 (C-5’), 25.7 (C-6’) (Miguel del 
Corral, et al., 1998). 
4.4.2 Synthesis of second series of naphthoquinone derivatives 
REPRESENTATIVE PROCEDURE 
6-(4-methylpent-3-en-1-yl)-2-(phenylamino) naphthalene-1, 4-dione (4.14) 
 
Naphthoquinone (4.10) (0.118 g, 0.4 mmoles), H2O (1 drop) and Cu(OAc)2 (0.008 g, 0.049 
mmoles) were dissolved in AcOH (5 ml) in a glass vial. Dissolution was facilitated by warming 
the mixture on a hot oil bath, after which aniline (0.046 g, 0.4 mmoles) was added and the 
reaction mixture heated between 60-70 °C for 30 mins under atmospheric O2. After cooling the 
reaction mixture to room temperature, the solvent was evaporated, followed by reconstitution 
of the remaining residue in CH2Cl2 (15 ml).  The collected CH2Cl2 sample was passed through 
a plug of silica gel (7 g), eluting with approximately 40 ml of CH2Cl2 and the solvent evaporated 
again under reduced pressure on the rotary evaporator to give 0.127 g of a deep red crude 
product (4.14) ( 96.2 % yield). The same method was used for the preparation of 4.14-4.19 
from compound 4.10 and the respective anilines. See the supplementary data for details (Table 
S4.3). 
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Compound 4.14A 
 
1H NMR (CDCl3):  6.40 (s, H-3), 7.92 (s, H-5), 7.46 (dd, 7.6 Hz; 1.5 Hz, H-7), 8.03 (d, 7.6 
Hz, H-8), 7.27 (d, 7.9 Hz, H-12), 7.42 (t, 7.6 Hz, H-13), 7.21 (t, 7.4 Hz, H-14), 7.42 (t, 7.6 Hz, 
H-15), 7.27 (d, 7.9 Hz, H-16), 2.76 (t, 7.6 Hz, H-1’), 2.34 (q, 7.6 Hz, H-2’), 5.13 (t, 7.1 Hz, H-
3’), 1.53 (s, H-5’), 1.67 (s, H-6’). 13C NMR (CDCl3):  181.8 (C-1), 144.8 (C-2), 103.2 (C-3), 
184.4 (C-4), 126.2 (C-5), 150.7 (C-6), 132.5 (C-7), 126.8 (C-8), 128.2 (C-9), 133.2 (C-10), 
137.5 (C-11), 122.5 (C-12), 129.6 (C-13), 125.5 (C-14), 129.6 (C-15), 122.5 (C-16), 36.5 (C-
1’), 29.3 (C-2’), 122.6 (C-3’), 133.1 (C-4’), 17.7 (C-5’), 25.7 (C-6’) (Miguel del Corral, et al., 
2005). 
Compound 4.14B 
5
8
2
O
O
NH
1214
16 1' 4'
5'
6'

1H NMR (CDCl3):  6.39 (s, H-2), 7.93 (s, H-5), 7.56 (dd, 7.9 Hz; 1.8 Hz, H-7), 8.01 (d, 7.8 
Hz, H-8), 7.27 (d, 7.7 Hz, H-12), 7.42 (t, 7.6 Hz, H-13), 7.21 (t, 7.5 Hz, H-14), 7.42 (t, 7.6 Hz, 
H-15), 7.27 (d, 7.7 Hz, H-16), 2.76 (t, 7.6 Hz, H-1’), 2.35 (q, 7.6 Hz, H-2’), 5.14 (t, 7.1 Hz, H-
3’), 1.54 (s, H-5’), 1.68 (s, H-6’). 13C NMR (CDCl3):  184.3 (C-1), 103.4 (C-2), 144.6 (C-3), 
182.5 (C-4), 126.4 (C-5), 147.6 (C-6), 135.0 (C-7), 126.1 (C-8), 131.2 (C-9), 130.4 (C-10), 
137.4 (C-11), 122.5 (C-12), 129.7 (C-13), 125.6 (C-14), 129.7 (C-15), 122.5 (C-16), 36.1 (C-
1’), 29.4 (C-2’), 122.6 (C-3’), 133.1 (C-4’), 17.6 (C-5’), 25.7 (C-6’) (Miguel del Corral, et al., 
2005). 
 
 
 
 
 
 
5
8
2
O
O
NH12
14
16
1' 4'
5'
6'
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Compound 4.15A 
5
8
2
O
O
NH12
16
1' 4'
5'
6'
7'
 
1H NMR (CDCl3):  6.33 (s, H-3), 7.92 (s, H-5), 7.45 (d, 7.9 Hz, H-7), 8.02 (d, 7.9 Hz, H-8), 
7.21 (d, 8.2 Hz, H-12), 7.16 (d, 8.2 Hz, H-13), 7.16 (d, 8.2 Hz, H-15), 7.21 (d, 8.2 Hz, H-16), 
2.76 (t, 7.5 Hz, H-1’), 2.34 (q, 7.5 Hz, H-2’), 5.13 (t, 7.1 Hz, H-3’), 1.54 (s, H-5’), 1.68 (s, H-
6’), 2.36 (s, H-7’). 13C NMR (CDCl3):  181.9 (C-1), 145.1 (C-2), 102.8 (C-3), 184.3 (C-4), 
126.2 (C-5), 150.7 (C-6), 132.4 (C-7), 126.7 (C-8), 133.3 (C-9), 128.3 (C-10), 135.5 (C-11), 
130.2 (C-12), 122.7 (C-13), 134.8 (C-14), 122.7 (C-15), 130.2 (C-16), 36.5 (C-1’), 29.4 (C-2’), 
122.7 (C-3’), 133.1 (C-4’), 17.7 (C-5’), 25.7 (C-6’), 21.0 (C-7’) (Lisboa, et al., 2011) (Miguel 
del Corral, et al., 2005). 
Compound 4.15B 
5
8
2
O
O
NH
12
16 1' 4'
5'
6'
7'

1H NMR (CDCl3):  6.32 (s, H-2), 7.92 (s, H-5), 7.55 (d, 7.9 Hz, H-7), 8.00 (d, 7.9 Hz, H-8), 
7.21 (d, 8.3 Hz, H-12), 7.16 (d, 8.3 Hz, H-13), 7.16 (d, 8.3 Hz, H-15), 7.21 (d, 8.3 Hz, H-16), 
2.76 (t, 7.6 Hz, H-1’), 2.34 (q, 7.4 Hz, H-2’), 5.13 (t, 7.2 Hz, H-3’), 1.53 (s, H-5’), 1.68 (s, H-
6’), 2.36 (s, H-7’). 13C NMR (CDCl3):  184.1 (C-1), 102.9 (C-2), 144.9 (C-3), 182.5 (C-4), 
126.4 (C-5), 147.5 (C-6), 135.1 (C-7), 126.2 (C-8), 131.2 (C-9), 128.8 (C-10), 135.5 (C-11), 
130.2 (C-12), 122.6 (C-13), 134.8 (C-14), 122.6 (C-15), 130.2 (C-16), 36.0 (C-1’), 29.4 (C-2’), 
122.6 (C-3’), 133.1 (C-4’), 17.7 (C-5’), 25.7 (C-6’), 21.0 (C-7’) (Lisboa, et al., 2011) (Miguel 
del Corral, et al., 2005). 
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Compound 4.16A 
5
8
2
O
O
NH
H3CO
12
16
1' 4'
5'
6'7'
 
1H NMR (CDCl3):  6.20 (s, H-3), 7.92 (s, H-5), 7.44 (d, 7.8 Hz, H-7), 8.01 (d, 7.8 Hz, H-8), 
7.19 (d, 8.9 Hz, H-12), 6.94 (d, 8.9 Hz, H-13), 6.94 (d, 8.9 Hz, H-15), 7.19 (d, 8.9 Hz, H-16), 
2.76 (t, 7.5 Hz, H-1’), 2.34 (q, 7.6 Hz, H-2’), 5.13 (t, 7.2 Hz, H-3’), 1.54 (s, H-5’), 1.67 (s, H-
6’), 3.83 (s, H-7’). 13C NMR (CDCl3):  181.9 (C-1), 145.8 (C-2), 102.3 (C-3), 184.1 (C-4), 
126.2 (C-5), 150.6 (C-6), 132.3 (C-7), 126.7 (C-8), 133.4 (C-9), 128.3 (C-10), 130.1 (C-11), 
124.8 (C-12), 114.9 (C-13), 157.7 (C-14), 114.9 (C-15), 124.8 (C-16), 36.5 (C-1’), 29.4 (C-2’), 
122.7 (C-3’), 133.0 (C-4’), 17.6 (C-5’), 25.6 (C-6’), 55.6 (C-7’) (Lisboa, et al., 2011) (Miguel 
del Corral, et al., 2005). 
Compound 4.16B 
5
8
2
O
O
NH
H3CO 12
16 1' 4'
5'
6'
7'

1H NMR (CDCl3):  6.19 (s, H-2), 7.92 (s, H-5), 7.55 (d, 7.8 Hz, H-7), 7.99 (d, 7.8 Hz, H-8), 
7.20 (d, 8.9 Hz, H-12), 6.94 (d, 8.9 Hz, H-13), 6.94 (d, 8.9 Hz, H-15), 7.20 (d, 8.9 Hz, H-16), 
2.76 (t, 7.5 Hz, H-1’), 2.35 (q, 7.6 Hz, H-2’), 5.14 (t, 7.2 Hz, H-3’), 1.54 (s, H-5’), 1.68 (s, H-
6’), 3.83 (s, H-7’). 13C NMR (CDCl3):  183.9 (C-1), 102.7 (C-2), 145.6 (C-3), 182.4 (C-4), 
126.3 (C-5), 147.4 (C-6), 135.0 (C-7), 126.2 (C-8), 131.3 (C-9), 130.3 (C-10), 130.1 (C-11), 
124.7 (C-12), 114.8 (C-13), 157.7 (C-14), 114.8 (C-15), 124.7 (C-16), 36.0 (C-1’), 29.4 (C-2’), 
122.7 (C-3’), 133.1 (C-4’), 17.7 (C-5’), 25.7 (C-6’), 55.6 (C-7’) (Lisboa, et al., 2011) (Miguel 
del Corral, et al., 2005). 
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Compound 4.17A 
5
8
2
O
O
NH
Cl
12
16
1' 4'
5'
6'7'

1H NMR (CDCl3):  6.33 (s, H-3), 7.92 (s, H-5), 7.47 (d, 7.8 Hz, H-7), 8.03 (d, 7.9 Hz, H-8), 
7.21 (d, 8.8 Hz, H-12), 7.33 (d, 8.8 Hz, H-13), 7.33 (d, 8.8 Hz, H-15), 7.21 (d, 8.8 Hz, H-16), 
2.77 (t, 7.5 Hz, H-1’), 2.35 (q, 7.5 Hz, H-2’), 5.13 (t, 7.2 Hz, H-3’), 1.54 (s, H-5’), 1.67 (s, H-
6’). 13C NMR (CDCl3):  183.2 (C-1), 144.5 (C-2), 103.5 (C-3), 184.3 (C-4), 126.2 (C-5), 150.9 
(C-6), 132.6 (C-7), 126.8 (C-8), 133.2 (C-9), 128.2 (C-10), 130.1 (C-11), 123.7 (C-12), 129.8 
(C-13), 136.1 (C-14), 129.8 (C-15), 123.7 (C-16), 36.5 (C-1’), 29.4 (C-2’), 122.6 (C-3’), 133.0 
(C-4’), 17.6 (C-5’), 25.7 (C-6’) HRESIMS: m/z: 366.1248 [M+H]+, C22H20ClNO2, calculated: 
366.1260; FTIR: 3315.41, 2924.32, 1677.28, 1606.12, and 1566.34 cm-1. 
Compound 4.17B 
5
8
2
O
O
NH
Cl 12
16 1' 4'
5'
6'
7'

1H NMR (CDCl3):  6.33 (s, H-2), 7.92 (s, H-5), 7.56 (d, 7.9 Hz, H-7), 8.00 (d, 7.8 Hz, H-8), 
7.22 (d, 8.7 Hz, H-12), 7.38 (d, 8.7 Hz, H-13), 7.38 (d, 8.7 Hz, H-15), 7.22 (d, 8.7 Hz, H-16), 
2.76 (t, 7.5 Hz, H-1’), 2.34 (q, 7.5 Hz, H-2’), 5.13 (t, 7.1 Hz, H-3’), 1.53 (s, H-5’), 1.68 (s, H-
6’). 13C NMR (CDCl3):  184.1 (C-1), 103.7 (C-2), 144.3 (C-3), 182.1 (C-4), 126.5 (C-5), 147.7 
(C-6), 135.2 (C-7), 126.3 (C-8), 131.0 (C-9), 130.7 (C-10), 130.1 (C-11), 123.7 (C-12), 129.8 
(C-13), 136.1 (C-14), 129.8 (C-15), 123.7 (C-16), 36.0 (C-1’), 29.4 (C-2’), 122.6 (C-3’), 133.2 
(C-4’), 17.6 (C-5’), 25.7 (C-6’), HRESIMS: m/z: 366.1249 [M+H]+, C22H20ClNO2, calculated: 
366.1260; FTIR: 3315.41, 2924.32, 1677.28, 1606.12, and 1566.34 cm-1. 
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Compound 4.18A 
5
8
2
O
O
NH
F3C
12
16
1' 4'
5'
6'7'

1H NMR (CDCl3):  6.50 (s, H-3), 7.93 (s, H-5), 7.49 (d, 7.9 Hz, H-7), 8.04 (d, 7.9 Hz, H-8), 
7.38 (d, 8.5 Hz, H-12), 7.67 (d, 8.5 Hz, H-13), 7.67 (d, 8.5 Hz, H-15), 7.38 (d, 8.5 Hz, H-16), 
2.77 (t, 7.5 Hz, H-1’), 2.35 (q, 7.5 Hz, H-2’), 5.13 (t, 7.1 Hz, H-3’), 1.53 (s, H-5’), 1.67 (s, H-
6’). 13C NMR (CDCl3):  181.4 (C-1), 143.7 (C-2), 104.7 (C-3), 184.4 (C-4), 126.3 (C-5), 151.0 
(C-6), 132.9 (C-7), 126.6 (C-8), 133.2 (C-9), 128.1 (C-10), 140.7 (C-11), 126.9 (C-12), 121.5 
(C-13), 141.0 (C-14), 121.5 (C-15), 126.9 (C-16), 36.5 (C-1’), 29.3 (C-2’), 122.6 (C-3’), 132.8 
(C-4’), 17.6 (C-5’), 25.7 (C-6’), 124.7 (C-7’) HRESIMS: m/z: 400.1512 [M+H]+, 
C23H20F3NO2, calculated: 400.1524; FTIR: 3309.86, 2923.15, 2853.84, 1736.26, 1672.20, 
1604.86 and 1588.08 cm-1. 
Compound 4.18B 
5
8
2
O
O
NH
F3C 12
16 1' 4'
5'
6'
7'

1H NMR (CDCl3):  6.50 (s, H-2), 7.94 (s, H-5), 7.58 (d, 7.9 Hz, H-7), 8.01 (d, 7.9 Hz, H-8), 
7.38 (d, 8.4 Hz, H-12), 7.67 (d, 8.5 Hz, H-13), 7.7 (d, 8.5 Hz, H-15), 7.38 (d, 8.4 Hz, H-16), 
2.77 (t, 7.5 Hz, H-1’), 2.35 (q, 7.5 Hz, H-2’), 5.13 (t, 7.2 Hz, H-3’), 1.53 (s, H-5’), 1.67 (s, H-
6’). 13C NMR (CDCl3):  184.2 (C-1), 104.9 (C-2), 143.5 (C-3), 182.0 (C-4), 126.3 (C-5), 148.0 
(C-6), 135.4 (C-7), 126.4 (C-8), 130.8 (C-9), 130.1 (C-10), 140.7 (C-11), 126.9 (C-12), 121.5 
(C-13), 141.0 (C-14), 121.5 (C-15), 126.9 (C-16), 36.0 (C-1’), 29.4 (C-2’), 122.6 (C-3’), 133.8 
(C-4’), 17.6 (C-5’), 25.7 (C-6’), 124.7 (C-7’) HRESIMS: m/z: 400.1509 [M+H]+, 
C23H20F3NO2, calculated: 400.1524; FTIR: 3309.86, 2923.15, 2853.84, 1736.26, 1672.20, 
1604.86 and 1588.08 cm-1. 
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Compound 4.19A 
5
8
2
O
O
NHO
O
12
16
1' 4'
5'
6'
17

1H NMR (CDCl3):  6.21 (s, H-3), 7.91 (d, 1.7 Hz, H-5), 7.45 (dd, 7.8; 1.8 Hz, H-7), 8.01 (d, 
7.8 Hz, H-8), 6.77 (d, 2.2 Hz, H-12), 6.83 (d, 8.2 Hz, H-15), 6.71 (dd, 8.2; 2.2 Hz, H-16), 6.01 
(s, H-17), 2.76 (t, 7.5 Hz, H-1’), 2.34 (q, 7.5 Hz, H-2’), 5.13 (t, 7.2 Hz, H-3’), 1.53 (s, H-5’), 
1.67 (s, H-6’). 13C NMR (CDCl3):  181.8 (C-1), 133.3 (C-2), 101.7 (C-3), 184.1 (C-4), 126.2 
(C-5), 150.6 (C-6), 132.6 (C-7), 126.7 (C-8), 131.3 (C-9), 128.8 (C-10), 148.5 (C-11), 104.9 
(C-12), 145.6 (C-13), 145.7 (C-14), 108.5 (C-15), 116.9 (C-16), 101,7 (C-17), 36.5 (C-1’), 29.3 
(C-2’), 122.7 (C-3’), 133.1 (C-4’), 17.7 (C-5’), 25.6 (C-6’) HRESIMS: m/z: 376.1537 [M+H]+, 
C23H21NO4, calculated: 376.1548; FTIR: 3321.78, 2969.75, 2913.94, 1738.11, 1670.63 and 
1628.45 cm-1. 
Compound 4.19B 
5
8
2
12
16 1'
4'
5'
6'
17
O
O
NH
O
O

1H NMR (CDCl3):  6.20 (s, H-2), 7.91 (d, 1.7 Hz, H-5), 7.55 (dd, 7.9; 1.8 Hz, H-7), 7.99 (d, 
7.9 Hz, H-8), 6.78 (d, 2.2 Hz, H-12), 6.83 (d, 8.2 Hz, H-15), 6.72 (dd, 8.3; 2.1 Hz, H-16), 6.01 
(s, H-17), 2.76 (t, 7.5 Hz, H-1’), 2.35 (q, 7.5 Hz, H-2’), 5.13 (t, 7.2 Hz, H-3’), 1.54 (s, H-5’), 
1.68 (s, H-6’). 13C NMR (CDCl3):  184.0 (C-1), 102.7 (C-2), 131.2 (C-3), 182.3 (C-4), 126.3 
(C-5), 148.4 (C-6), 135.0 (C-7), 126.2 (C-8), 131.3 (C-9), 130.3 (C-10), 145.5 (C-11), 104.8 
(C-12), 147.5 (C-13), 147.7 (C-14), 108.6 (C-15), 116.1 (C-16), 101,5 (C-17), 36.0 (C-1’), 29.4 
(C-2’), 122.7 (C-3’), 133.1 (C-4’), 17.7 (C-5’), 25.6 (C-6’) HRESIMS: m/z: 376.1534 [M+H]+, 
C23H21NO4, calculated: 376.1548; FTIR: 3321.78, 2969.75, 2913.94, 1738.11, 1670.63 and 
1628.45 cm-1. 
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4.4.3 Synthesis of third series of naphthoquinone derivatives 
REPRESENTATIVE PROCEDURE 
6-(4-methylpent-3-en-1-yl)-2-(prop-2-en-1-ylamino)naphthalene-1,4-dione (4.20) 
To a dissolved sample of naphthoquinone 4.10 (0.120 g, 0.5 mmoles) in MeOH (5 ml) in a 
glass vial, was added allylamine (0.028 g, 0.5 mmoles) and the reaction mixture stirred at room 
temperature for 48 hours under atmospheric O2. The solvent was removed under reduced 
pressure on a rotavap and the crude product obtained (0.106 g, 71.8 % yield) purified by column 
chromatography using Hex/EtOAc 8:2 to give a mixture of regioisomers. The same method 
was used for the preparation of 4.21-4.23 from compound 4.10. See the supplementary data for 
details (Table S4.4).  
Compound 4.20A 
5
8
213
1' 4'
5'
6'
O
O
NH
11
9
10
 
1H NMR (CDCl3):  5.71 (s, H-3), 7.91 (s, H-5), 7.41 (d, 7.9 Hz, H-7), 7.95 (d, 7.9 Hz, H-8), 
3.83 (t, 5.7 Hz, H-11), 5.87 (m, H-12), 5.29 (m, H-13), 2.76 (t, 7.6 Hz, H-1’), 2.33 (q, 7.7 Hz, 
H-2’), 5.12 (t, 7.2 Hz, H-3’), 1.53 (s, H-5’), 1.66 (s, H-6’). 13C NMR (CDCl3):  181.6 (C-1), 
148.0 (C-2), 101.3 (C-3), 183.4 (C-4), 126.5 (C-5), 150.5 (C-6), 132.1 (C-7), 126.2 (C-8), 128.3 
(C-9), 133.5 (C-10), 44.8 (C-11), 131.5 (C-12), 118.1 (C-13), 36.4 (C-1’), 29.3 (C-2’), 122.7 
(C-3’), 133.0 (C-4’), 17.6 (C-5’), 25.6 (C-6’), HRESIMS: m/z: 296.1638 [M+H]+, C19H21NO2, 
calculated: 296.1650; FTIR: 3380.08, 2925.76, 1736.64, 1673.66 and 1608.06 cm-1.  
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Compound 4.20B 
5
8
2
13
1' 4'
5'
6'
11
9
10
O
O
NH

1H NMR (CDCl3):  5.70 (s, H-2), 7.86 (s, H-5), 7.52 (d, 7.9 Hz, H-7), 7.99 (d, 7.9 Hz, H-8), 
3.83 (t, 5.7 Hz, H-11), 5.88 (m, H-12), 5.29 (m, H-13), 2.73 (t, 7.5 Hz, H-1’), 2.33 (q, 7.6 Hz, 
H-2’), 5.12 (t, 7.2 Hz, H-3’), 1.52 (s, H-5’), 1.67 (s, H-6’). 13C NMR (CDCl3):  183.3 (C-1), 
101.4 (C-2), 147.7 (C-3), 182.1 (C-4), 126.3 (C-5), 147.1 (C-6), 135.0 (C-7), 126.2 (C-8), 
131.6.3 (C-9), 130.3 (C-10), 44.9 (C-11), 131.4 (C-12), 118.2 (C-13), 35.9 (C-1’), 29.4 (C-2’), 
122.7 (C-3’), 133.0 (C-4’), 17.7 (C-5’), 25.6 (C-6’) HRESIMS: m/z: 296.1642 [M+H]+, 
C19H21NO2, calculated: 296.1650; FTIR: 3380.08, 2925.76, 1736.64, 1673.66 and 1608.06 cm-
1
.  
Compound 4.22A 
5
8
2
1' 4'
5'
6'
11
9
10
O
O
NH
OH
13
14
1816

1H NMR (CDCl3):  5.74 (s, H-3), 7.93 (s, H-5), 7.40 (d, 7.8 Hz, H-7), 7.92 (d, 7.8 Hz, H-8), 
3.40 (q, 6.9 Hz, H-11), 2.90 (t, 7.2 Hz, H-12), 6.80 (d, 8.5, Hz, H-14), 7.08 (d, 8.5 Hz, H-15), 
7.08 (d, 8.5 Hz, H-17), 6.80 (d, 8.5 Hz, H-18), 2.74 (t, 7.5 Hz, H-1’), 2.33 (q, 7.5 Hz, H-2’), 
5.12 (t, 7.2 Hz, H-3’), 1.53 (s, H-5’), 1.67 (s, H-6’). 13C NMR (CDCl3):  181.5 (C-1), 147.9 
(C-2), 101.1 (C-3), 183.4 (C-4), 126.5 (C-5), 150.6 (C-6), 132.1 (C-7), 126.2 (C-8), 128.4 (C-
9), 133.6 (C-10), 43.7 (C-11), 33.7 (C-12), 129.9 (C-13), 116.0 (C-14), 129.8 (C-15), 154.8 (C-
16), 129.8 (C-17), 116.0 (C-18), 36.5 (C-1’), 29.7 (C-2’), 122.9 (C-3’), 133.0 (C-4’), 17.9 (C-
5’), 25.7 (C-6’) HRESIMS: m/z: 376.1903 [M+H]+, C24H25NO3, calculated: 376.1919; FTIR: 
3353.55, 2922.73, 2853.68, 1677.19 and 1558.48 cm-1. 
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Compound 4.22B 
5
8
2
1' 4'
5'
6'
11
9
10
O
O
NH
OH
13
14
18
16

1H NMR (CDCl3):  5.73 (s, H-2), 7.83 (s, H-5), 7.52 (d, 7.8 Hz, H-7), 7.99 (d, 7.8 Hz, H-8), 
3.39 (q, 7.0 Hz, H-11), 2.90 (t, 7.1 Hz, H-12), 6.80 (d, 8.5, Hz, H-14), 7.08 (d, 8.5 Hz, H-15), 
7.08 (d, 8.5 Hz, H-17), 6.80 (d, 8.5 Hz, H-18), 2.72 (t, 7.5 Hz, H-1’), 2.32 (q, 7.5 Hz, H-2’), 
5.12 (t, 7.1 Hz, H-3’), 1.52 (s, H-5’), 1.67 (s, H-6’). 13C NMR (CDCl3):  183.2 (C-1), 100.8 
(C-2), 147.7 (C-3), 182.1 (C-4), 126.3 (C-5), 147.1 (C-6), 135.0 (C-7), 126.2 (C-8), 130.4 (C-
9), 131.5 (C-10), 43.8 (C-11), 33.4 (C-12), 129.9 (C-13), 115.7 (C-14), 129.8 (C-15), 154.6 (C-
16), 129.8 (C-17), 115.7 (C-18), 35.9 (C-1’), 29.4 (C-2’), 122.7 (C-3’), 133.0 (C-4’), 17.6 (C-
5’), 25.6 (C-6’) HRESIMS: m/z: 376.1906 [M+H]+, C24H25NO3, calculated: 376.1919; FTIR: 
3353.55, 2922.73, 2853.68, 1677.19 and 1558.48 cm-1. 
Compound 4.23A 
5
8
2
1' 4'
5'
6'
11
9
10
13
O
O
NH

1H NMR (CDCl3):  5.81 (s, H-3), 7.92 (s, H-5), 7.43 (d, 7.9 Hz, H-7), 7.96 (d, 7.9 Hz, H-8), 
3.98 (s, H-11), 2.34 (m, H-13), 2.75 (t, 7.6 Hz, H-1’), 2.34 (m, H-2’), 5.12 (t, 7.1 Hz, H-3’), 
1.53 (s, H-5’), 1.67 (s, H-6’). 13C NMR (CDCl3):  181.3 (C-1), 147.1 (C-2), 102.4 (C-3), 183.5 
(C-4), 126.5 (C-5), 150.8 (C-6), 132.4 (C-7), 126.3 (C-8), 128.3 (C-9), 133.3 (C-10), 32.3 (C-
11), 88.0 (C-12), 73.1 (C-13), 36.4 (C-1’), 29.3 (C-2’), 122.7 (C-3’), 133.0 (C-4’), 17.7 (C-5’), 
25.6 (C-6’) HRESIMS: m/z: 294.1490 [M+H]+, C19H19NO2, calculated: 294.1493; FTIR: 
3377.96, 3215.60, 2924.82, 1669.05 and 1629.36 cm-1. 
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Compound 4.23B 
5
8
2
1' 4'
5'
6'
11
9
10
13
O
O
NH
 
1H NMR (CDCl3):  5.80 (s, H-2), 7.86 (s, H-5), 7.53 (d, 7.8 Hz, H-7), 8.00 (d, 7.8 Hz, H-8), 
3.98 (s, H-11), 2.33 (m, H-13), 2.74 (t, 7.5 Hz, H-1’), 2.33 (m, H-2’), 5.12 (t, 7.1 Hz, H-3’), 
1.52 (s, H-5’), 1.67 (s, H-6’). 13C NMR (CDCl3):  183.3 (C-1), 102.5 (C-2), 147.4 (C-3), 181.8 
(C-4), 126.4 (C-5), 147.0 (C-6), 135.0 (C-7), 126.2 (C-8), 130.3 (C-9), 131.2 (C-10), 32.2 (C-
11), 88.0 (C-12), 73.3 (C-13), 35.9 (C-1’), 29.4 (C-2’), 122.7 (C-3’), 133.1 (C-4’), 17.7 (C-5’), 
25.6 (C-6’) HRESIMS: m/z: 294.1484 [M+H]+, C19H19NO2, calculated: 294.1493; FTIR: 
3377.96, 3215.60, 2924.82, 1669.05 and 1629.36 cm-1. 
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6-(4-methylpent-3-en-1-yl)-2/3-(morpholin-4-yl)naphthalene-1,4-dione (4.24) 
A mixture of morpholine (0.116 g, 1.3 mmoles), Cu(OAc)2 (0.080 g, 0.4 mmoles) and H2O (2 
drops) was dissolved in MeOH (3 ml) facilitated by warming on a heated oil bath. The 
naphthoquinone 4.10 (0.107 g, 0.4 mmoles) dissolved on the side in MeOH (2 ml) was then 
added to the mixture with vigorous stirring, and the stirring continued for an hour at room 
temperature under atmospheric O2. After 1 hour, the solvent was evaporated under reduced 
pressure and the residue remaining dissolved in Et2O (5 ml) and 4 % H2SO4 (5 ml). The organic 
layer was collected and the aqueous mixture further extracted using CH2Cl2 (3 x 15 ml). Pooled 
layers were dried over anhydrous Mg2SO4 and the organic solvent evaporated to yield 0.104 g 
(80.4 % yield) of a mixture of Regioisomers. 
Compound 4.24A 
5
8
2
1' 4'
5'
6'
11
9
10
O
O
N
O
13

1H NMR (CDCl3):  5.98 (s, H-3), 7.85 (s, H-5), 7.45 (d, 7.9 Hz, H-7), 7.90 (d, 7.9 Hz, H-8), 
3.49 (t, 4.9 Hz, H-11), 3.86 (t, 4.9 Hz, H-12), 3.86 (t, 4.9 Hz, H-13), 3.49 (t, 4.9 Hz, H-14), 
2.74 (t, 7.5 Hz, H-1’), 2.33 (q, 7.4 Hz, H-2’), 5.12 (t, 7.2 Hz, H-3’), 1.53 (s, H-5’), 1.67 (s, H-
6’). 13C NMR (CDCl3):  182.7 (C-1), 153.9 (C-2), 111.9 (C-3), 184.1 (C-4), 125.5 (C-5), 149.6 
(C-6), 132.8 (C-7), 127.0 (C-8), 130.7 (C-9), 132.2 (C-10), 49.2 (C-11), 66.4 (C-12), 66.4 (C-
13), 49.2 (C-14), 36.3 (C-1’), 29.3 (C-2’), 122.3 (C-3’), 133.0 (C-4’), 17.8 (C-5’), 25.7 (C-6’) 
HRESIMS: m/z: 326.1746 [M+H]+, C20H23NO3, calculated: 326.1755; FTIR: 2964.12, 
2922.40.60, 2856.01, 1672.21 and 1632.54 cm-1. 
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Compound 4.24B 
5
8
2
1' 4'
5'
6'
11
9
10
13
O
O
N
O

1H NMR (CDCl3):  5.98 (s, H-2), 7.81 (s, H-5), 7.50 (d, 7.9 Hz, H-7), 7.94 (d, 7.9 Hz, H-8), 
3.48 (t, 4.9 Hz, H-11), 3.86 (t, 4.9 Hz, H-12), 3.86 (t, 4.9 Hz, H-13), 3.48 (t, 4.9 Hz, H-14), 
2.74 (t, 7.6 Hz, H-1’), 2.33 (q, 7.5 Hz, H-2’), 5.13 (t, 7.2 Hz, H-3’), 1.53 (s, H-5’), 1.67 (s, H-
6’). 13C NMR (CDCl3):  183.9 (C-1), 112.2 (C-2), 153.7 (C-3), 183.2 (C-4), 126.6 (C-5), 147.9 
(C-6), 134.3 (C-7), 125.8 (C-8), 130.3 (C-9), 132.6 (C-10), 49.2 (C-11), 66.4 (C-12), 66.4 (C-
13), 49.2 (C-14), 36.1 (C-1’), 29.4 (C-2’), 122.7 (C-3’), 133.0 (C-4’), 17.7 (C-5’), 25.7 (C-6’) 
HRESIMS: m/z: 326.1746 [M+H]+, C20H23NO3, calculated: 326.1755; FTIR: 2964.12, 
2922.40.60, 2856.01, 1672.21 and 1632.54 cm-1. 
 
6-(2-(3,3-dimethyloxiran-2-yl)ethyl)-2-(4-hydroxyphenethylamino)naphthalene-1,4-dione 
(4.25) 
A sample of naphthoquinone 4.10 (0.250 g, 1.0 mmoles) was dissolved in anhydrous CH2Cl2 
(25 ml), and to it added NaHCO3 (0.874 g, 10.0 mmoles) with vigorous stirring for 1 min. m-
chloroperoxybenzoic acid (mCPBA) (0.897 g, 5.0 mmoles) was added afterwards to the 
reaction mixture and stirring continued for an hour at room temperature. The reaction was 
quenched by addition of 10% Na2S2O3 (30 ml) and CH2Cl2 (20 ml), followed by collection of 
the organic layer which was dried over anhydrous Na2SO4. The solvent was evaporated off and 
the crude product (4.27) obtained (0.233 g, 91.3 % yield) used in the following reaction with 
no further purification. A reaction mixture of the epoxide 4.27 (0.110 g, 0.4 mmoles) and 
tyramine (0.077 g, 0.5 mmoles) dissolved in EtOH/H2O (10 ml, 1:1 mixture) was stirred at 
room temperature for 18 hours. During the work up, H2O (10 ml) and Et2O (10 ml) were added 
and the organic layer collected.  The aqueous layer was further extracted using Et2O (2 x 25 
ml) and the pooled organic layers dried over anhydrous Na2SO4. The solvent was then removed 
under pressure on a rotary evaporator to yield 0.094 g (59.8 % yield) of compound 4.25. 
Compound 4.26 was prepared from 4.27 using the same method and details are the 
supplementary section. 
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Compound 4.25A 
5
8
2
1' 4'
5'
6'
11
9
10
13
14
1816
O
O
NH
OH
O

1H NMR (CDCl3):  5.74 (s, H-3), 7.94 (s, H-5), 7.44 (d, 7.8 Hz, H-7), 7.95 (d, 7.8 Hz, H-8), 
3.38 (q, (t), 6.8 Hz, H-11), 2.88 (t, 7.1 Hz, H-12), 6.81 (d, 8.4 Hz, H-14), 7.07 (d, 8.4 Hz, H-
15), 7.07 (d, 8.4 Hz, H-17), 6.81 (d, 8.4 Hz, H-18), 2.88 (m, H-1’), 1.89 (m, H-2’), 2.76 (t, 6.22 
Hz, H-3’), 1.16 (s, H-5’), 1.28 (s, H-6’). 13C NMR (CDCl3):  181.4 (C-1), 148.0 (C-2), 100.7 
(C-3), 183.2 (C-4), 126.1 (C-5), 149.5 (C-6), 132.2 (C-7), 126.8 (C-8), 128.7 (C-9), 130.5 (C-
10), 43.8 (C-11), 33.4 (C-12), 129.6 (C-13), 115.8 (C-14), 129.7 (C-15), 154.8 (C-16), 129.7 
(C-17), 115.8 (C-18), 32.7 (C-1’), 30.1 (C-2’), 63.5 (C-3’), 58.7 (C-4’), 18.6 (C-5’), 24.7 (C-
6’) HRESIMS: m/z: 392.1843 [M+H]+, C24H25NO4, calculated: 392.1861; FTIR: 3358.95, 
2926.80, 1676.77 and 1557.80 cm-1. 
Compound 4.25B 
5
8
2
1' 4'
5'
6'
11
9
10
13
14
18
16
O
O
NH
OH
O

1H NMR (CDCl3):  5.74 (s, H-2), 7.86 (s, H-5), 7.56 (d, 7.8 Hz, H-7), 8.02 (d, 7.8 Hz, H-8), 
3.39 (q, (t), 6.8 Hz, H-11), 2.90 (t, 7.1 Hz, H-12), 6.80 (d, 8.4 Hz, H-14), 7.08 (d, 8.4 Hz, H-
15), 7.08 (d, 8.4 Hz, H-17), 6.80 (d, 8.4 Hz, H-18), 2.89 (m, H-1’), 1.89 (m, H-2’), 2.75 (t, 6.30 
Hz, H-3’), 1.16 (s, H-5’), 1.27 (s, H-6’). 13C NMR (CDCl3):  183.0 (C-1), 101.0 (C-2), 147.7 
(C-3), 182.0 (C-4), 126.0 (C-5), 146.2 (C-6), 135.0 (C-7), 126.5 (C-8), 130.5 (C-9), 131.8 (C-
10), 43.9 (C-11), 35.5 (C-12), 129.9 (C-13), 115.7 (C-14), 129.8 (C-15), 154.6 (C-16), 129.8 
(C-17), 115.7 (C-18), 32.7 (C-1’), 30.2 (C-2’), 63.5 (C-3’), 58.6 (C-4’), 18.6 (C-5’), 24.7 (C-
6’), HRESIMS: m/z: 392.1850 [M+H]+, C24H25NO4, calculated: 392.1861; FTIR: 3358.95, 
2926.80, 1676.77 and 1557.80 cm-1. 
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Compound 4.26A 
5
8
2
1'
4'
5'
6'
11
9
10
13
O
O
N
O
O
 
1H NMR (CDCl3):  5.99 (s, H-3), 7.88 (s, H-5), 7.48 (d, 7.9 Hz, H-7), 7.94 (d, 7.9 Hz, H-8), 
3.50 (t, 4.8 Hz, H-11), 3.86 (t, 4.8 Hz, H-12), 3.86 (t, 4.8 Hz, H-13), 3.50 (t, 4.8 Hz, H-14), 
2.90 (m, H-1’), 1.90 (m, H-2’), 2.75 (t, 6.2 Hz, H-3’), 1.16 (s, H-5’), 1.28 (s, H-6’). 13C NMR 
(CDCl3):  182.6 (C-1), 153.7 (C-2), 111.9 (C-3), 183.9 (C-4), 125.4 (C-5), 148.5 (C-6), 132.9 
(C-7), 127.3 (C-8), 130.9 (C-9), 132.4 (C-10), 49.2 (C-11), 66.5 (C-12), 66.5 (C-13), 49.2 (C-
14), 33.0 (C-1’), 30.2 (C-2’), 63.7 (C-3’), 58.6 (C-4’), 18.8 (C-5’), 24.7 (C-6’) HRESIMS: m/z: 
342.1699 [M+H]+, C20H23NO4, calculated: 342.1705; FTIR: 2925.98, 1736.12, 1672.30 and 
1630.33 cm-1. 
Compound 4.26B 
5
8
2
1' 4'
5'
6'
11
9
10
13
O
O
N
O
O
 
1H NMR (CDCl3):  5.99 (s, H-2), 7.84 (s, H-5), 7.54 (d, 7.9 Hz, H-7), 7.97 (d, 7.9 Hz, H-8), 
3.48 (t, 4.7 Hz, H-11), 3.86 (t, 4.7 Hz, H-12), 3.86 (t, 4.5 Hz, H-13), 3.48 (t, 4.7 Hz, H-14), 
2.89 (m, H-1’), 1.90 (m, H-2’), 2.75 (t, 6.22 Hz, H-3’), 1.17 (s, H-5’), 1.29 (s, H-6’). 13C NMR 
(CDCl3):  183.7 (C-1), 112.2 (C-2), 153.7 (C-3), 183.0 (C-4), 126.7 (C-5), 147.2 (C-6), 134.3 
(C-7), 126.0 (C-8), 130.5 (C-9), 132.8 (C-10), 49.3 (C-11), 66.6 (C-12), 66.6 (C-13), 49.3 (C-
14), 32.9 (C-1’), 30.3 (C-2’), 63.6 (C-3’), 58.6 (C-4’), 19.1 (C-5’), 24.6 (C-6’) HRESIMS: m/z: 
342.1697 [M+H]+, C20H23NO4, calculated: 342.1705; FTIR: 2925.98, 1736.12, 1672.30 and 
1630.33 cm-1. 
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4.4.4 Synthesis of fourth series of naphthoquinone derivatives 
8-(4-methylpent-3-en-1-yl)-3,4-dihydro-2H-naphtho[2,3-b][1,4]thiazine-5,10-dione 1,1-
dioxide (4.28) 
Hypotaurine (0.033 g, 0.3 mmoles in 1 ml H2O) was added in portions to a pre-dissolved 
naphthoquinone 4.10 (0.050 g, 0.2 mmoles) in CH3CN/EtOH (10 ml, 1:1) maintained at a 
temperature of 70 °C. The reaction mixture was allowed to reflux at 70 °C for 2.5 hours, after 
which it was cooled to room temperature and the solvent evaporated. The remaining residue 
was reconstituted in H2O (20 ml) and extracted using EtOAc (3 x 25 ml). The pooled EtOAc 
fractions were washed twice with H2O (2 x 20 ml) and dried over anhydrous Na2SO4. The 
solvent was then removed under reduced pressure to give 0.047 g (68.3 % yield) of crude 
product which was purified by column chromatography (Hex/EtOAc 25:75). 
Compound 4.28 
5
8
2
1'
4'
5'
6'
11 9
10
12
O
O
S
N
H
O O

1H NMR (CDCl3):  8.01 (s, H-5), 7.47 (d, 7.8 Hz, H-7), 7.96 (d, 7.9 Hz, H-8), 3.36 (m, H-11), 
4.13 (m, H-12), 2.77 (t, 7.5 Hz, H-1’), 2.33 (q, 7.3 Hz, H-2’), 5.09 (t, 7.1 Hz, H-3’), 1.51 (s, H-
5’), 1.66 (s, H-6’). Anal. (C18H19NO4S). 13C NMR (CDCl3):  178.6 (C-1), 113.3 (C-2), 145.4 
(C-3), 175.7 (C-4), 127.2 (C-5), 152.7 (C-6), 133.4 (C-7), 127.1 (C-8), 127.2 (C-9), 132.6 (C-
10), 49.1 (C-11), 39.9 (C-12), 36.6 (C-1’), 29.2 (C-2’), 122.3 (C-3’), 133.3 (C-4’), 17.6 (C-5’), 
25.7 (C-6’) (Aiello, et al., 2003). 
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2-methyl-2-(4-methylpent-3-en-1-yl)-2H-benzo[g]chromene-5, 10-dione (4.29) 
A mixture of reagents, 2-hydroxynaphthoquinone (1.470 g, 8.44 mmoles), citral (0.479 g, 2.8 
mmoles), -alanine (0.038 g, 0.4 mmoles) and AcOH (0.2 ml) was dissolved in C6H6 (100 ml) 
in a 250 ml round bottomed flask and refluxed at 80-85 °C for 3 hours. The reaction mixture 
was then cooled to room temperature and the solvent evaporated off under vacuum. The 
resulting crude was passed through a plug of silica gel eluting in step-gradient fashion, initially 
with 9:1 (Hex/EtOAc), 50:50 (Hex/EtOAc and 100 % MeOH. 50:50 (Hex/EtOAc) fraction 
yield compound 4.30 ( 2.076 g, 79.8 % yield) in its pure form. 
 
Compound 4.29 
82
1'
4'
5'
6'
11
9
1014
O
O
O 7' 
1H NMR (CDCl3):  5.69 (d, 10.1 Hz, H-7), 6.68 (d, 10.1 Hz, H-8), 8.06 (dd, 7.5; 1.4 Hz, H-
11), 7.67 (m, H-12), 7.67 (m. H-13), 8.06 (dd, 7.5; 1.4 Hz, H-14), 1.93 (m, H-1’), 2.11 (m, H-
2’), 5.03 (t, 7.1 Hz, H-3’), 1.53 (s, H-5’), 1.60 (s, H-6’), 1.50 (s, H-7’). 13C NMR (CDCl3):  
181.3 (C-1), 131.5 (C-2), 131.5 (C-3), 179.6 (C-4), 83.1 (C-6), 129.7 (C-7), 116.0 (C-8), 117.4 
(C-9), 152.7 (C-10), 126.1 (C-11), 133.9 (C-12), 133.1 (C-13), 126.1 (C-14), 41.2 (C-1’), 22.6 
(C-2’), 123.5 (C-3’), 132.2 (C-4’), 17.6 (C-5’), 25.8 (C-6’), 27.6 (C-7’) (Jung, et al., 2010). 
 
 
 
 
 
 
 
 
 


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CHAPTER FIVE 
 
Biological activity of truncated prenylated naphthoquinones 
Abstract 
Cytotoxicity and client protein degradation assays were conducted on selected natural products and 
synthesized truncated prenylated naphthoquinones. The synthesized analogues showed improved 
cytotoxicity compared to the natural products, and also demonstrated moderate activity for Hsp90 
inhibition. Arylamino-naphthoquinones (4.14-4.19) were the most cytotoxic derivatives, whilst SQA 
(2.47) showed the most potency as an Hsp90 protein inhibitor. Binding to Hsp90 protein was somehow 
different compared to geldanamycin’s (2.28) interaction with the chaperone, as no Hsp70 induction was 
noticed with both SQA (2.47) and selected naphthoquinone derivatives, which could potentially mean 
binding to the C-terminus of Hsp90 protein. The assays are described in more detail in this chapter.    
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5.1 Introduction 
In vitro assays were conducted to determine cytotoxic properties of the synthesized truncated 
prenylated naphthoquinones (4.10-4.29) and natural products (2.47, 3.1-3.3, 3.5 and 3.6-3.11). 
Client protein degradation assays were also done as a measure for Hsp90 inhibition. Our main 
goal was to develop cytotoxic compounds that inhibit Hsp90 function as a potential class of 
anticancer compounds.   
5.1.1 Cytotoxicity assays 
Cytotoxicity studies with cell culture systems provide useful information during the screening 
of substances with potential anticancer properties. Several indicators are used to determine the 
toxic effect of compounds on cancer cells. The most readily observed effect of cytotoxicity is 
morphological changes in the cells, which can be done microscopically. Other indicators 
include altered cell growth/cell reproduction measured by cell count, and determination of cell 
death by use of vital dyes and cell proliferation reagents to measure cell viability (Gerets, et 
al., 2009). A number of approaches have been developed to rapidly evaluate the cytotoxic 
activity of test substances (Liu, et al., 1997). Accepted methods used to quantify cell viability 
in cell-based assays include lactate dehydrogenase (LDH) release assays, trypan blue 
exclusion, and 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) 
reduction assays (Kim, et al., 2009). 
5.1.1.1 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) reduction 
assays 
This assay measures the conversion of a yellow tetrazolium salt, MTT (5.1), into purple 
formazan crystals (5.2) by redox activity of metabolically active cells (Vistica, et al., 1991) 
(Scheme 5.1). The MTT (5.1) reagent is absorbed via endocytosis and reduction occurs in 
active cellular mitochondria (Burdon, et al., 1993). Reduction to formazan (5.2) is effected by 
intracellular NAD(P)H oxidoreductases enzymes (Berridge, et al., 2005) and the formazan 
(5.2) dye formed is quantified by absorbance at 550 nm and 650 nm using a scanning multi-
well spectrophotometer (ELISA plate reader). Cell viability is proportional to the increase in 
formazan product (5.2) formed. Conversely, a decrease in MTT (5.1) reduction can be used as 
a marker for cell damage/death.  
 

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Scheme 5.1: Reduction of MTT (5.1) to a formazan (5.2) salt by viable cells 
Various different tetrazolium dyes can be used for colorimetric assays. A common alternative 
to MTT (5.1) involves the use of disodium mono (4-(3-(-iodophenyl)-2-(4-nitrophenyl)-2H-
tetrazol-3-ium-5-yl) benzene-1, 3-disulfonate (WST-1), as a cell proliferation reagent. It is also 
a tetrazolium salt and works on similar principles as MTT (5.1), namely that it is reduced to 
formazan dye by active cellular mitochondria, which indicates cell viability (Ngamwongsatit, 
et al., 2008). The WST-1 formazan product is detected by absorbance at 440 nm and a decrease 
in WST-1 reduction signifies cell damage or death.  
Mammalian cell culture is an important component of research in understanding disease 
profiles and possible treatments especially in the cancer field. The majority of breast cancer 
research is conducted using established breast cancer cell lines as in-vitro models and these 
include cell lines such as the MCF7 and MDA-MB-231 breast adenocarcinoma and Hs578T 
breast carcinoma (Burdall, et al., 2003). Immortalised cell lines are relatively easy to handle, 
easy to replace from frozen stocks in case of contamination and have the ability to grow to 
infinite quantities when cultured. However they are susceptible to genotypic and phenotypic 
changes when continuously cultured. Despite some disadvantages, cell cultures are still 
commonly used for cancer research. For this study, we used the Hs578T breast carcinoma 
(triple negative) and its properties are briefly discussed below. 
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5.1.1.2 Hs578T breast carcinoma 
Hs578T breast carcinoma belongs to a rare subset of cancer known as metaplastic breast 
cancers. Morphology of the tumour comprises of adenocarcinoma cells that co-exist with an 
admixture of spindle cell, squamous, chondroid or bone-forming neoplastic cells. (Schwartz, 
et al., 2013). Under the NCI guidelines, Hs578T breast carcinoma cells are categorized as a 
triple negative form of breast cancer and are extremely difficult to treat (Chavez, et al., 2010). 
Their growth is not influenced by the hormones oestrogen and progesterone nor by the presence 
of human epidermal growth factor receptors 2 (HER 2), therefore cannot be treated by 
hormonal therapy such as tamoxifen or HER 2 receptor blockers like Herceptin (Otvos, et al., 
2011). Since this form of cancer is difficult to treat, the Hs578T breast carcinoma cell line is a 
good choice to use in cytotoxic studies for novel anticancer compounds. 
5.1.2 Client protein degradation assays 
Several in vitro assays have been developed to assess Hsp90 inhibition by monitoring 
concentrations of oncogenic client proteins before and after exposure of the chaperone to 
suspected inhibitors (Jhaveri, et al., 2012). While it is possible to obtain a direct measure of 
Hsp90 activity by assessing ATPase activity, the low in vitro ATPase activity of human Hsp90 
means that these assays are technically challenging. In addition, ATPase activity is only 
relevant for Hsp90 inhibitors that bind to the N-terminal ATPase domain. The routine and 
accepted assays for inhibition of Hsp90 depend on assessment of the levels of proteins 
associated and regulated by its action.  As previously indicated, Hsp90 inhibition leads to 
ubiquitination of client proteins prior to proteasomal degradation (Zuehlke and Johnson, 2010). 
Several canonical client proteins such as CDK4, Raf-1 and c-KIT are reduced in concentration 
in the presence of Hsp90 inhibitors. Hsp70 induction can also be used as a marker for inhibition 
of Hsp90 function, and is used in several cancer models to assess Hsp90 activity (Jhaveri, et 
al., 2012). 
5.1.3 Aim of study 
The aim of the study was to determine the cytotoxicity of the synthesized analogues (4.10-
4.29) in comparison to the natural compounds SQA (2.47) and SNQA (3.5), and to assess 
Hsp90 function in the presence of selected naphthoquinones by monitoring client protein 
concentrations. The rationale for the synthesis of these analogues was to develop a series of 
cytotoxic molecules that have Hsp90 inhibition properties, and we also aimed to determine if 
any correlation exists between cytotoxicity and Hsp90 inhibition.  
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NB: i) Chemical structures have been redrawn for convenience ii) Only C-2 substituted naphthoquinones are displayed but 
both isomers were tested for biological activity 
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5.2 Results and discussion  
5.2.1 Cytotoxicity of natural product quinones 
The reported in vitro assays were conducted by Dr Adrienne L. Edkins and Dr Jo Anne de 
Mare of the Biomedical Biotechnology Research Unit (BioBRU) at Rhodes University, South 
Africa. Cytotoxicity assays were conducted in triplicate against MDA-MB-231 cell line for the 
meroterpenoids (de la Mare, et al., 2012) and against Hs578T cell line for lapachol (3.6) and 
its related compounds. Both cell lines are classified as triple negative forms of cancer and are 
difficult to treat. The results obtained are shown in Table 5.1. 
Table 5.1: Cytotoxicity of natural product quinones 
Sample MDA-MB-231 
IC50 (µM) 
Hs578T  
IC50 (µM) 
3.1 70.0 - 
2.47 658.0 - 
3.2 69.0 - 
3.3 56.0 - 
3.4 - - 
3.5 2140.0 - 
3.6 - 38.4 
3.7 - 13.0 
3.8 - 1.2 
3.9 - 4.2 
3.10 - 2.1 
3.11 - 15.1 
 
The meroterpenoids (2.47, 3.1-3.4 and 3.5) isolated from S. incisifolium displayed moderate 
cytotoxic properties. The transition from the hydroquinone - quinone - naphthoquinone in 
compounds 3.1, 2.47 and 3.5 showed a decrease in activity. Compound 3.3, containing a 
chromene moiety exhibited the highest potency of the meroterpenoid series (IC50 = 56.0 µM) 
while sarganaphthoquinoic acid (3.5) was in essence non-toxic. Interestingly, lapachol and its 
derivatives (3.6-3.11) showed enhanced cytotoxicity, with values as low as 1.2 µM for 
compound 3.8. Given the data above, the challenge was to improve on the cytotoxicity of SQA 
(2.47) while maintaining its ability to inhibit Hsp90 function. Attention was given to a 
prenylated naphthoquinone series because of the increased cytotoxicity of lapachol 
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naphthoquinones and the reported Hsp90 inhibition potential of acetamide and benzamide 
naphthoquinone analogues (Hadden, et al., 2009). 
5.2.2 Cytotoxicity of truncated prenylated naphthoquinones 
The first series of naphthoquinones contained H, Cl, CH3 and CH3O at the 2- or 3- position. 
These compounds closely resemble sarganaphthoquinoic acid (3.5), the lead structure for this 
series. Naphthoquinones (4.10-4.13) were evaluated in a three point assay against Hs578T 
breast cancer carcinoma (triple negative), with taxol as the control. An MTT assay was used to 
determine percentage cell survival after 96 hours, and percentage cell survival results obtained 
at 10 µM are displayed in Table 5.2. Percentage cell survival results at 1 µM and 100 µM are 
shown in the supplementary section (Figures S5.1-S5.8)  
Table 5.2: Percentage cell survival at 10 µM concentrations 
Sample Breast carcinoma Hs578T 
(Percentage survival at 10 
µM  concentration) 
4.10 10.3 
4.11A 54.3 
4.11B 66.9 
4.12A 63.9 
4.12B 56.3 
4.13A 57.8 
4.13B 24.3 
 
Estimated IC50 values for compounds in this series suggested either similar or improved 
cytotoxicity when compared to the natural products. This is remarkable especially when one 
compares naphthoquinone 4.13A to sarganaphthoquinoic acid (3.5) (IC50 = 2140.0 µM). The 
main difference between these two compounds is the shortened prenylated chain in 4.13A. The 
unsubstituted naphthoquinone, 4.10, was more cytotoxic than the substituted compounds 4.11-
4.13. A possible explanation could be its increased likelihood to undergo redox cycling and an 
increased susceptibility to nucleophilic attack by biological nucleophiles. 
Cytotoxicity of aryl and alkyl amino-substituted naphthoquinone derivatives 4.14-4.29 is 
shown in Table 5.3. Assays were also conducted against the Hs578T breast cancer carcinoma 
(triple negative) at a concentration range between 0.005 to 50 µM.  The assays were done in 
triplicate for an incubation period of 96 hours and analysed by MTT assay.  
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Table 5.3: Cytotoxicity of aryl and alkyl amino-substituted naphthoquinone derivatives against 
Hs578T breast cancer carcinoma (triple negative) 
Sample Breast carcinoma Hs578T 
IC50 values (µM) 
4.10 9.6 
Arylamino analogues 
4.14A 2.3 
4.14B 4.3 
4.15A 0.3 
4.15B 0.6 
4.16A 0.3 
4.16B 1.8 
4.17A 4.9 
4.17B 2.7 
4.18A  50 
4.18B 0.8 
4.19A 0.9 
4.19B 0.9 
Alkylamino analogues 
4.20A 7.6 
4.20B  50 
4.21 2.6 
4.22A  50 
4.22B 15.6 
4.23A 8.6 
4.23B  50 
4.24A  50 
4.24B  50 
4.25A  50 
4.25B  50 
4.26A  50 
4.26B  50 
Tricyclic analogues 
4.28 8.4 
4.29 10.7 
Natural Product: sargaquinoic acid 
2.47  50 
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Substitution with arylamino moieties for compounds 4.14-4.19 resulted in an increase in 
cytotoxicity, with some IC50 values falling within the nanomolar range. No clear trends could 
be observed from this group although activity seemed to be enhanced by electron donating 
groups in the para-position of the aniline moiety. Compounds 4.15 and 4.16 that had -CH3 and 
-OCH3 groups respectively on the para-position of the aniline moiety were the most active with 
IC50 values as low as 0.3 µM. Oxygenated substituents e.g. 4.19 also showed enhanced 
cytotoxic properties. Differences in cytotoxic activity between regioisomers was relatively 
small indicating that C-2 or C-3 substitution does not necessarily influence cytotoxic behaviour 
except for compounds 4.18A and 4.18B.  
With regards to alkylamino-naphthoquinones (4.20-4.26), our preliminary results showed that 
they were less potent than the arylamino substituted compounds (4.14-4.19).  The most active 
compound amongst the alkylamino-naphthoquinones was 4.21 with an IC50 value of 2.6 µM. 
Introduction of an aryl moiety in exchange of the tertiary amine in 4.21, to prepare 4.22 resulted 
in a less potent molecule. A terminal amino-moiety might be influential in increasing cytotoxic 
activity of these naphthoquinones.  
Attempts to increase the water solubility of naphthoquinones by attaching a morpholino 
functionality resulted in less cytotoxic compounds (4.24 and 4.26). Their IC50 values were 
undetermined since the cut off activity in our studies was 50 µM. Any manipulation of the 
prenyl side chain also resulted in less potent molecules. Introduction of an epoxide 
functionality rendered the naphthoquinones 4.25 and 4.26 inactive which was surprising given 
that epoxides are reactive species that are more likely to interact with macromolecules in a 
biological system.  
Tricyclic prenylated naphthoquinones 4.28 and 4.29 were more active than the parent natural 
product but comparable to the unsubstituted naphthoquinone 4.10. The recorded IC50 values 
were 8.4 µM and 10.7 µM for compounds 4.28 and 4.29 respectively, whilst for compound 
4.10, it was 9.6 µM.  
According to these preliminary results, substitution with arylamines at the C-2 or C-3 position 
of the quinone increases potency of naphthoquinones as cytotoxic agents, approximately 700 
times and 2000 times more compared to natural compounds 2.47 and 3.5, respectively. 
Questions may arise with regards to how redox potential is affected by such substitution but it 
is probable that a new mode of action is at play with arylamino substituted naphthoquinones. 
Improved cytotoxicity values from the synthesized derivatives were encouraging, and with the 
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goal of developing cytototoxic Hsp90 inhibitiors, in vitro assays to assess the ability of 
naphthoquinones to inhibit Hsp90 protein and its functions were advocated for. Client protein 
degradation assays were conducted as a measure for Hsp90 function. It was however not 
possible to screen all synthesized derivatives in these studies due to limited protein availability, 
and a selected few were chosen. 
5.2.3 Selected naphthoquinones for client protein degradations assays 
Compounds for client protein degradation assays were chosen based on the cytotoxicity data 
discussed. The obtained cytotoxic results enabled compounds to be categorized into three 
groups i.e. active (IC50 value: nanomolar range), less active (IC50 value: 1-50 µM) and inactive 
(IC50 value:  50 µM) compounds. One or two compounds from each of these groups were 
selected i.e. 4.16A, 4.28, 4.29, 2.47 and 4.20A. Compound 4.16A was the most active 
naphthoquinone with an IC50 value of 0.3 µM. Compounds 4.28 and 4.29 were less active with 
IC50 values of 8.4 µM and 10.7 µM respectively, whilst 2.47 had an undetermined IC50 value 
greater than 50 µM. Compound 4.20A had an interesting allylamine moiety observed on 17-
AAG (2.29) and was included in the study. The effect of these compounds was compared to 
treatment with an equivalent level of the known N-terminal Hsp90 inhibitor, geldanamycin 
(2.28). The selection was done as indicated so as to assess Hsp90 inhibition properties across 
the board, from cytotoxic to non-cytotoxic molecules.  
O
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5.2.4 Client protein degradation assays results 
The discussed assays were conducted by Dr Adrienne L. Edkins and Dr Jo Anne de Mare of 
the Biomedical Biotechnology Research Unit (BioBRU) at Rhodes University, South Africa. 
Hs578T breast cancer cells were treated with 1 µM concentrations of compounds 4.16A, 
4.20A, 4.28, 4.29 and 2.47 for 16 hours. Equal cell numbers were probed for the levels of 
CDK4, Hsp70 and Histone H3 (loading control for total protein). A densitometry graph was 
plotted from data obtained from the Western blot. The signal of either CDK4 or Hsp70 was 
normalised to the loading control by dividing the densitometry of CDK4 or Hsp70 by the 
densitometry of the Histone H3 band in the respective lanes (Figure 5.1). 
 
 
Figure 5.1: Western Blot indicating bands for Hsp70, CDK4 and histone 
All signals were normalised to the untreated that was assigned a value of 1 with the rest being 
relative to this value. The results obtained are shown in the Figure 5.2 below:  
 
 
Figure 5.2: A densitometry graph showing levels of Hsp70 and CDK4 in the presence of 
selected inhibitors 
  GA    UN  4.16A   4.20  4.29   4.28   2.47  
Hsp70 
CDK4 
Histone 
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TREATMENT 
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The positive control used was geldanamycin (2.28) which gave the anticipated increase in 
Hsp70 levels (relative to the untreated) and decrease in CDK4 levels (relative to the untreated). 
Increase in Hsp70 levels is consistent with published reports for N-terminal inhibitors and has 
been established to be a source of Hsp90 drug resistance and failed cancer therapies with this 
target (Piper and Millson, 2011). N-terminal domain inhibitors result in the formation of active 
heat shock transcription factor 1 (HSF 1) that induces a heat shock response and increases 
cellular levels of pro-survival chaperones like Hsp27 and Hsp70 (Bagatell, et al., 2000). These 
chaperones inhibit cytochrome c and TNF-mediated cell death as part of their pro-survival core 
functions with enhanced ability to evade apoptosis (McCollum, et al., 2006; Powers, et al., 
2008). Silencing of Hsp70 expression has been shown to promote proteasome-dependant 
degradation of Hsp90 client proteins. In other human cancer cell lines, G1 cell cycle arrest 
occurs, together with extensive tumour specific apoptosis (Powers, et al., 2008). This setback 
is common in other classes of compounds e.g. purines and resorcinol derivatives (McCollum, 
et al., 2008).  
The set of compounds tested showed moderate Hsp90 inhibition by reducing levels of CDK4, 
but interestingly showed no increase in Hsp70 concentrations. Compound 2.47 displayed 
inhibition comparable to that of geldanamycin (2.28) with regards to CDK4 reduction. Of the 
naphthoquinones, 4.20A was the most potent Hsp90 inhibitor, with 4.29 showing the least 
potency. No correlation between cytotoxicity and Hsp90 inhibition could be made. 
Interestingly, 2.47 was deemed non-toxic but demonstrated the most potential as an Hsp90 
inhibitor in this assay. Unfortunately, sarganaphthoquinoic acid (3.5) could not be assessed in 
the same assay. The most cytotoxic compounds from the naphthoquinones, 4.16A, and the less 
active cytotoxic compounds 4.28 and 4.29, all exhibited average Hsp90 inhibition. 4.20A 
included on the basis of it having the allylamine moiety found on 17 AAG (2.29) was the 
second most potent Hsp90 inhibitor after compound 2.47. Although there was no correlation 
between cytotoxicity and Hsp90 inhibition, the positive results obtained indicated the 
possibility of developing a molecule that possesses both cytotoxic and Hsp90 inhibition 
properties.  
Lack of Hsp70 induction by these molecules is favourable and most likely lessens the chances 
of drug resistance development. Lack of Hsp70 induction also suggests C-terminal binding on 
Hsp90 that promotes client protein degradation without activation of HSF1 function; hence no 
increase in Hsp70 or Hsp27 concentrations occurs (Shelton, et al., 2009).  Research has been 
shifting in designing inhibitors that bind to this C terminal pocket in preference to the N-
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terminal domain. One such inhibitor being researched on is KU135 (Shelton, et al., 2009). 
Other studies are focusing on blocking the effects of HSF1 though such a route has its own 
draw backs of compromising normal tissue functioning (de Billy, et al., 2009). Combination 
therapy with N-terminal inhibitors is also being considered to reduce drug resistance (Piper and 
Millson, 2011).  
5.3 Conclusion 
Further studies to determine N- or C- terminal binding of naphthoquinones were conducted 
using Saturation Transfer Difference (STD) NMR and molecular docking studies. We aimed 
to deduce whether our series of naphthoquinones bind to the C-terminal domain, or bind to 
both with a higher affinity for the C-terminus. Was it also possible that they were binding to 
the N-terminal domain with no increase in Hsp70 concentrations? All these questions were 
attempted to be answered in the next chapter that deals with interactions of the 
naphthoquinones with the Hsp90 protein’s active sites. 
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5.4 Experimental 
5.4.1 Cell culture 
Hs578T breast cancer cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) 
(Gibco) supplemented with 10 % (v/v) heat inactivated fetal bovine serum (FBS), 100 U/ml  
penicillin, 100 µg/ml streptomycin and 2.5 g/ml  amphotericin (Lonza) in T75 culture flasks 
(Corning). The flasks were incubated at 10 % CO2, 37 ºC until cell confluency was observed 
under the microscope. The cells were then harvested by aspirating the media from the flask, 
washing the cells with a phosphate buffered saline solution (PBS) and adding 0.5 ml of 
trypsin/ethylenediaminetetra acetic acid (EDTA) (Gibco) to facilitate dislodging of adherent 
cells. The trypsinized flask was incubated at 10 % CO2, 37 ºC for 5-7 minutes for the cells to 
be lifted. Once cells had been dislodged, trypsin was quenched by addition of 10 ml of DMEM 
supplemented with FCS. The cells were transferred to a 15 ml centrifuge tube and centrifuged 
(Eppendorf centrifuge 5804R instrument) at 2000 rpm for 2 minutes, and resuspended in 10 ml 
of growth medium. A cell count was then carried out using a haemocytometer and volumes 
adjusted so as to obtain a cell density of 1.2 x 105 (120 000) cells per ml. 
 
5.4.2 Cytotoxicity assay 
Hs578T breast cancer cells were seeded in 96 well microplates at a concentration of 6000 cells 
per well (i.e. 50 l of 1.2 x 105 cells/ml cell suspension was added to each well), and the plates 
were incubated overnight at 37ºC, 10 % CO2. Concentrations between a range of 0.005 to 50 
µM were chosen. Sample analogues were first dissolved in sterile DMSO (Sigma). The assay 
was validated by including paclitaxel as a positive control on each 96 well microplate, at 
concentrations ranging from 50 nM to 10 µM. Duplicate wells were left blank with only cells 
and media with no dosing, and another set dosed with DMSO only. These acted as negative 
controls of the assay. Dosed plates were then incubated at 37 ºC, 10% CO2 for 96 h. 
Cytotoxicity testing for the individual analogues was carried out in duplicate. 
A qualitative analysis of the cells was done by viewing respective wells under a microscope 
after 96 h. The morphology and density of cells were noted as additional indicators of 
cytotoxicity. Quantitative analysis was done using a Cell Proliferation Kit 1 (MTT) (Roche) 
whereby 10 µl of MTT cell proliferation reagent was added to each well, followed by an 
incubation period of 4 hours at 37 ºC and 10% CO2. A 100 µl volume of solubilization solution 
was added to all the wells and overnight incubation done at 37 ºC and 10 % CO2. The colour 
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change from yellow to purple for each well was measured using a multi-well spectrophotometer 
(PowerWave) set at dual wavelengths, 550 nm and 650 nm. The average absorbance for each 
analogue at different concentrations was calculated and wells with cells and media only, 
assigned a 100% cell survival.Percentage survival of cells at each concentration for all the 
analogues was calculated relative to the DMEM control. The calculation of the IC50 value 
(which represents the concentration of compound resulting in 50% growth inhibition) was 
determined by taking the log10 of the concentrations and plotting percentage survival against 
log10 concentration, to which a trendline was added and IC50 values calculated using the 
equation of the line y = mx + c.  
5.4.3 Client protein degradation assay 
Hs578T breast cancer cells were cultured in Dulbecco’s modified Eagle’s Medium (DMEM) 
supplemented with 5 % (v/v) foetal calf serum (FCS), 2 mM glutamine and 100 U/mL 
penicillin-streptomycin-amphotericin. Hs578T cells were seeded on to tissue culture plastic 
and allowed to adhere overnight prior to treatment with 1 µM concentrations of 
compounds 4.16A, 4.20A, 4.28, 4.29 and 2.47 or vehicle control (DMSO) for 16 hours. Cells 
were harvested by trypsinisation, counted using a haemocytometer and resuspended to the same 
cell density in SDS-PAGE lysis buffer (250 mM Tris-HCl, pH 6.8, 10% w/v SDS, 30% v/v 
glycerol, 5% v/v -mercaptoethanol, 0.02% w/v bromophenol blue) and boiled for 5 minutes. 
Total protein from equal cell numbers were resolved by SDS-PAGE according to the protocol 
of Laemmli (1970). The proteins were separated by electrophoresis for 1 hour and 30 minutes 
at 100 V in 1 x SDS running buffer (0.25 mM Tris, 192 mM glycine, 1% w/v SDS) using a 
12% (v/v) resolving gel (1.5 M Tris-HCl, pH 8.8), and a 4% (v/v) stacking gel (0.5 M Tris-
HCl, pH 6.8). Proteins were subsequently transferred on to nitrocellulose, and the levels of 
CDK4, Hsp70 and Histone H3 (loading control for total protein) determined by Western blot 
analysis with chemiluminescent detection according to the protocol of Towbin (1979). The 
chemiluminescent patterns were captured electronically and the densitometry of the bands 
detected using ImageJ. A densitometry graph was plotted from data obtained from the Western 
blot, whereby the signal of either CDK4 or Hsp70 was normalised to the loading control by 
dividing the densitometry of CDK4 or Hsp70 by the densitometry of the Histone H3 band in 
the respective lanes" 
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CHAPTER SIX 
 
Molecular modelling and STD NMR studies 
Abstract 
Binding interactions of selected naphthoquinone derivatives with Hsp90 protein were assessed using 
molecular docking and saturation transfer difference (STD) NMR techniques. Molecular docking 
results indicated N-terminal binding with aryl amino-naphthoquinones (4.14-4.19) having binding 
energies comparable to ATP. However STD NMR results were inconclusive, and no binding was 
observed on both the N- and C- terminal ends, probably due to weak binding and poor water solubility 
of the selected compounds. This chapter describes the two techniques separately and the results obtained 
for each technique.   
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6.1 Introduction 
In chapter five, we provided indirect evidence for Hsp90 inhibition by the synthesized 
naphthoquinones. In this chapter we explored additional studies to assess the direct interaction 
of naphthoquinones with Hsp90 protein, and to determine whether binding occurs at the N- or 
C- terminal domain. Molecular docking studies were advocated for but are insufficient as 
“stand alone” experiments to deduce accurate conclusions about actual binding interactions. 
Saturation Transfer Difference (STD) NMR studies were attempted to complement results that 
were obtained from docking studies. The two techniques are described in detail in this chapter.  
6.1.1 Molecular docking 
Geldanamycin (2.28) was the first natural product isolated from Streptomyces hygroscopicus 
that exhibited Hsp90 inhibition properties (He, et al., 2006; Neckers and Workman, 2012). It 
comprises of a benzoquinone moiety bridged by an aliphatic chain as shown in chapter two 
(section 2.3.2). Naphthoquinones possess a similar benzoquinone moiety fused to a benzenoid 
ring that could potentially fit the ATP binding site at the N-terminus of Hsp90. Reports have 
previously been published suggesting that 1, 4-naphthoquinones possibly bind to the C-
terminal domain of Hsp90 (Hadden, et al., 2009), but conflicting results were obtained in 
studies involving the effect of lapachol on modulation of  subcellular localisation and 
expression levels of Hsp90, Hsp70, Hop, HSF1 and selected Hsp90 client proteins (pSTAT3, 
STAT3 and AKT) in the MDA-MB-231 breast cancer cell line. The results suggested that 
binding of this naphthoquinone based natural product occurs at the N-terminus of Hsp90 
(Moyo, 2013). We therefore undertook in silico docking studies in order to investigate the 
possibility of our series of naphthoquinones binding to the N-terminus of Hsp90. 
Unfortunately, a comparative in silico assessment of binding to the C-terminus of Hsp90 was 
not possible via our method since a co-crystal structure of the C-terminus of Hsp90 with a 
ligand is not yet available. It should be noted that published reports of naphthoquinones which 
show potential Hsp90 inhibition have structural features related to lapachol (3.6) (Hadden, et 
al., 2009). Our class of compounds contained a short prenyl chain system on the benzenoid 
ring offering a new set of compounds that could possibly act as Hsp90 inhibitors.   
In silico assessment of small molecules against drug targets is a powerful tool in drug 
discovery, as a method of large scale screening as well as optimizing ligand drug interactions 
through a rational design approach (Trott and Olson, 2010). This technique has proven to be a 
cost effective method of accurately screening libraries of molecules (Bailey and Brown, 2001), 
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which the pharmaceutical industry increasingly relies upon (Stark and Powers, 2012). 
Interactions between small molecules and their respective binding sites on a given receptor can 
be visualized and characterized at an atomic level following two basic concepts centred at 
predictions of the ligand conformation and assessment of binding affinities via sampling 
algorithms and scoring functions respectively (McConkey, et al., 2001).  
6.1.2 Sampling algorithm 
Docking studies aim to give an accurate prediction of interactions between ligands and 
receptors. However one critical limitation is associated with this technique. Docking studies 
represent the receptor as a rigid structure determined by NMR spectroscopy, X-ray 
crystallography or homology modelling. It does not take into consideration changes in receptor 
conformations that occur when in solution and during binding with a ligand (Yuriev, et al., 
2011). Docking simulation methods give details of the ligand-receptor complex. They allow 
flexibility in the ligand to explore conformations that can fit a particular active site (Morris, et 
al., 1998). AutoDock Vina now takes into consideration a limited degree of flexibility on 
selected regions of the receptor. A set number of amino acids can be selected and modelled 
separately to allow conformational changes to occur during ligand binding (Trott and Olson, 
2010). It should be noted that such a selection is mainly determined by assessing the 
conformation of a receptor with its bound ligand that was present during the receptor’s 
structural determination. Ligands screened against this conformation may be over or 
underestimated, depending on results that will be obtained in in vitro assays.   
With regards to ligand flexibility, it is virtually impossible to predict all possible conformations 
a ligand can assume in the active site, hence the use of sampling algorithms. AutoDock Vina 
makes use of a Lamarckian genetic algorithm to perform adaptive global—local searches of 
optimal ligand binding (Morris, et al., 1998; Trott and Olson, 2010). A set of values which 
describe translation, orientation and conformation of a ligand in relation to its receptor 
represents the ligands ‘genotype’ (Morris, et al., 1998). Genetic algorithms randomly assign 
these values to a ligand in order to generate a diverse population of conformations for the 
ligand. The algorithm allows for these possible conformations to evolve over several 
generations through cross over between parent conformations and random mutations of the 
genotype in order to generate off spring which will be more or less fit for their environment 
than their parents. Fitness, in this context is assessed by total interaction energy between the 
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ligand and receptor. Less fit individuals will not be allowed to produce further generations and 
therefore less optimal interactions will be lost.  
The Lamarckian element of the genetic algorithm consists of an inverse mapping function 
whereby conformational information gleaned from local minima searches can be mapped back 
onto the genotype therefore producing a non-random mutation to the genotype (Figure 6.1). It 
ensures that a local search around a specific state will have an influence on future generations 
which may encounter similar local minima (Morris, et al., 1998; Wiley, et al., 2006). 
 
Figure 6.1: Illustration of the difference between Darwinian (right) and Lamarckian search 
(left) with the fitness function depicted f (x) (Morris, et al., 1998). 
6.1.3 Scoring function 
The scoring functions focus on the binding affinities between the ligand and the receptor, which 
can be divided into three groups that take into consideration different interactions between the 
ligand and receptor. The classical force-field based scoring function focuses on binding 
energies that are as a result of non-bonded (electrostatic and van der Waals forces) interactions, 
with some extensions to hydrogen bonding and solvation. (Kollman, 1993). The empirical 
scoring function gives final binding energies as a sum of hydrogen bonding, ionic interaction, 
hydrophobic effect and binding entropy (Bohm, 1998) whilst the knowledge-based scoring 
function makes use of interatomic contact frequencies and distances between the ligand and 
Chapter Six Molecular modelling and STD NMR studies

148

protein (Muegge and Martin, 1999). All these aspects have been integrated in computational 
softwares like Autodock Vina (Trott and Olson, 2010) that was used for this study.  
6.1.4 Aim of study 
As previously highlighted, geldanamycin (2.28) contains a benzoquinone system that is 
thought to be essential for Hsp90 protein inhibition via binding to the ATP binding site of the 
N-terminal domain (Neckers and Workman, 2012). Inhibition of ATPase activity of Hsp90 
affects all six hallmarks of cancer making it an ideal target for drug design and development 
(Miyata, et al., 2013). Our series of truncated sarganaphthoquinoic acid derivatives consists of 
a similar quinone moiety fused to a benzenoid ring (naphthoquinone), which sparked our 
interest in investigating their interactions with Hsp90 protein. In the previous chapter, we 
discussed the cytotoxicity of the synthesized naphthoquinones which on some occasions 
displayed IC50 values in the nanomolar range, which may be accredited to their ability to take 
part in redox reactions according to literature (Castro, et al., 2008). The ability to inhibit Hsp90 
protein activity will be an added advantage to this class of molecules. It would suggest several 
modes of action for quinone systems, which is advantageous in preventing drug resistance from 
cancer cells. Our aims and objectives were therefore to  
• To determine whether any of our naphthoquinones had the potential to interact with the 
ATP binding site of Hsp90 by way of molecular docking. 
• Assess docking conformations and binding affinities in comparison to those of ATP 
and geldanamycin (2.28) with Hsp90 protein. 
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6.2 Results and discussion 
6.2.1 Docking software 
The molecular docking studies discussed in this chapter were conducted using Autodock Vina 
(Trott and Olson, 2010). Discovery Studio 4.0 visualizer (Accelrys Software Inc., Discovery 
Studio Modeling Environment, Release 4.0, San Diego: Accelrys Software Inc., 2013) was 
used to process all results obtained and to visualize the docking conformations and orientations.  
6.2.2 Preparation of Hsp90 protein and ligand for docking 
One protomer of Hsp90 protein bound with ATP in the N-terminal domain (PDB accession 
number 1AM1) was obtained from the RCSB Protein Data Bank as a PDB text file. The original 
ligand and additional water molecules were removed from the protein, leaving the ATP binding 
site vacant for docking and the protein in its apo form (Figure 6.2) 
  
Figure 6.2: Hsp90 protein bound with ATP (left) and in its apo form (right) 
Preparation of the apo protein using AutoDock tools involved merging all non-polar hydrogens 
followed by the addition of polar ones. Atoms were assigned by Autodock 4 typing rules while 
electrostatic charges were computed as Gasteiger charges. The original ligand found in PDB 
1AM1 (ATP) was prepared for docking using AutoDock tools, whereby Gasteiger charges 
were added, 8 non-polar hydrogens merged and 5 aromatic carbons and 9 rotatable bonds were 
detected. ATP docking experiments were conducted as a means to validate the method and 
parameters set, and will be discussed briefly in the next section. All additional ligands reported 
in this chapter were prepared for docking using the same method. 
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6.2.3 Validation: Interactions and binding affinities 
Initial experiments involved docking ATP into its active site as a means of validating and 
optimizing the parameters set for docking studies. A ‘search space area’ for ligand docking was 
constrained to a box of 30 Å in each of the three spacial dimensions, centered on a coordinate 
randomly chosen in the known ATP binding site. The docking of ATP was done two times, 
with the aim of obtaining similar docking conformations and binding energies for validation to 
pass. Autodock Vina gives an output consisting of several active conformations that are ranked 
according to their binding energies.  The first run was conducted with an exhaustiveness of 32 
to adequately search the binding site, and the second one done at an exhaustiveness of 8. The 
highest ranking conformations were identical in both runs (Figure 6.3) suggesting that an 
exhaustiveness of 8 was adequate for the docking studies of our compounds.   
 
Figure 6.3: Illustration of similar docking conformations of ATP in the N-terminal domain of 
Hsp90 in validation experiments 
The binding energies obtained were also similar for all conformations as displayed in Table 
6.1. 
Table 6:1 Binding energies for ATP docking studies on Hsp90 Protein 
ATP docking 
experiment 
Exhaustiveness Binding Energy 
(kcal/mol) 
1 32 −7.6 
2 8 −7.3 
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It was noticed that ATP interacts with seven amino acids in its active site and has a network of 
six hydrogen bonds with ASN37, ASP79, LYS98, GLY123 and PHE124.  The overall type of 
interactions involved are shown in Figure 6.4 
 
Figure 6.4: ATP interactions within the active site of Hsp90 
It should be noted that other bond-bond interactions i.e., Pi-alkyl interactions, charge-charge 
interactions, amide-pi stacked interactions etc. contribute to the binding energies that result, in 
addition to the hydrogen bonds that are mainly considered, and care should be taken in the 
interpretation of results obtained not to ignore these interactions. 
Confirmation of similar docking conformations and binding energies indicated that the set 
parameters were accurate and reproducible. The method set was deemed validated and suitable 
for docking studies discussed in the next sections. Only hydrogen bonding interactions are 
reported within this chapter, and other bond-bond interactions between the ligand and the active 
site are highlighted in the supplementary section.  
6.2.4 First series of naphthoquinone analogues 
We had hypothesized that naphthoquinones bind to Hsp90 in a similar way to geldanamycin 
(2.28), therefore it was included in the study. Nine active conformations were detected with an 
exhaustiveness of 8. The best docked conformation was selected based on the docking energy, 
visual examination of how close in orientation it is to the ATP results obtained and the 
hydrogen bond network around the ligand.  
As expected ATP displayed the best binding energy of −7.6 kcal/mol, followed by 
geldanamycin (2.28). The naphthoquinones all exhibited encouraging binding energies ranging 
Chapter Six Molecular modelling and STD NMR studies

152

between −6.4 and −7.1 kcal/mol. Compound 4.11B displayed the best binding energy to Hsp90 
(−7.1 kcal/mol) in addition to having the highest number interactions with amino acids within 
the active site. It also showed two hydrogen bonding interactions of the carbonyl functionalities 
on the quinone moiety to ASN37 and THR171. Its regioisomer 4.11A however indicated the 
worst binding energy of -6.4 kcal/mole, with no hydrogen bonding occurring. Overall, C-2 or 
C-3 substitution had no influence on the binding affinity of this series to Hsp90 except in the 
case of compounds 4.11A and 4.11B. These results are displayed in Table 6.2.  
Docking orientations of all naphthoquinones within the active site were similar. When overlaid, 
the naphthoquinone component of the docked ligands occupied a similar region to the purine 
moiety of ATP, with the prenyl side chain of the ligands occupying similar regions to the sugar 
moiety and triphosphate chain of ATP (Figure 6.5A). Further analysis of the docking 
conformations indicated deep grove docking for ATP and naphthoquinones, while for 
geldanamycin (2.28), half of the molecule only gets embedded into the active site (Figure 
6.5B). This could be attributed to the size of the molecule, but nonetheless demonstrated better 
binding with more hydrogen bonding interactions than most of the naphthoquinones   
             
Figure 6.5: A. Compound 4.11B and ATP docked in the same active site of Hsp90 B. 
Compound 4.10, geldanamycin (2.28) and ATP docked in the same active site of Hsp90 
 
 
 
 
 
A B 
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Table 6.2: Binding energies of first series of naphthoquinones in comparison to ATP and 
Geldanamycin (2.28) 
 
Compound Structure Binding 
energies 
kcal/mol 
Number of 
hydrogen 
bonds 
Number of 
amino acids in 
interactions 
ATP 
N
N N
N
NH2
O
OH OH
O P
O
O P
O
O P
O
OH
OHOH OH
 
 
−7.6 
 
6 
 
10 
Geldanamycin 
2.28 
O
O
N
H
H3CO
OH
O
O
NH2
O
H3CO
H3CO
 
 
 
−7.1 
 
 
4 
 
 
11 
4.7 O
O
 
 
−6.8 
 
0 
 
7 
4.9A O
O
Cl
 
 
−6.8 
 
1 
 
8 
4.9B O
O
Cl
 
 
−6.8 
 
1 
 
5 
4.11A O
O
H3CO
 
 
−6.4 
 
0 
 
9 
4.11B O
O
H3CO
 
 
−7.1 
 
2 
 
10 
4.13A O
O
 
 
−7.0 
 
1 
 
8 
4.13B O
O
 
 
−6.7 
 
1 
 
6 
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6.2.5 Second series of naphthoquinone analogues (arylamino naphthoquinones) 
The second series of analogues that comprised of aniline coupled naphthoquinones was docked 
in the same way as described above. The binding energies obtained are shown in Table 6.3 
Table 6.3: Binding energies of aryl amino naphthoquinones in comparison to ATP and 
Geldanamycin (2.28) 
Compound Structure Binding 
energies 
kcal/mol 
Number of 
hydrogen 
bonds 
Number of 
amino acids in 
interactions 
ATP 
N
N N
N
NH2
O
OH OH
O P
O
O P
O
O P
O
OH
OHOH OH
 
 
−7.6 
 
6 
 
10 
Geldanamycin 
2.28 
O
O
N
H
H3CO
OH
O
O
NH2
O
H3CO
H3CO
 
 
 
−7.1 
 
 
4 
 
 
11 
4.14A O
O
NH
 
 
−7.5 
 
2 
 
5 
4.14B O
O
NH
 
 
−7.5 
 
2 
 
4 
4.15A O
O
NH
 
 
−7.7 
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Compound Structure Binding 
energies 
kcal/mol 
Number of 
hydrogen 
bonds 
Number of 
amino acids in 
interactions 
4.17A O
O
NH
Cl
 
 
−7.6 
 
2 
 
5 
4.17B O
O
NH
Cl
 
 
−7.6 
 
2 
 
5 
4.18A O
O
NH
F3C
 
 
−7.3 
 
2 
 
7 
4.18B O
O
NH
F3C
 
 
−8.1 
 
4 
 
9 
4.19A O
O
NHO
O
 
 
−7.4 
 
4 
 
9 
4.19B O
O
NH
O
O
 
 
−8.2 
 
3 
 
6 
 
Addition of the arylamino moiety improved binding energies of the naphthoquinones (4.14-
4.19) to Hsp90 to values above −7.0 kcal/mol. However more active conformations were 
predicted from docking. The reported results were based on visual assessments of a 
conformation that matched that of ATP and of results that showed a root mean square distance 
(rmsd) of 2 or less Å. Whilst other molecules had an average number of two hydrogen bonds, 
enhanced binding was observed in compounds 4.18B and 4.19B with four and three hydrogen 
bonds respectively. It demonstrated the importance of having hydrogen bond centres offered 
by H bond acceptors on CF3 and methylenedioxy moieties. The general trend observed was 
that C-2 substituted arylamino-naphthoquinones interacted via hydrogen bonding using the C-
4 ketone on the quinone with GLY123 and PHE124, whilst C-3 substituted arylamino - 
naphthoquinones interacted with ASN37 and GLY121 via C-4 ketone and the –NH linker 
moiety used for coupling amines to naphthoquinones. This is displayed in Figure 6.6 using 
4.14 A and 4.14B as examples.  
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 A                                                                             B 
      
Figure 6.6: A. C-2 substituted-naphthoquinone 4.14A interaction with GLY123 and PHE124 
via hydrogen bonding B. C-3 substituted-naphthoquinone 4.14B interaction with ASN37 and 
GLY121via hydrogen bonding 
The most active conformation assumed with aryl amino naphthoquinones was in a reverse 
orientation to that observed with the first series of naphthoquinones. The prenyl side chain was 
embedded into the active site together with the purine nucleoside moiety of ATP, whilst the 
naphthoquinone functionality orientated with the phosphate groups and aniline component 
orientated out of the active site.  
Introduction of aryl amino moieties influenced the binding behaviour of these molecules. It 
resulted in molecules possessing comparable binding energies to ATP, with some exhibiting 
higher binding affinities for Hsp90. An investigation into substituting aryl amino- moieties 
with alkyl amines was conducted.  
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6.2.6 Third series of naphthoquinone analogues (alkyl amino naphthoquinones) 
The same parameters and preparation protocols were adapted, and docking was conducted as 
indicated in the first two series of naphthoquinones. The binding energies obtained are shown 
in Table 6.4 
Table 6.4: Binding energies of alkyl amino naphthoquinones in comparison to ATP and 
Geldanamycin (2.28) 
Compound Structure Binding 
energies 
kcal/mol 
Number of 
hydrogen 
bonds 
Number of 
amino acids in 
interactions 
ATP 
N
N N
N
NH2
O
OH OH
O P
O
O P
O
O P
O
OH
OHOH OH
 
 
−7.6 
 
6 
 
10 
Geldanamycin 
2.28 
O
O
N
H
H3CO
OH
O
O
NH2
O
H3CO
H3CO
 
 
 
−7.1 
 
 
4 
 
 
11 
4.20A O
O
NH
 
 
−7.3 
 
2 
 
5 
4.20B O
O
NH
 
 
−7.7 
 
0 
 
6 
4.21A O
O
NH
N
 
 
−6.4 
 
2 
 
5 
4.21B O
O
NH
N
 
 
−6.6 
 
1 
 
6 
4.22A O
O
NH
OH
 
 
−7.8 
 
3 
 
7 
4.22B O
O
NH
OH
 
 
−7.2 
 
3 
 
9 
Chapter Six Molecular modelling and STD NMR studies

158

Compound Structure Binding 
energies 
kcal/mol 
Number of 
hydrogen 
bonds 
Number of 
amino acids in 
interactions 
4.23A O
O
NH
 
 
−7.3 
 
2 
 
6 
4.23B O
O
NH
 
 
−7.2 
 
1 
 
8 
4.24A O
O
N
O
 
 
−7.1 
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4 
4.24B O
O
N
O
 
 
−6.8 
 
2 
 
8 
4.25A O
O
NH
OH
O
 
 
−7.1 
 
4 
 
11 
4.25B O
O
NH
OH
O
 
 
−7.3 
 
3 
 
8 
4.26A O
O
N
O
O
 
 
−6.7 
 
3 
 
3 
4.26B O
O
N
O
O
 
 
−7.3 
 
0 
 
5 
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Introduction of alkyl amines in exchange for aryl amines to the core structure slightly lowered 
the binding affinity of the naphthoquinones to the active site of Hsp90. The best binding energy 
was observed for compound 4.22A, with two hydrogen bond interactions between the phenolic 
OH with GLU33 and SER36, and a third observed between the ketone moiety of the quinone 
and ASN37. Epoxide containing molecules (4.25-4.26) had more hydrogen bond interactions 
within the active site, however their binding affinity was not enhanced to a greater level. 
Introduction of a morpholino moiety (4.24) also did not enhance binding. The conformation 
which the ligand assumes within the active site is essential in assuring that functional groups 
on the ligand and relevant amino acids that can potentially interact with each other are in close 
proximity within the active site during binding.  
Compounds 4.20 and 4.21 had allylamine and N, N-dimethylethane-1, 2-diamine moieties at 
C-2 or C-3 positions that mimicked 17-AAG (2.29) and 17 DMAG (2.30) respectively. 4.20 
displayed a better binding energy than 4.21, which showed the worst binding energy within 
this series. It is possible that the presence of a terminal tertiary amine in 4.21 is not favourable 
for binding to the active site. 
With regards to the docking conformation, there was no uniform direction from this series of 
compounds. Compounds 4.20 and 4.23 orientated in a similar way to the first series of 
compounds, the naphthoquinone moiety occupying the same region as the purine nucleoside 
of ATP and the prenyl side chain overlaying the sugar and phosphate groups. The rest of the 
molecules had the prenyl system embedded into the active site, with the naphthoquinone 
moiety and C-2 or C-3 substituted groups overlaying the sugar and phosphate groups. The 
docked orientations are available in the supplementary data.  
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6.2.7 Fourth series of analogues 
The effect of having a thiazino- moiety or chromene-hybrid system was also investigated for 
Hsp90 inhibition. The natural product sargaquinoic acid (2.47), sarganaphthoquinonic (3.5) 
and lapachol (3.6) were also included for comparison purposes to the synthesized derivatives. 
Docking experiments were conducted as above and the binding energies obtained are displayed 
in Table 6.5 
Table 6.5: Binding energies of tricyclic naphthoquinones in comparison to ATP and 
Geldanamycin (2.28) 
Compound Structure Binding 
energies 
kcal/mol 
Number of 
hydrogen 
bonds 
Number of 
amino acids 
in interactions 
ATP 
N
N N
N
NH2
O
OH OH
O P
O
O P
O
O P
O
OH
OHOH OH
 
 
−7.6 
 
6 
 
10 
Geldanamycin 
2.28 
O
O
N
H
H3CO
OH
O
O
NH2
O
H3CO
H3CO
 
 
 
−7.1 
 
 
4 
 
 
11 
 
4.28 
O
O
S
N
H
O O
 
 
−7.9 
 
0 
 
6 
 
4.29 
O
O
O
 
 
−7.6 
 
1 
 
7 
 
3.6 
O
O
OH

 
−7.0 
 
1 
 
6 
 
2.47 
O
O
COOH
 
 
−6.7 
 
3 
 
5 
 
3.5 
O
O
COOH
 
 
−7.2 
 
1 
 
7 
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Thiazino-naphthoquinone (4.28) and the chromene-naphthoquinone hybrid (4.29) also had 
comparable binding energies to ATP but lacked extensive hydrogen bond networks. Compound 
4.29 only had 1 hydrogen bond of the carbonyl to ASN37, with 4.28 having none. This further 
indicates the importance of other bond-bond interactions that take place within the binding 
pocket. The two compounds occupied similar regions of the active site and interacted with 
almost similar numbers of amino acids. Compounds 2.47, 3.5 and 3.6 displayed lesser binding 
affinities compared to 4.28 and 4.29. 2.47, however had an established hydrogen bond system 
with ASN37, GLY123 and PHE124 and displayed a folding conformation to fit within the 
active site (Figure 6.7A). Compound 3.11 also exhibited a similar folding conformation to 2.47 
and occupied the same space (Figure 6.7B). 
 A                                                                           B 
      
Figure 6.7: A. Sargaquinoic acid (2.47) folding to fit within the N-terminal active site of 
Hsp90 B. Folding conformations of 2.47 and 3.5 within the N-terminal active site of Hsp90 
Compounds 2.47 and 3.5 had docking orientations similar to the first series of 
naphthoquinones. The long prenyl chain system however folds on itself, whereas in the first 
series of naphthoquinones, the chain is shorter and just fits into the active site. Their binding 
energies were also comparable to those of the first series of compounds, with 2.47 slightly 
lower. This indicated that the prenyl side chain could be shortened with no influence on the 
biological activity of these molecules. 
These preliminary results indicated that naphthoquinone derivatives possibly bind to the N-
terminus of Hsp90 protein. Substitution with aryl amino compounds on the quinone moiety of 
the naphthoquinone is favoured for better binding and results obtained were comparable to 
those of ATP. No significant differences were apparent with regards to binding energies 
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between regioisomers. C-2 or C-3 substitution could not be ascertained as important in 
conformations assumed by the ligands during the study.  
From the docking studies, compounds 4.15A, 4.16B, 4.18B, 4.19B, 4.22A and 4.28 showed 
binding affinities slightly better than ATP and presented themselves as potential Hsp90 
inhibitors. However it should be noted that molecular docking is a virtual screening tool, which 
solely depends on estimations and predictions. Definitive conclusions relating to a particular 
compound and its activity cannot be drawn with certainty unless further studies are conducted.  
The results shown are contradictory to those obtained in client protein degradation assays that 
seemed to suggest C-terminal binding rather than N-terminal binding to Hsp90 due to lack of 
Hsp70 induction. However, one short-fall with this technique in assessing Hsp90 inhibition is 
that there is no crystal structure for the C-terminal domain for comparable docking studies to 
be done. The question still remained unanswered as to the active site to which naphthoquinones 
bind. Saturation transfer difference (STD) NMR studies that focus on interactions on both 
binding domains of Hsp90 were attempted.  
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6.3 Saturation transfer difference (NMR) studies 
Molecular interactions between small ligands and relevant biological macromolecules can be 
studied using Nuclear Magnetic Resonance (NMR) (Lepre, et al., 2004). Saturation Transfer 
Difference (STD) NMR has become a useful tool in characterizing ligand-receptor complexes 
in solution, and has been useful in identifying lead structures and ligand moieties that are 
essential for binding as part of rational drug-discovery process. It makes use of reduced 
protein/receptor concentrations and can be applied on large molecular weight proteins, giving 
this technique advantages over other NMR techniques (Mayer and Meyer, 1999).  
6.3.1 Principles of STD NMR 
STD NMR experiments make use of nuclear Overhauser effects in observing ligand resonance 
signals that are in contact with the receptor (Viegas, et al, 2011).  As the name suggests, STD 
takes into account the difference between the on-resonance and off-resonance spectra. It 
involves subtracting signal intensities of the on resonance spectrum denoted ISAT, from signal 
intensities of the off resonance spectrum IO, to obtain a difference spectrum ISTD, that is 
represented by the following formula 
 ISTD = IO - ISAT  
The on-resonance experiment encompasses selective saturation by irradiating a region of the 
spectrum that contains only resonances of the receptor, normally between _1 ppm and 0 ppm 
where majority of methyl resonances for folded proteins appear. The off resonance is set at an 
irradiation frequency that is far from any ligand or protein signal e.g. 40 ppm.  In the difference 
spectrum, only ligand signals that would have received saturation transfer via spin diffusion 
from the receptor are displayed (Kalk and Berendsen, 1984). Saturation is propagated from the 
selected receptor protons to other receptor protons via intramolecular 1H-1H cross relaxation 
pathways, and via 1H-1H cross relaxation and chemical exchange mechanisms at the ligand-
receptor interface to bound molecules. Dissociated molecules carry the saturation state back 
into solution whilst fresh unsaturated ligands exchange on and off the receptor site. Saturation 
energy is maintained by application of irradiation energy which results in an increase in 
saturated free ligands in solution.  
Other molecules that do not bind to the receptor and might be present in the sample will not 
receive saturation transfer, hence the difference spectrum will not show any signals. The on 
resonance and off resonance signals will be of the same intensity. This is demonstrated in 
Chapter Six Molecular modelling and STD NMR studies

164

Figure 6.8 that indicates the differences in IO, ISAT and ISTD spectra of the ligand and non-ligand 
entities.   
 
 
 
Figure 6.8: A schematic representation of the STD-NMR experiment. The exchange between 
free and bound ligand allows intermolecular transfer of magnetization from the receptor to the 
bound small molecule (Viegas, et al, 2011). 
For the bound ligand, hydrogens that are  5 Å in proximity to the protein interface receive 
saturation transfer and appear in the difference spectrum. The closer the hydrogen to the 
receptor/protein, the greater the intensity of the signal observed due to efficient saturation 
transfer (Viegas, et al, 2011). It should also be noted that only signals of the ligand appear on 
the spectrum. The receptor resonances are normally not visible due to the concentrations used, 
and lessen the complexity of the spectra obtained. However a T1 filter can be used to remove 
disturbing protein signals prior to detection, otherwise a simple 1D 1H spectrum of the bound 
ligands is obtained. 
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6.3.2 Limitations of STD NMR studies 
Several aspects have been identified that affect the quality of results obtained from STD NMR 
experiments. Sensitivity is a big factor for this technique. It is highly dependent on ligand 
concentrations that are normally in excess (between 10-100 fold), such that the probability of 
molecules in solution that receive saturation is increased. However high ligand concentrations 
in relation to the protein may also result in non-specific ligand binding, causing interference 
with the obtained STD spectrum. An optimal ligand concentration has to be decided upon or 
additional experiments are done to negate the effect of non-specific binding (Viegas, et al., 
2011).  
Saturation times set on the instrument are important to allow transfer of saturation from the 
receptor to more than one ligand molecule in the solution. Long saturation times of up to three 
seconds are usually suggested, thereby increasing signal intensities observed on the STD 
spectrum.  This compensates for the minute concentrations of the protein used during the 
experiments, and are a critical factor in these studies that can compromise the quality of results 
obtained (Viegas, et al., 2011; Yan, et al, 2003). 
The STD NMR methods also fall short in analysing high affinity ligands. Saturation is not 
transferred to the solution effectively due to the longer periods spend by the ligand bound to 
the receptor. At the same time, probability of weaker ligands being in the active site during 
irradiation is very low, resulting in weak STD signals. It therefore suggests that this technique 
is depended on the receptor in question and the value of KD for a particular ligand which should 
fall within the range of 10-8 < KD < 10-3 M for the STD experiment to be successful (Ji, et al., 
2009).  
Despite these limitations, STD NMR is still being used extensively in the analysis of ligand-
protein complexes in solution (Haselhorst, et al., 2009). Care should be taken in setting the 
parameters and optimizing the experiment to suit the study at hand. For our work, we employed 
this technique to obtain preliminary results for Hsp90 binding at N- and C- terminal domains.  
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6.3.3 Aim of study 
The client protein degradation assay results (section 5.3) showed a lack of Hsp70 activation. 
This was suggestive of C-terminal binding of naphthoquinones to Hsp90. However, molecular 
docking results also indicated potential N-terminal binding for these compounds. Such 
conflicting results led us to decide on an alternative technique that could allow us to visualize 
and characterize interactions of naphthoquinones with both N- and C-terminal domains of 
Hsp90. Saturation transfer difference (STD) NMR seemed to be the most appropriate technique 
to employ as it is quick, easy to do and does not require characterization of the protein’s binding 
site for it only focuses on signals of the ligand. Therefore the main aim of this section was to 
perform STD NMR studies on selected naphthoquinones on both N- and C- terminal domains 
to determine the actual site for naphthoquinone binding.   
6.3.4 N- and C-terminal domains of Hsp90 
The Hsp90 N- and C-terminal domains used were expressed and purified by Dr Adrienne L. 
Edkins and Lorraine Mutsvunguma of the Biomedical Biotechnology Research Unit (BioBru) 
at Rhodes University, South Africa. The protein was expressed and tagged to glutathione S-
transferase (GST), whose DNA sequence is frequently integrated into expression vectors for 
the production of recombinant proteins. GST is normally incorporated due to its stable folding 
conformation and highly soluble nature, which promotes solubility of the recombinant protein 
and greater protein expression compared to expression without the tag (Harper and Speicher, 
2001). 
The GST tag also allows purification of the protein based on the ability of GST to bind to its 
substrate, glutathione (GSH). Reduced GSH is immobilized on a solid support such as cross-
linked beaded agarose, and such enzyme-substrate reactions ensure that pure GST tagged 
proteins are isolated from other non-bonded components. The pure tagged protein is recovered 
by addition of excess reduced GSH that competitively dislodges the GST tagged protein from 
the solid support and is then eluted from the affinity column. The GST tag can be removed 
after the purification step if need be, by use of protease enzymes provided a cleavage site had 
been included between the GST and protein in the DNA design of the vector (Harper and 
Speicher, 2011). For this study, GST (used as a control) and the GST-tagged Hsp90 fusion 
proteins were purified by GST batch purification and a Coomassie stained SDS-PAGE showing 
the respective domains of Hsp90 protein (Figure 6.9).  
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Figure 6.9: GST-tagged Hsp90 N, M and C domains. 
Coomassie stained SDS-PAGE showing the purification of GST and GST-Hsp90 fusion proteins after GSH 
affinity chromatography using a batch purification protocol. Lane M: Molecular weight marker with sizes 
indicated as kDA, Lane 1-2: GST-Hsp90N elution fractions, Hsp90 N-terminal domain fused to an N-terminal 
GST tag, Lane 3-4: GST-Hsp90M elution fractions, Hsp90 M domain fused to an N-terminal GST tag, Lane 5-6: 
GST-Hsp90C elution fractions, Hsp90 C-terminus fused to an N-terminal GST tag, Lane 7-8: GST protein elution 
fractions. 
6.3.5 Selected naphthoquinones 
Due to limited amounts of protein, we could only analyse a small selection of compounds. 
Compounds 2.47, 4.16A, 4.20A, 4.28 and 4.29 used for the client protein degradation assays 
were also selected for use in the STD NMR studies. This was done such that comparisons could 
be made between the various techniques reported in this thesis for the assessment of Hsp90 
inhibition i.e. molecular docking, client protein degradation assays and STD NMR studies.  
6.3.6 Standardization of the STD experimental conditions 
An STD assay using bovine serum albumin (BSA) with L-tryptophan and glucose was carried 
out to validate and optimize the STD parameters. L-tryptophan is a known ligand of BSA 
whereas glucose, a non-ligand was added as a negative control. Solutions of BSA (8.4 x 10-5 
M), L-tryptophan (7.75 x 10-3 M) and D-glucose (5.32 x 10-2 M) were made in 50 mM Tris/HCl 
buffer (pH 7.3). A total volume sample of 500 µL was prepared in an NMR tube containing 25 
µL of D2O, 240 µL of BSA, 120 µL of Tris/HCl buffer, 130 µL of L-tryptophan and 19 µL of 
glucose such that the final assay solution constituted 40 µM BSA, 2 mM L-tryptophan and 2 
mM glucose in Tris/HCl buffer. The STD NMR experiment was run on a 500 MHz Bruker 
NMR spectrometer using water suppression at 4.7 ppm, with the on-resonance pulse train set 
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to 422 Hz and the off resonance pulse train set to 20 000 Hz ppm with phase cycling. The pre-
saturation Gaussian pulse was applied for 2 ms and 16 scans were run.   
The STD-NMR spectrum obtained for the mixture of BSA, L-tryptophan, and glucose is 
depicted in Figure 6.10. The reference spectrum (A) for the mixture under study displayed 
signals of the two ligands whilst in (B), only strong STD signals from L-tryptophan were 
noticeable. The absence of STD signals from glucose is in accordance with the fact that glucose 
does not bind to BSA, whilst L-tryptophan is an active ligand of the protein. The validation 
was therefore successful and set parameters on the instrument were used in the STD 
experiments conducted with selected naphthoquinones and Hsp90 N- and C-terminal domains.  
1.  
Figure 6.10: The STD-NMR validation experiment: (A) reference 1H spectrum for the mixture 
of BSA, L- tryptophan and glucose and (B) corresponding STD-NMR spectrum. 
6.3.7 Results and discussion 
The STD NMR experiments with Hsp90 N- and C- terminal domains were initially conducted 
using novobiocin (2.41), a known C-terminal inhibitor. According to our knowledge, this was 
the “first” STD NMR study of novobiocin (2.41) and the C-terminal domain of Hsp90.  
Novobiocin (2.41) binds to the C-terminus of Hsp90, and as expected saturation transfer was 
observed to the bound ligand in the STD NMR spectrum (Figure 6.11). The fairly visible 
signals of the chromene moiety on novobiocin (2.41) suggested that the chromene system was 
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in close proximity to the C-terminal receptor interface during binding, hence received more 
saturation.  Results for the N-terminal binding of Hsp90 by novobiocin (2.41) showed a very 
weak interaction (Figure 6.12). A positive result with novobiocin (2.41) and the C-terminus 
confirmed the appropriateness of the set parameters on the NMR instrument, and also 
confirmed the integrity of the protein being used.  
 
Figure 6.11: (A) reference 1H spectrum for the mixture of C-terminal domain of Hsp90 and 
novobiocin (2.41) (B) corresponding STD-NMR spectrum 
 
Figure 6.12: (A) reference 1H spectrum of the N-terminal domain of Hsp90 and novobiocin 
(2.41) (B) corresponding STD-NMR spectrum 
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6.3.7.1 Attempted STD NMR studies of selected naphthoquinones  
The selected naphthoquinones were insoluble in the 50 mM Tris/HCl buffer solution, therefore 
stock solutions of the individual compounds were first prepared in deuterated DMSO, and 
dilutions made accordingly to required concentrations in NMR tubes. The set NMR parameters 
used for the experiments with novobiocin were employed for the selected set of 
naphthoquinone derivatives. The reference 1H NMR spectra and the corresponding STD NMR 
spectra obtained for compounds 4.20A, 4.28 and 2.47 and the C-terminus are shown in Figures 
6.13 - 6.15. 
 
Figure 6.13: (A) reference 1H spectrum for the mixture of C-terminal domain of Hsp90 and 
4.20A (B) corresponding STD-NMR spectrum 
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Figure 6.14: (A) reference 1H spectrum of the C-terminal domain of Hsp90 and 4.28 (B) 
corresponding STD-NMR spectrum 
 
Figure 6.15: (A) reference 1H spectrum of the C-terminal domain of Hsp90 and 2.47 (B) 
corresponding STD-NMR spectrum 
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Resonance signals of the synthesized naphthoquinones were absent from all the NMR spectra 
obtained. The signals observed at  2.0,  2.45,  2.85 and  3.25 were present in each and 
every spectrum, possibly indicating the presence of an impurity in the tested samples. After 
careful analysis, the signals noticed belonged to glutathione introduced during the protein’s 
purification. The same results were observed in the STD NMR experiments conducted of the 
test compounds and the N-terminus. Resonances due to the synthesized compounds could also 
not be observed as shown in Figures 6.16 – 6.18.  
 
Figure 6.16: (A) reference 1H spectrum of the N-terminal domain of Hsp90 and 4.20A (B) 
corresponding STD-NMR spectrum 
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Figure 6.17: (A) reference 1H spectrum of the N-terminal domain of Hsp90 and 4.28 (B) 
corresponding STD-NMR spectrum 
 
 
Figure 6.18: (A) reference 1H spectrum of the N-terminal domain of Hsp90 and 2.47 (B) 
corresponding STD-NMR spectrum. 
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Lack of STD NMR signals corresponding to the test compounds indicated no saturation transfer 
at the receptor-ligand interface. The NMR parameters set on the spectrometer had been 
validated using BSA / L-tryptophan, and novobiocin / C-terminus experiments. The possibility 
of inaccurate STD NMR parameters used in conducting experiments with the naphthoquinones 
was therefore ruled out. The ligand: protein ratio of 60:1 used for the selected synthesized 
compounds and Hsp90 was similar to that used for novobiocin and the C-terminus. Lack of 
resonance signals on the STD NMR spectra could also not be attributed to incorrect ligand: 
protein ratios during the runs. One of two reasons might have been responsible for the lack of 
resonance signals on the STD NMR spectra, i.e. weak binding of the ligands to the N- or C- 
termini of Hsp90 or poor water solubility of the naphthoquinone derivatives in the test solution.  
Weak binding to the relevant active site results in a lesser than optimum time required for the 
ligand to be in contact with the receptor to receive saturation, hence the STD signals obtained 
are either weak or non-existent. As indicated previously, the value of KD for a particular ligand 
should fall within the range of 10-8 < KD < 10-3 M for the STD experiment to be successful (Ji, 
et al., 2009). We hypothesize that the synthesized naphthoquinones might have been out of this 
range, hence the lack of STD NMR resonances corresponding to the tested compounds. 
However this aspect requires further investigation.  
With regards to solubility, the initial attempts to dissolve the naphthoquinones in the 50 mM 
Tris/HCl buffer were unsuccessful. DMSO was added to aid the solubility of the compounds 
in the buffer before the STD NMR experiments were conducted. However absolute dissolution 
could not be guaranteed as a limited volume of DMSO constituting to 3 % of the total volume 
of solvent in the NMR tube could not be exceeded. Poor water solubility could have 
compromised interaction between the ligand and the protein which resulted in no ligand 
binding being observed.  
 Further STD studies are required to investigate molecular interactions between 
naphthoquinones and Hsp90 N- and C-terminal domains. Client protein degradations assays 
indicated some form of inhibition of the protein, which we are confident occurs. An increase 
in both ligand and protein concentrations can be attempted to increase the sensitive of the 
technique, and more scans can be used during the runs to observe any weak binding interactions 
that might occur. Unfortunately the presented STD NMR data was inconclusive, and posted 
questions regarding N- terminal or C-terminal binding by naphthoquinones could not be 
answered in this regard.  
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 The STD NMR spectra for 4.16A and 4.29 are presented in the supplementary data and also 
showed negative results as indicated for the other tested compounds (Figures S6.81, S6.83, 
S6.85 and S6.88). 
6.4 Conclusion 
The STD NMR results obtained showed ligand binding to neither the N-terminus nor C-
terminus of Hsp90, a result which did not support the data from the client protein degradation 
assays. We propose lack of solubility of naphthoquinones in the test solution or weak binding 
interactions between the naphthoquinones and Hsp90 as possible reasons why negative results 
were obtained with this technique. However, little is known with regards to Hsp90 and STD 
NMR experiments and this serves as a platform on which experiments can be conducted to 
assess binding to Hsp90 domains, especially at the C-terminal domain that has a co-crystal 
structure that still has to be resolved. Molecular docking studies had indicated that 
naphthoquinones could potentially bind to the N-terminal domain, however computational 
methods are based on estimations and predictions which in some cases can give misleading 
results. In light of these preliminary results, the new series of naphthoquinone derivatives that 
was synthesized inhibit Hsp90 function, but conclusions could not be drawn as to which active 
site they bind to, either the N- terminus or C-terminus.  
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6.5 Experimental 
6.5.1 In silico Hsp90 inhibition assay 
6.5.1.1 Ligand preparation for docking 
Structures of all ligands described in this chapter were sketched in Discovery Studio Visualizer 
4.0 with the hydrogens missing, which were later added and geometry of all bonds corrected 
before saving as pdb files. The pdb files were reopened in AutoDock Vina and addition of 
gasteiger charges was carried out. All non-polar hydrogens were merged and TORSDOF set. 
The individual files were then saved as PDBQT files that were used for docking experiments. 
6.5.1.2 Hsp90 Protein Preparation for Docking 
The X-ray crystal structure of the N-terminal domain of Hsp90 protein (PDB code: 1AM1) was 
obtained from the Protein Data Bank. The water molecules and ATP ligand were stripped off 
prior to saving it as an apo protein in PDB format. Preparation of the apo protein using 
AutoDock tools involved merging all non-polar hydrogens with the addition of polar ones. A 
total gasteiger charge of -9.9969 was added and an AD4 type assigned to all atoms before 
saving it as a PDBQT file that was used for docking experiments.  
6.5.1.3 Docking Experiments 
The ‘search space’ in the coordinate system of the receptor was chosen. The experimental 
bound ligand structure was used and coordinates were selected that were 30 Å larger for each 
dimension i.e. x, y, z from the selected centre point. The centre coordinates chosen that included 
the target site for binding were 15.253, -1.123, -4.212 for x, y, z respectively. Dockings were 
conducted twice for comparison, firstly with an exhaustiveness of 32 and then an 
exhaustiveness of 8. A Lamarckian genetic algorithm was employed for the docking simulation 
in AutoDock vina and default genetic algorithm parameters were used. 
The docked conformations were visualized in Discovery Studio Visualizer 4.0. The docked 
conformers were assessed based on binding energies, hydrogen bond networks and other bond-
bond interactions, and visual assessment of the orientation of the conformers at the active site 
of the enzyme.  
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6.5.2 Expression and purification of N- and C- terminal domains of Hsp90 
6.5.2.1 Plasmids 
Recombinant GST was expressed from the pGEX-4T1 plasmid, while recombinant GST-
tagged Hsp90 domains were expressed from plasmids GST-Hsp90 N(9-236) (Addgene plasmid 
#22481), GST-Hsp90 M(272-617) (Addgene plasmid #22482) and GST-Hsp90 C(626-732) 
(Addgene plasmid #22483) kindly provided by William Sessa.  
6.5.2.2 Plasmid expression and protein purification 
XL Blue 1 E. coli cells were transfected with different GST-tagged Hsp90 domain plasmids 
indicated above, after which protein expression was induced for 3 hours with 1 mM IPTG. Post 
expression, cell were harvested by centrifugation at 4 °C for 10 minutes at 6000 x g and the 
pellet resuspended in Phosphate buffered saline (PBS) containing lysozyme and 
phenylmethylsulfonyl fluoride (PMSF) at a final concentration of 1 mg/ml and 1 mM, 
respectively and stored at -80°C. The lysates were thawed on ice, followed by 10 rounds of 
sonication for 30 seconds with 15 second cooling periods in between. Lysate clarification was 
done by centrifuging at 10000 x g for 30 minutes at 4 °C.  The clarified lysates were added to 
pre-washed Protino® Glutathione Agarose resin (Thermo Scientific, USA) and the mixture 
incubated for 30 minutes at room temperature with gentle shaking. The mixture was centrifuged 
at 500 x g for 5 minutes. The supernatant was decanted, and the resin washed three times with 
10 bead volumes of PBS. Each wash step was followed by centrifugation at 500 x g for 5 
minutes. After the wash steps, 1 bead volume of GST elution buffer (50 mM Tris pH 8, 10 mM 
glutathione) was added to the agarose resin and incubated with gentle shaking at room 
temperature for 10 minutes, followed by centrifugation at 500 x g for 5 minutes. The elution 
step was repeated twice, with the resulting supernatant transferred to new Eppendorf tubes. 
Four aliquots of each for the N terminus, C-terminus and GST control were prepared at a 
concentration of 1.05 mg/ml, 1.14 mg/ml and 7 mg/ml respectively and kept at -80 °C until 
use. Success of the purification protocol was evaluated by SDS-PAGE and Coomassie blue 
staining. 
 
 
 
Chapter Six Molecular modelling and STD NMR studies

178

6.5.3 STD NMR studies 
6.5.3.1 STD NMR studies of novobiocin and the C-terminus of Hsp90 
Novobiocin (2.5 x 10-7 moles)(2.41) was dissolved in a Tris/HCl 50 mM buffer and transferred 
to the NMR tube such that its final concentration was 0.5 mM in a total NMR volume of 500 
µL. The C-terminal protein was thawed and a sample (4.2 x 10-8 moles) transferred to the same 
NMR tube with novobiocin (2.41) with the aim of having a final protein concentration of 9 µM 
in a 500 µL volume of sample, and a protein to ligand ratio of approximately 1:60. 25 µL D2O 
was added, with the deficit volume covered by the Tris/HCl buffer to a total volume of 500 µL.  
6.5.3.2 STD NMR studies of naphthoquinones and the N- and C- termini of Hsp90 
Weighed samples (1-2 mg) of test compounds (2.47, 4.16A, 4.20A, 4.28 and 4.29) were 
dissolved in pre-calculated volumes of deuterated DMSO that resulted in 15 µL of the 
individual stock solutions containing 2.5 x 10 -7 moles of the ligand. Each aliquot of the protein 
contained 0.1 mg of the N- or C-terminal domain in 100 µL of Tris/HCl buffer, of which half 
the volume was used for each sample preparation which was equivalent to 4.2 x 10-8 moles of 
the C-terminus and 2 x 10-9 moles of the N-terminus. For the C-terminal domain sample 
preparations, 15 µL of ligand stock solution, 50 µL of C-terminal domain solution, 25 µL of 
D2O and 410 µL of Tris/HCl 50 mM buffer were constituted in the NMR tube for the STD 
NMR experiments. For the N-terminal domain sample preparations, 7.2 µL of ligand stock 
solution, 50 µL of N-terminal domain solution, 25 µL of D2O and 417.8 µL of Tris/HCl 50 mM 
buffer were constituted in the NMR tube for the STD NMR experiments.  
6.5.3.3 STD NMR parameters: As set in the standardization experiment.  
The STD NMR experiments were run on a 500 MHz Bruker NMR spectrometer using water 
suppression at 4.7 ppm, with the on-resonance pulse train set to 422 Hz and the off resonance 
pulse train set to 20 000 Hz ppm with phase cycling. The pre-saturation Gaussian pulse was 
applied 2 ms and 16 scans were run. 
 
 

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CHAPTER SEVEN 
 
Conclusion 
All results obtained for cytotoxicity and Hsp90 inhibition assays/experiments were pooled together in 
this chapter and conclusions drawn to determine if our set goal was achieved. From the preliminary 
results obtained, cytotoxicity of naphthoquinones was successfully enhanced into the nanomolar range. 
A degree of Hsp90 inhibition was imparted by introduction of alkylamines and a thiazino-moiety on 
the naphthoquinone. Overall, moderately cytotoxic Hsp90 inhibitors were synthesized that could serve 
as lead compounds for further development. 
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It was previously shown that sargaquinoic acid (2.47) inhibited Hsp90 function. However, this 
compound exhibited relatively weak cytotoxic activity against a MDA-MB-231 breast cancer 
cell line. The recent discovery of naphthoquinone derivatives as Hsp90 inhibitors (Hadden, et 
al., 2009) encouraged us to explore the potential of prenylated naphthoquinones as Hsp90 
inhibitors.   
The main goal of the study was therefore to develop cytotoxic Hsp90 inhibitors, inspired by 
chemical structures of sargaquinoic acid (2.47), sarganaphthoquinoic acid (3.5) and lapachol 
(3.6). Isolated metabolites from S. incisifolium demonstrated weak cytotoxic activities with 
IC50 values of 658.0 µM and 2140.0 µM against a MDA-MB-231 breast cancer cell line for 
compounds 2.47 and 3.5 respectively. The naphthoquinone, lapachol (3.6) showed much better 
activity against Hs578T breast cancer carcinoma (triple negative) with an IC50 value of 2.1 µM.  
The synthesized naphthoquinones showed improved cytotoxic properties, especially the aryl 
amino-naphthoquinones (4.14-4.19). Compounds 4.15 and 4.16 were the most potent with 
average IC50 values of 0.5 µM and 1.1 µM, respectively against Hs578T breast cancer 
carcinoma (triple negative). No significant differences were noticed between the isomers in 
terms of their biological activity except for compound 4.18. It was deduced that for cytotoxic 
enhancement of naphthoquinones, aryl amino-moieties gave the best results.  
Hsp90 inhibition was assessed using in vitro and in silico methods. In vitro assessment of the 
naphthoquinones was conducted via client protein degradation assays in which moderate 
Hsp90 inhibition by test compounds was observed. In this study, not all compounds could be 
tested, therefore selection was done based on the cytotoxicity results obtained. Compounds 
2.47, 4.16A, 4.20A, 4.28 and 4.29 were selected and 2.47 displayed the most potency as an 
Hsp90 inhibitor, followed by 4.20A. The allylamine moiety on 4.20A that is also observed on 
17-AAG (2.29) seemed influential in Hsp90 binding. Compounds 4.16A, 4.28 and 4.29 were 
less potent, with 4.29 being the least amongst the group. With all these compounds, no Hsp70 
induction was noticed as was with the case with geldanamyin (2.28) that was used as a control. 
It led us to postulate that most likely Hsp90 binding was occurring at the C-terminus. This 
conclusion was made on the basis of novobiocin (2.41) having a similar effect of not inducing 
an increase in Hsp70 concentrations in client protein degradation assays. Perhaps two controls 
should have been used that represented both N- and C- terminal domains of Hsp90. Several 
deductions could be made from the client protein degradation assay results that needed 
clarification and included; 
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i) naphthoquinones possibly binding to the C-terminal domain of Hsp90  
ii) naphthoquinones binding to both domains but with a higher affinity for the C-
terminal end 
iii) naphthoquinones binding to the N-terminus but with no Hsp70 induction.   
We had hypothesized that this series of naphthoquinones might bind to the N-terminus since 
functionalities of geldanamycin (2.28) and its analogues (2.29-2.30) were incorporated onto 
the naphthoquinone scaffold. We therefore assessed possible binding to the N-terminus using 
molecular docking studies. 
Analysis of possible binding to the N-terminus of Hsp90 was conducted using AutoDock Vina. 
All synthesized derivatives (4.10-4.31), 2.47, 3.5 and 3.6 were docked and comparable binding 
energies to ATP were noticed from arylamino-naphthoquinones (4.14-4.19) and 4.20B. 
According to the results obtained, it seemed to suggest that the N-terminal domain of Hsp90 is 
the binding site for naphthoquinones especially with binding energies that were comparable to 
ATP. Unfortunately, the co-crystal structure of the C-terminal end has not been resolved yet, 
therefore comparable docking studies on the C-terminus could not be conducted. Interaction 
on the C-terminal end could only be assessed by STD NMR studies. 
The STD NMR experiments were conducted on both N- and C-terminal domains of Hsp90. 
Novobiocin (2.41) was used as a control and to our knowledge such a study involving STD 
NMR experiments of novobiocin and the C-terminal domain of Hsp90 had not be done. This 
gave some preliminary exciting results that indicated binding of novobiocin to the C-terminus 
via its chromene type system. Similar compounds used in the client protein degradation assays 
were also used for the STD NMR experiments. However no binding interactions could be 
observed on both N- and C- termini all the NMR spectra obtained, which could be attributed 
to limited sensitivity of the technique. Meaningful conclusions could not be drawn from the 
STD NMR experiments. 
In summary we successfully developed a new set of moderately active compounds with 
cytotoxic and Hsp90 inhibition properties. The best candidates from amongst the series of 
naphthoquinones prepared were compounds 4.20 and 4.28. These two derivatives can serve as 
lead compounds for further development in the treatment of cancer. 
Further structural modifications can be conducted on the naphthoquinone scaffold to enhance 
cytotoxicity and Hsp90 inhibition properties. Of interest will be to convert this class of 
compounds into molecular probes that can be used in in vivo studies. From our series, we 
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managed to synthesize compound 4.23 that contains an alkyne functionality. A deeper 
understanding into the mechanism of action of naphthoquinones can be probed via fluorescent 
probe synthesis using click chemistry reactions with compound 4.23, or by attaching biotin in 
an effort to pull out proteins to which naphthoquinones bind to in cancer cells. 
Naphthoquinones are a promising class of compounds that can be probed further as lead 
compounds in drug designing and development for treatment of cancer.  
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Supplementary data 
 
Isolation and characterization of selected natural products 
The selected natural product quinones presented in chapter three are known compounds, and have been 
published in literature. The 13C NMR spectra for these compounds that were not shown in the thesis are 
displayed in this section. 
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Figure S3.5: 13C NMR spectrum (150 MHz, CDCl3) of compound 3.7 
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Synthesis of truncated sarganaphthoquinonic acid (SNQA) derivatives 
The characterization of synthesized naphthoquinones involved use of 1D and 2D NMR spectroscopy, 
Infra-red and high resolution mass spectroscopy (HRMS). The relevant data that was not included in 
the body of the thesis is shown in this section, including chromatograms obtained during separation of 
the different isomers via normal phase HPLC.  
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Figure S4.63: HSQC NMR spectrum of compound 4.20A 
Figure S4.64: HRMS spectrum of compound 4.20A 
Figure S4.65: 13C NMR spectrum (150 MHz, CDCl3) of compound 4.20B 
Figure S4.66: COSY NMR spectrum of compound 4.20B 
Figure S4.67: HSQC NMR spectrum of compound 4.20B 
Figure S4.68: HMBC NMR spectrum of compound 4.20B 
Figure S4.69: HRMS of compound 4.20B 
Figure S4.70: HPLC chromatogram showing the retention times for the two isomers: 4.20A: 
24.0 min and 4.20B: 27.2 min
Figure S4.71: IR spectrum of compound 4.20B 
Figure S4.72: COSY NMR spectrum of compound 4.21 mixture 
Figure S4.73: DEPT135 NMR spectrum of compound 4.21 mixture 
Figure S4.74: HRMS of compound 4.21 mixture 
Figure S4.75: IR spectrum of compound 4.21 mixture
Figure: S4.76: Stacked 1H NMR spectra (600 MHz, CDCl3) of alkyl amino-naphthoquinone 
4.22 illustrating the mixture of isomers before and after HPLC  
Figure: S4.77: 1H NMR spectra (600 MHz, CDCl3) of alkyl amino-naphthoquinone 4.22 
showing differences between the isomers in the aromatic region 
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Figure S4.78: 13C NMR spectrum (150 MHz, CDCl3) of compound 4.22A 
Figure S4.79: COSY NMR spectrum of compound 4.22A 
Figure S4.80: HSQC NMR spectrum of compound 4.22A 
Figure S4.81: HRMS of compound 4.22A 
Figure S4.82: 13C NMR spectrum (150 MHz, CDCl3) of compound 4.22B 
Figure S4.83: COSY NMR spectrum of compound 4.22B 
Figure S4.84: HRMS of compound 4.22B 
Figure S4.85: HPLC chromatogram showing the retention times for the two isomers: 4.22A: 
19.3 min and 4.22B: 21.6 min 
Figure S4.86: IR spectrum of compound 4.22 
Figure: S4.87: 1H NMR spectra (600 MHz, CDCl3) of alkylamino-naphthoquinone 4.23 
illustrating the mixture of isomers before and after HPLC  
Figure: S4.88: 1H NMR spectra (600 MHz, CDCl3) of alkylamino-naphthoquinone 4.23 
showing differences between the isomers in the aromatic region 
Figure S4.89: 13C NMR spectrum (150 MHz, CDCl3) of compound 4.23A 
Figure S4.90: COSY NMR spectrum of compound 4.23A 
Figure S4.91: HMBC NMR spectrum of compound 4.23A 
Figure S4.92: HSQC NMR spectrum of compound 4.23A 
Figure S4.93: HRMS of compound 4.23A 
Figure S4.94: 13C NMR spectrum (150 MHz, CDCl3) of compound 4.23B 
Figure S4.95: COSY NMR spectrum of compound 4.23B 
Figure S4.96: HRMS of compound 4.23B 
Figure S4.97: HPLC chromatogram showing the retention times for the two isomers: 4.23A: 
25.7 min and 4.23B: 28.1 min 
Figure S4.98: IR spectrum of compound 4.23 
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Figure: S4.99: 1H NMR spectra (600 MHz, CDCl3) of alkylamino-naphthoquinone 4.24 
illustrating the mixture of isomers before and after HPLC  
Figure: S4.100: 1H NMR spectra (600 MHz, CDCl3) of alkylamino-naphthoquinone 4.24 
showing differences between the isomers in the aromatic region 
Figure S4.101: 13C NMR spectrum (150 MHz, CDCl3) of compound 4.24A 
Figure S4.102: COSY NMR spectrum of compound 4.24A 
Figure S4.103: HMBC NMR spectrum of compound 4.24A 
Figure S4.104: HSQC NMR spectrum of compound 4.24A 
Figure S4.105: HRMS of compound 4.24A 
Figure S4.106: 13C NMR spectrum (150 MHz, CDCl3) of compound 4.24B 
Figure S4.107: HMBC NMR spectrum of compound 4.24B 
Figure S4.108: HSQC NMR spectrum of compound 4.24B 
Figure S4.109: HRMS of compound 4.24B 
Figure S4.110: HPLC chromatogram showing the retention times for the two isomers: 4.24A: 
38.1 min and 4.24B: 35.4 min
Figure S4.111: IR spectrum of compound 4.24 
Figure S4.112: 1H NMR spectra (600 MHz, CDCl3) of alkylamino-naphthoquinone 4.25 
illustrating the mixture of isomers before and after HPLC  
Figure S4.113: 1H NMR spectra (600 MHz, CDCl3) of alkylamino-naphthoquinone 4.25 
showing differences between the isomers in the aromatic region 
Figure S4.114: 13C NMR spectrum (150 MHz, CDCl3) of compound 4.25A 
Figure S4.115: HMBC NMR spectrum of compound 4.25A 
Figure S4.116: HSQC NMR spectrum of compound 4.25A 
Figure S4.117: COSY NMR spectrum of compound 4.25A 
Figure S4.118: HRMS of compound 4.25A 
Figure S4.119: 13C NMR spectrum (150 MHz, CDCl3) of compound 4.25B 
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Figure S4.120: HMBC NMR spectrum of compound 4.25B 
Figure S4.121: HSQC NMR spectrum of compound 4.25B 
Figure S4.122: COSY NMR spectrum of compound 4.25B 
Figure S4.123: HRMS of compound 4.25B 
Figure S4.124: HPLC chromatogram showing the retention times for the two isomers: 4.25A: 
14.9 min and 4.25B: 21.5 min 
Figure S4.125: IR spectrum of compound 4.25 
Figure S4.126: 1H NMR spectra (600 MHz, CDCl3) of alkylamino-naphthoquinone 4.26 
illustrating the mixture of isomers before and after HPLC  
Figure S4.127: 1H NMR spectra (600 MHz, CDCl3) alkylamino-naphthoquinone 4.26 showing 
differences between the isomers in the aromatic region 
Figure S4.128: 13C NMR spectrum (150 MHz, CDCl3) of compound 4.26A 
Figure S4.129: HMBC spectrum of compound 4.26A 
Figure S4.130: HSQC spectrum of compound 4.26A 
Figure S4.131: COSY spectrum of compound 4.26A 
Figure S4.132: HRMS of compound 4.26A 
Figure S4.133: 13C NMR spectrum (150 MHz, CDCl3) of compound 4.26B 
Figure S4.134:  HMBC spectrum of compound 4.26B 
Figure S4.135:  HSQC spectrum of compound 4.26B 
Figure S4.136:  COSY spectrum of compound 4.26B 
Figure S4.137: HRMS spectrum of compound 4.26B 
Figure S4.138: HPLC chromatogram showing the retention times for the two isomers: 4.26A: 
22.0 min and 4.26B: 21.5 min 
Figure S4.139: IR spectrum of compound 4.26 
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Table S4.1: Preparation of Diels-Alder products from selected benzoquinones 
Table S4.2: Aromatization of Diels-Alder products to the naphthoquinone 
Table S4.3: Oxidative coupling of naphthoquinone 4.10 with para-substituted anilines 
Table S4.4: Coupling of alkyl amines with naphthoquinone 4.10 
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Figure S4.1: 13C NMR spectrum (150 MHz, CDCl3) of compound 4.11A 
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Figure S4.2: 13C NMR spectrum (150 MHz, CDCl3) of compound 4.11B 
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Figure S4.3: 1H NMR spectrum (600 MHz, CDCl3) of compound 4.12A 
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Figure S4.4: 1H NMR spectrum (600 MHz, CDCl3) of compound 4.12B 
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Figure S4.5: HPLC chromatogram showing the retention times for the two isomers: 4.12A: 
34.1 min and 4.12B: 35.7 min 
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Figure S4.6: 1H NMR spectrum (600 MHz, CDCl3) of compound 4.13A 
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Figure S4.7: 13C NMR spectrum (150 MHz, CDCl3) of compound 4.13A 
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Figure S4.8: 1H NMR spectrum (600 MHz, CDCl3) of compound 4.13B 
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Figure S4.9: 13C NMR spectrum (150 MHz, CDCl3) of compound 4.13B 
 

Figure S4.10: HPLC chromatogram showing the retention times for the two isomers: 4.13A: 
23.9 min and 4.13B: 25.0 min 

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Figure S4.11: 1H NMR spectra (600 MHz, CDCl3) of compound 4.14 as a mixture and of the 
individual isomers after separation by normal phase HPLC. 
 
Figure S4.12: 1H NMR spectra (600 MHz, CDCl3) of compound 4.14 showing the splitting of 
aromatic protons. 
Chapter Four Synthesis of truncated sarganaphthoquinoic acid (SNQA) derivatives 
 
5
8
2
O
O
NH12
14
16
1' 4'
5'
6'

4.14A 
 
Figure S4.13: 1H NMR spectrum (600 MHz, CDCl3) of compound 4.14A 
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Figure S4.14: 13C NMR spectrum (150 MHz, CDCl3) of compound 4.14A 
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Figure S4.15: HMBC correlations of compound 4.14A 
 
 
Figure S4.16: 1H NMR spectrum (600 MHz, CDCl3) of compound 4.14B 
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Figure S4.17: 13C NMR spectrum (150 MHz, CDCl3) of compound 4.14B 
 
 
Figure S4.18: HPLC chromatogram showing the retention times for the two isomers: 4.14A: 
23.8 min and 4.14B: 26.8 min 
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Figure S4.19: 1H NMR spectrum (600 MHz, CDCl3) of compound 4.15A 
 
 
Figure S4.20: 13C NMR spectrum (150 MHz, CDCl3) of compound 4.15A 
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Figure S4.21: 1H NMR spectrum (600 MHz, CDCl3) of compound 4.15B 
 
 
Figure S4.22: 13C NMR spectrum (150 MHz, CDCl3) of compound 4.15B 
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Figure S4.23: HPLC chromatogram showing the retention times for the two isomers: 4.15A: 
23.5 min and 4.15B: 27.1 min 
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Figure S4.24: 1H NMR spectrum (600 MHz, CDCl3) of compound 4.16A 
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Figure S4.25: 13C NMR spectrum (150 MHz, CDCl3) of compound 4.16A 
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Figure S4.26: 1H NMR spectrum (600 MHz, CDCl3) of compound 4.16B 
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Figure S4.27: 13C NMR spectrum (150 MHz, CDCl3) of compound 4.16B 
 
 
Figure S4.28: HPLC chromatogram showing the retention times for the two isomers: 4.16A: 
22.3 min and 4.16B: 25.3 min 
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Figure S4.29: 1H NMR spectrum (600 MHz, CDCl3) of compound 4.17A 
 
 
Figure S4.30: 1H NMR spectrum (150 MHz, CDCl3) of compound 4.17A 
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Figure S4.31: 1H NMR spectrum (600 MHz, CDCl3) of compound 4.17B 
 
 
Figure S4.32: 13C NMR spectrum (150 MHz, CDCl3) of compound 4.17B 
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Figure S4.33: HPLC chromatogram showing the retention times for the two isomers: 4.17A: 
23.5 min and 4.17B: 23.9 min 
 
 
Figure S4.34: HRMS of compound 4.17A 
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Figure S4.35: HRMS of compound 4.17B 
 
 
Figure S4.36: IR spectrum of compound 4.17 
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Figure S4.37: 1H NMR spectrum (600 MHz, CDCl3) of compound 4.18A 
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Figure S4.38: 1H NMR spectrum (600 MHz, CDCl3) of compound 4.18B 
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Figure S4.39: 13C NMR spectrum (150 MHz, CDCl3) of compound 4.18B 
 
Figure S4.40: HPLC chromatogram showing the retention times for the two isomers: 4.18A: 
21.0 min and 4.18B: 23.4 min 
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Figure S4.41: HRMS of compound 4.18A 
 
Figure S4.42: HRMS of compound 4.18B 
 
 
Figure S4.43: IR spectrum of compound 4.18B 
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Figure S4.44: 1H NMR spectrum (600 MHz, CDCl3) of compound 4.19A 
 
 
Figure S4.45: 13C NMR spectrum (150 MHz, CDCl3) of compound 4.19A 
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Figure S4.46: COSY NMR spectrum of compound 4.19A 
 
 
Figure S4.47: HSQC NMR spectrum of compound 4.19A 
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Figure S4.48: HMBC NMR spectrum of compound 4.19A 
 
 
Figure S4.49: HRMS of compound 4.19A 
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Figure S4.50: 1H NMR spectrum (600 MHz, CDCl3) of compound 4.19B 
 
 
Figure S4.51: 13C NMR spectrum (150 MHz, CDCl3) of compound 4.19B 
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Figure S4.52: COSY NMR spectrum of compound 4.19B 
 
 
Figure S4.53: HMBC NMR spectrum of compound 4.19B 
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Figure S4.54: HSQC NMR spectrum of compound 4.19B 
 
 
Figure S4.55: HRMS of compound 4.19B 
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Figure S4.56: IR spectrum of compound 4.19B 
 
Figure S4.57: HPLC chromatogram showing the retention times for the two isomers: 4.19A: 
19.6 min and 4.19B: 21.3 min 
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Figure S4.58: 1H NMR spectra (600 MHz, CDCl3) of alkylamino-naphthoquinone 4.20 
illustrating the mixture of isomers before and after normal phase HPLC.  
 
 
Figure S4.59: 1H NMR spectra (600 MHz, CDCl3) of alkylamino-naphthoquinone 4.20 
showing differences between the isomers in the aromatic region 
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Figure S4.60: 13C NMR spectrum (150 MHz, CDCl3) of compound 4.20A 
 
 
Figure S4.61: COSY NMR spectrum of compound 4.20A 
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Figure S4.62: HMBC NMR spectrum of compound 4.20A 
 
 
Figure S4.63: HSQC NMR spectrum of compound 4.20A 
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Figure S4.64: HRMS spectrum of compound 4.20A 
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Figure S4.65: 13C NMR spectrum (150 MHz, CDCl3) of compound 4.20B 
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 ppm
Chapter Four Synthesis of truncated sarganaphthoquinoic acid (SNQA) derivatives 
 
 
Figure S4.66: COSY NMR spectrum of compound 4.20B 
 
Figure S4.67: HSQC NMR spectrum of compound 4.20B 
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Figure S4.68: HMBC NMR spectrum of compound 4.20B 
 
Figure S4.69: HRMS of compound 4.20B 
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Figure S4.70: HPLC chromatogram showing the retention times for the two isomers: 4.20A: 
24.0 min and 4.20B: 27.2 min 
 

5.
95
0
10
.
09
7
10
.
62
7
11
.
07
1
11
.
57
4
12
.
69
6
13
.
22
5
13
.
84
0
14
.
33
3
14
.
86
7
15
.
63
9
16
.
92
4
24
.
07
9
27
.
21
6
M
V
2460.00
2480.00
2500.00
2520.00
2540.00
2560.00
2580.00
2600.00
2620.00
2640.00
2660.00
2680.00
2700.00
2720.00
Minutes
5.00 10.00 15.00 20.00 25.00 30.00
Chapter Four Synthesis of truncated sarganaphthoquinoic acid (SNQA) derivatives 
 
 
Figure S4.71: IR spectrum of compound 4.20B 
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Figure S4.72: COSY NMR spectrum of compound 4.21 mixture 
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Figure S4.73: DEPT135 NMR spectrum of compound 4.21 mixture 
 
 
Figure S4.74: HRMS of compound 4.21 mixture 
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Figure S4.75: IR spectrum of compound 4.21 mixture 
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Figure: S4.76: Stacked 1H NMR spectra (600 MHz, CDCl3) of alkylamino-naphthoquinone 
4.22 illustrating the mixture of isomers before and after HPLC  
 
Figure: S4.77: 1H NMR spectra (600 MHz, CDCl3) of alkylamino-naphthoquinone 4.22 
showing differences between the isomers in the aromatic region 
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Figure S4.78: 13C NMR spectrum (150 MHz, CDCl3) of compound 4.22A 
 
 
Figure S4.79: COSY NMR spectrum of compound 4.22A 
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Figure S4.80: HSQC NMR spectrum of compound 4.22A 
 
 
Figure S4.81: HRMS of compound 4.22A 
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Figure S4.82: 13C NMR spectrum (150 MHz, CDCl3) of compound 4.22B 
 
 
Figure S4.83: COSY NMR spectrum of compound 4.22B 
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Figure S4.84: HRMS of compound 4.22B 
 
 
Figure S4.85: HPLC chromatogram showing the retention times for the two isomers: 4.22A: 
19.3 min and 4.22B: 21.6 min 
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Figure S4.86: IR spectrum of compound 4.22 
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Figure: S4.87: 1H NMR spectra (600 MHz, CDCl3) of alkylamino-naphthoquinone 4.23 
illustrating the mixture of isomers before and after HPLC  
 
Figure: S4.88: 1H NMR spectra (600 MHz, CDCl3) of alkylamino-naphthoquinone 4.23 
showing differences between the isomers in the aromatic region 
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Figure S4.89: 13C NMR spectrum (150 MHz, CDCl3) of compound 4.23A 
 

Figure S4.90: COSY NMR spectrum of compound 4.23A 
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Figure S4.91: HMBC NMR spectrum of compound 4.23A 


Figure S4.92: HSQC NMR spectrum of compound 4.23A 
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Figure S4.93: HRMS of compound 4.23A 
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Figure S4.94: 13C NMR spectrum (150 MHz, CDCl3) of compound 4.23B 
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Figure S4.95: COSY NMR spectrum of compound 4.23B 
 

Figure S4.96: HRMS of compound 4.23B 
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
Figure S4.97: HPLC chromatogram showing the retention times for the two isomers: 4.23A: 
25.7 min and 4.23B: 28.1 min 


Figure S4.98: IR spectrum of compound 4.23 
 
2.
46
7
6.
31
9
10
.
12
3
10
.
68
1
11
.
12
6
11
.
62
3
12
.
63
4
13
.
15
0
14
.
08
7
15
.
00
0 15
.
48
8
16
.
15
0
16
.
66
7
22
.
08
7
23
.
00
2
25
.
72
5 2
8.
14
7
35
.
62
2M
V
2460.00
2470.00
2480.00
2490.00
2500.00
2510.00
2520.00
2530.00
2540.00
2550.00
2560.00
2570.00
Minutes
5.00 10.00 15.00 20.00 25.00 30.00 35.00
Chapter Four Synthesis of truncated sarganaphthoquinoic acid (SNQA) derivatives 
 
 
Figure: S4.99: 1H NMR spectra (600 MHz, CDCl3) of alkylamino-naphthoquinone 4.24 
illustrating the mixture of isomers before and after HPLC  
 
Figure: S4.100: 1H NMR spectra (600 MHz, CDCl3) of alkylamino-naphthoquinone 4.24 
showing differences between the isomers in the aromatic region 
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Figure S4.101: 13C NMR spectrum (150 MHz, CDCl3) of compound 4.24A 
 
 
Figure S4.102: COSY NMR spectrum of compound 4.24A 
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Figure S4.103: HMBC NMR spectrum of compound 4.24A 
 
Figure S4.104: HSQC NMR spectrum of compound 4.24A 
 
 
Figure S4.105: HRMS of compound 4.24A 
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Figure S4.106: 13C NMR spectrum (150 MHz, CDCl3) of compound 4.24B 
 
Figure S4.107: HMBC NMR spectrum of compound 4.24B 
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Figure S4.108: HSQC NMR spectrum of compound 4.24B 
 
 
Figure S4.109: HRMS of compound 4.24B 
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Figure S4.110: HPLC chromatogram showing the retention times for the two isomers: 4.24A: 
38.1 min and 4.24B: 35.4 min 
 
Figure S4.111: IR spectrum of compound 4.24 
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Figure S4.112: 1H NMR spectra (600 MHz, CDCl3) of alkylamino-naphthoquinone 4.25 
illustrating the mixture of isomers before and after HPLC  
 
 
Figure S4.113: 1H NMR spectra (600 MHz, CDCl3) of alkylamino-naphthoquinone 4.25 
showing differences between the isomers in the aromatic region 
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Figure S4.114: 13C NMR spectrum (150 MHz, CDCl3) of compound 4.25A 
 

Figure S4.115: HMBC NMR spectrum of compound 4.25A 
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Figure S4.116: HSQC NMR spectrum of compound 4.25A 

Figure S4.117: COSY NMR spectrum of compound 4.25A 
 

ppm
9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
140
120
100
80
60
40
20
0
Chapter Four Synthesis of truncated sarganaphthoquinoic acid (SNQA) derivatives 
 
Figure S4.118: HRMS of compound 4.25A 
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Figure S4.119: 13C NMR spectrum (150 MHz, CDCl3) of compound 4.25B 
 

Figure S4.120: HMBC NMR spectrum of compound 4.25B 
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Figure S4.121: HSQC NMR spectrum of compound 4.25B 
 
 
Figure S4.122: COSY NMR spectrum of compound 4.25B 
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Figure S4.123: HRMS of compound 4.25B 
 
 
 
Figure S4.124: HPLC chromatogram showing the retention times for the two isomers: 4.25A: 
14.9 min and 4.25B: 21.5 min 
9.
50
2 10
.
27
5
11
.
16
1
11
.
50
4
12
.
24
0
13
.
44
6
14
.
24
4
14
.
99
5
21
.
56
6
M
V
2210.00
2220.00
2230.00
2240.00
2250.00
2260.00
2270.00
2280.00
2290.00
2300.00
2310.00
2320.00
2330.00
Minutes
2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00
Chapter Four Synthesis of truncated sarganaphthoquinoic acid (SNQA) derivatives 
 
 
Figure S4.125: IR spectrum of compound 4.25 
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Figure S4.126: 1H NMR spectra (600 MHz, CDCl3) of alkylamino-naphthoquinone 4.26 
illustrating the mixture of isomers before and after HPLC  
 
Figure S4.127: 1H NMR spectra (600 MHz, CDCl3) of alkylamino-naphthoquinone 4.26 
showing differences between the isomers in the aromatic region 
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Figure S4.128: 13C NMR spectrum (150 MHz, CDCl3) of compound 4.26A 
 
 
Figure S4.129: HMBC spectrum of compound 4.26A 
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Figure S4.130: HSQC spectrum of compound 4.26A 
 
 
Figure S4.131: COSY spectrum of compound 4.26A 
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Figure S4.132: HRMS of compound 4.26A 
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Figure S4.133: 13C NMR spectrum (150 MHz, CDCl3) of compound 4.26B 
 
Figure S4.134:  HMBC spectrum of compound 4.26B 
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Figure S4.135:  HSQC spectrum of compound 4.26B 
 
Figure S4.136:  COSY spectrum of compound 4.26B 
 
Figure S4.137: HRMS spectrum of compound 4.26B 
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Figure S4.138: HPLC chromatogram showing the retention times for the two isomers: 4.26A: 
22.0 min and 4.26B: 21.5 min 
 
Figure S4.139: IR spectrum of compound 4.26 
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Figure S4.140: 1H NMR spectrum (CDCl3, 600 MHz) of a mixture of isomers 4.21A and 4.21B 
 
Figure S4.141:  13C NMR spectrum (CDCl3, 150 MHz) of a mixture of isomers 4.21A and 
4.21B 
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Table S4.1: Preparation of Diels-Alder products from selected benzoquinones 
 Quinone Myrcene EtOH Mass/Weight 
of product 
% yield 
2-chloro-
benzoquinone 
0.500 g, 3.5 
mmoles 
0.955 g, 7.0 
mmoles 
 10 ml 0.840 g 86.1 
2-methoxy-
benzoquinone 
0.500 g, 3.6 
mmoles 
0.963 g, 7.2 
mmoles 
20 ml 0.568 g 57.5 
2-methyl-
benzoquinone 
0.224 g, 1.8 
mmoles  
0.500 g, 3.6 
mmol 
20 ml 0.350 g 75.2 
 
Table S4.2: Aromatization of Diels-Alder products to the naphthoquinone 
 Diels-Alder 
Product 
MnO2 C6H6 Product Mass/Weight 
of product 
% yield 
2-Cl 0.200 g, 0.7 
mmoles 
0.374 g, 4.3 
mmoles 
10 ml 4.11 0. 160g 83.3 
2-OCH3 0.200 g, 0.7 
mmoles 
0.380 g, 4.3 
mmoles 
10 ml 4.12 0. 160g 84.6 
2-CH3 0.100 g, 0.3 
mmoles 
0.201 g, 2.3 
mmoles 
10 ml 4.13 0. 075 g 98.4 
 
 
Table S4.3: Oxidative coupling of naphthoquinone 4.10 with para-substituted anilines 
p-substituent Aniline 4.7 Cu(OAc)2 Product Mass/Weight  % yield 
-CH3-aniline 0.0499 g, 
0.4 mmoles 
0.112 g, 0.4 
mmoles 
0.010 g, 0.04 
mmoles 
4.15 0.109 g 79.5 
-OCH3-aniline 0.0568 g, 
0.4 mmoles 
0.111 g, 0.4 
mmoles 
0.010 g, 0.04 
mmoles 
4.16 0.129 89.3 
-Cl-aniline 0.059 g, 
0.4 mmoles 
0.112 g, 0.4 
mmoles 
0.010 g, 0.04 
mmoles 
4.17 0.123 84.3 
-CF3-aniline 0.078 g, 
0.4 mmoles 
0.117 g, 0.4 
mmoles 
0.010 g, 0.04 
mmoles 
4.18 0.115 72.1 
methylenedioxy 
aniline 
0.057 g, 
0.4 mmoles 
0.100 g, 0.4 
mmoles 
0.010 g, 0.04 
mmoles 
4.19 0.122 81.9 
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Table S4.4: Coupling of alkyl amines with naphthoquinone 4.10 
 Amine 
mmol) 
4.7 Product Mass/Weight  % yield 
N, N 
dimethylethyleneamine 
0.036 g, 0.4 
mmoles 
0.100 g, 0.4 
mmoles 
4.21 0.0912 69.9 
tyramine 0.057 g, 0.4 
mmoles 
0.100 g, 0.4 
mmoles 
4.22 0.107 71.7 
propargylamine HCl 0.038 g, 0.4 
mmoles 
0.100 g, 0.4 
mmoles 
4.23 0.086 73.5 
 
6-[2-(3,3-dimethyloxiran-2-yl)ethyl]-2-(morpholin-4-yl)naphthalene-1,4-dione (4.26) 
 
+
N
H
O
EtOH/H2O, rt, 18h
4.27 4.26
O
O
O
O
O
O
N
O
 
A similar method used for the preparation of 4.25 was used to synthesize 4.26. Morpholine 
(0.044 g, 0.4 mmoles) was reacted with 4.27 (0.102 g, 0.4 mmoles) in EtOH/H2O (10 ml, 1:1 
mixture) with stirring at room temperature for 18 hours to yield 0.076 g (55.7 % yield) of 4.26. 
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CHAPTER FIVE 
 
Supplementary data 
 
Biological activity of truncated prenylated naphthoquinones 
Cytotoxicity data for the first series of naphthoquinones was conducted using as a three point assay. 
IC50 values were not determined, instead percentage survival of cancer cells was calculated at 1 µM, 10 
µM and 100 µM concentrations of the compounds (4.10-4.13) used. The calculated percentage survival 
rates are presented in this section as bar and line graphs.  
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and 100 µM concentrations of compound 4.12A 
Figure S5.5: Bar graph representation of percentage survival of cancer cells at 1 µM, 10 µM 
and 100 µM concentrations of compound 4.12B 
Figure S5.6: Bar graph representation of percentage survival of cancer cells at 1 µM, 10 µM 
and 100 µM concentrations of compound 4.13A 
Figure S5.7: Bar graph representation of percentage survival of cancer cells at 1 µM, 10 µM 
and 100 µM concentrations of compound 4.13B 
Figure S5.8: A line graph presentation of the first series of naphthoquinones, showing trends 
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Figure S5.1: Bar graph representation of percentage survival of cancer cells at 1 µM, 10 µM 
and 100 µM concentrations of compound 4.10 
 
Figure S5.2: Bar graph representation of percentage survival of cancer cells at 1 µM, 10 µM 
and 100 µM concentrations of compound 4.11A 
 
 Figure S5.3: Bar graph representation of percentage survival of cancer cells at 1 µM, 10 µM 
and 100 µM concentrations of compound 4.11B 
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Figure S5.4: Bar graph representation of percentage survival of cancer cells at 1 µM, 10 µM 
and 100 µM concentrations of compound 4.12A 
 
Figure S5.5: Bar graph representation of percentage survival of cancer cells at 1 µM, 10 µM 
and 100 µM concentrations of compound 4.12B 
 
Figure S5.6: Bar graph representation of percentage survival of cancer cells at 1 µM, 10 µM 
and 100 µM concentrations of compound 4.13A 
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Figure S5.7: Bar graph representation of percentage survival of cancer cells at 1 µM, 10 µM 
and 100 µM concentrations of compound 4.13B 
 
 
Figure S5.8: A line graph presentation of the first series of naphthoquinones, showing trends 
NB: The book codes displayed in the graph correspond to the compound numbers displayed below 
• MC13(3)-29(1) – 4.11A 
• MC13(3)-29(2) – 4.11B 
• MC13(3)-30(1) – 4.12A 
• MC13(3)-30(2) – 4.12B 
• MC13(3)-32(1) – 4.13A 
• MC13(3)-32(2) – 4.13B 
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CHAPTER SIX 
 
Supplementary data 
 
Molecular modelling and STD NMR studies 
All molecular docking conformations of the synthesized truncated naphthoquinones (4.10-4.31), SQA 
(2.47), lapachol (3.5) and SNQA (3.11) are presented in this chapter. The different bond interactions 
within the N-terminal ATP binding site of Hsp90 are also included. Known Hsp90 inhibitor e.g. 
geldanamycin (2.28) was also docked a control and for comparison purposes with our set of compounds.  
The different STD NMR spectra obtained for the selected naphthoquinones 4.16A, 4.20A, 4.28, 4.29 
and 2.47 are shown, for both N- and C- terminal domains.  
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Molecular Docking 
 
 
Figure S6.1: Geldanamycin (2.28) bond interactions with the N-terminal ATP binding site of 
Hsp90 
 
Figure S6.2: Ball and stick presentation of geldanamycin (2.28) showing its orientation within 
the active site. The quinone system sticks out of the binding site.  
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First series of naphthoquinone analogues 
 
 
Figure S6.3: Bond-bond interactions of 4.10 with the N-terminal ATP binding site of Hsp90 
 
 
 
Figure S6.4: Docking conformations of ATP, geldanamycin (2.28) and 4.10 in the same 
active site of N-terminal domain. 
 
 
Chapter Six Molecular modelling and STD NMR studies

 
 
 
Figure S6.5: Bond-bond interactions of 4.11A with the N-terminal ATP binding site of 
Hsp90 
 
 
 
Figure S6.6: ATP and 4.11A docked in the same active site of the N-terminal domain 
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Figure S6.7: Bond-bond interactions of 4.11B with the N-terminal ATP binding site of 
Hsp90 
 
 
 
 
Figure S6.8: ATP and 4.11B docked in the same active site of the N-terminal domain 
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Figure S6.9: Bond-bond interactions of 4.12A with the N-terminal ATP binding site of 
Hsp90 
 
 
 
 
Figure S6.10: ATP and 4.12A docked in the same active site of the N-terminal domain 
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Figure S6.11: Bond-bond interactions of 4.12B with the N-terminal ATP binding site of 
Hsp90 
 
 
 
Figure S6.12: ATP and 4.12B docked in the same active site of the N-terminal domain 
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Figure S6.13: Bond-bond interactions of 4.13A with the N-terminal ATP binding site of 
Hsp90 
 
 
 
Figure S6.14: ATP and 4.13A docked in the same active site of the N-terminal domain 
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Figure S6.15: Bond-bond interactions of 4.13B with the N-terminal ATP binding site of 
Hsp90 
 
 
Figure S6.16: ATP and 4.13B docked in the same active site of the N-terminal domain 
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Second series of naphthoquinone analogues 
 
 
Figure S6.17: Bond-bond interactions of 4.14A with the N-terminal ATP binding site of 
Hsp90 
 
 
Figure S6.18: ATP and 4.14A docked in the same active site of the N-terminal domain 
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Figure S6.19: Bond-bond interactions of 4.14B with the N-terminal ATP binding site of 
Hsp90 
 
 
 
Figure S6.20: ATP and 4.14B docked in the same active site of the N-terminal domain 
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Figure S6.21: Bond-bond interactions of 4.15A with the N-terminal ATP binding site of 
Hsp90 
 
 
Figure S6.22: ATP and 4.15A docked in the same active site of the N-terminal domain 
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Figure S6.23: Bond-bond interactions of 4.15B with the N-terminal ATP binding site of 
Hsp90 
 
 
Figure S6.24: ATP and 4.15B docked in the same active site of the N-terminal domain 
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Figure S6.25: Bond-bond interactions of 4.16A with the N-terminal ATP binding site of 
Hsp90 
 
 
Figure S6.26: ATP and 4.16A docked in the same active site of the N-terminal domain 
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Figure S6.27: Bond-bond interactions of 4.16B with the N-terminal ATP binding site of 
Hsp90 
 
 
 
Figure S6.28: ATP and 4.16B docked in the same active site of the N-terminal domain 
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Figure S6.29: Bond-bond interactions of 4.17A with the N-terminal ATP binding site of 
Hsp90 
 
 
Figure S6.30: ATP and 4.17A docked in the same active site of the N-terminal domain 
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Figure S6.31: Bond-bond interactions of 4.17B with the N-terminal ATP binding site of 
Hsp90 
 
 
 
Figure S6.32: ATP and 4.17B docked in the same active site of the N-terminal domain 
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Figure S6.33: Bond-bond interactions of 4.18A with the N-terminal ATP binding site of 
Hsp90 
 
 
 
Figure S6.34: ATP and 4.18A docked in the same active site of the N-terminal domain 

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Figure S6.35: Bond-bond interactions of 4.18B with the N-terminal ATP binding site of 
Hsp90 
 
 
 
Figure S6.36: ATP and 4.18B docked in the same active site of the N-terminal domain 
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Figure S6.37: Bond-bond interactions of 4.19A with the N-terminal ATP binding site of 
Hsp90 
 
 
 
Figure S6.38: ATP and 4.19A docked in the same active site of the N-terminal domain 
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Figure S6.39: Bond-bond interactions of 4.19B with the N-terminal ATP binding site of 
Hsp90 
 
 
 
Figure S6.40: ATP and 4.19B docked in the same active site of the N-terminal domain 
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Third series of naphthoquinone analogues 
 
 
Figure S6.41: Bond-bond interactions of 4.20A with the N-terminal ATP binding site of 
Hsp90 
 
 
 
Figure S6.42: ATP and 4.20A docked in the same active site of the N-terminal domain 
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Figure S6.43: Bond-bond interactions of 4.20B with the N-terminal ATP binding site of 
Hsp90 
 
 
Figure S6.44: ATP and 4.20B docked in the same active site of the N-terminal domain 
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Figure S6.45: Bond-bond interactions of 4.21A with the N-terminal ATP binding site of 
Hsp90 
 
 
Figure S6.46: ATP and 4.21A docked in the same active site of the N-terminal domain 
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Figure S6.47: Bond-bond interactions of 4.21B with the N-terminal ATP binding site of 
Hsp90 
 
 
Figure S6.48: ATP and 4.21B docked in the same active site of the N-terminal domain 
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Figure S6.49: Bond-bond interactions of 4.22A with the N-terminal ATP binding site of 
Hsp90 
 
 
Figure S6.50: ATP and 4.22A docked in the same active site of the N-terminal domain 
Chapter Six Molecular modelling and STD NMR studies

 
Figure S6.51: Bond-bond interactions of 4.22B with the N-terminal ATP binding site of 
Hsp90 
 
 
Figure S6.52: ATP and 4.22B docked in the same active site of the N-terminal domain 
Chapter Six Molecular modelling and STD NMR studies

 
Figure S6.53: Bond-bond interactions of 4.23A with the N-terminal ATP binding site of 
Hsp90 
 
 
Figure S6.54: ATP and 4.23A docked in the same active site of the N-terminal domain 
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Figure S6.55: Bond-bond interactions of 4.23B with the N-terminal ATP binding site of 
Hsp90 
 
 
Figure S6.56: ATP and 4.23B docked in the same active site of the N-terminal domain 
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Figure S6.57: Bond-bond interactions of 4.24A with the N-terminal ATP binding site of 
Hsp90 
 
 
Figure S6.58: ATP and 4.24A docked in the same active site of the N-terminal domain 
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Figure S6.59: Bond-bond interactions of 4.24B with the N-terminal ATP binding site of 
Hsp90 
 
Figure S6.60: ATP and 4.24B docked in the same active site of the N-terminal domain 
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Figure S6.61: Bond-bond interactions of 4.25A with the N-terminal ATP binding site of 
Hsp90 
 
Figure S6.62: ATP and 4.25A docked in the same active site of the N-terminal domain 
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Figure S6.63: Bond-bond interactions of 4.25B with the N-terminal ATP binding site of 
Hsp90 
 
 
Figure S6.64: ATP and 4.25B docked in the same active site of the N-terminal domain 
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Figure S6.65: Bond-bond interactions of 4.26A with the N-terminal ATP binding site of 
Hsp90 
 
 
Figure S6.66: ATP and 4.26A docked in the same active site of the N-terminal domain 
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Figure S6.67: Bond-bond interactions of 4.26B with the N-terminal ATP binding site of 
Hsp90 
 
 
Figure S6.68: ATP and 4.26B docked in the same active site of the N-terminal domain 
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Fourth series of naphthoquinone analogues 
 
 
Figure S6.69: Bond-bond interactions of 4.28 with the N-terminal ATP binding site of Hsp90 
 
 
Figure S6.70: ATP and 4.28 docked in the same active site of the N-terminal domain 
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Figure S6.71: Bond-bond interactions of 4.29 with the N-terminal ATP binding site of Hsp90 
 
 
 
Figure S6.72: ATP and 4.29 docked in the same active site of the N-terminal domain 
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Natural Products 
 
 
Figure S6.73: Bond-bond interactions of 2.47 with the N-terminal ATP binding site of Hsp90 
 
 
Figure S6.74: ATP and 2.47 docked in the same active site of the N-terminal domain 
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Figure S6.75: Bond-bond interactions of 3.11 with the N-terminal ATP binding site of Hsp90 
 
 
Figure S6.76: ATP and 3.11 docked in the same active site of the N-terminal domain 
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Figure S6.77:  2.47 and 3.11 docked in the same N-terminal domain of Hsp90 
 
 
 
Figure S6.78: Bond-bond interactions of 3.5 with the N-terminal ATP binding site of Hsp90 
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Figure S6.79: ATP and 3.5 docked in the same active site of the N-terminal domain 
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Saturation Transfer Difference NMR spectra 
STD NMR spectra for the C-terminal experiments 
 
Figure S6.80: (A) reference 1H spectrum of the C-terminal domain of Hsp90 and 2.47 (B) 
corresponding STD-NMR spectrum 
 
Figure S6.81: (A) reference 1H spectrum of the C-terminal domain of Hsp90 and 4.16A (B) 
corresponding STD-NMR spectrum 
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Figure S6.82: (A) reference 1H spectrum of the C-terminal domain of Hsp90 and 4.28 (B) 
corresponding STD-NMR spectrum 
 
Figure S6.83: (A) reference 1H spectrum of the C-terminal domain of Hsp90 and 4.29 (B) 
corresponding STD-NMR spectrum 
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STD NMR spectra for the N-terminal experiments 
 
 
Figure S6.84: (A) reference 1H spectrum of the N-terminal domain of Hsp90 and novobiocin 
(2.41) (B) corresponding STD-NMR spectrum 
 
Figure S6.85: (A) reference 1H spectrum of the N-terminal domain of Hsp90 and 4.16A (B) 
corresponding STD-NMR spectrum 
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Figure S6.86: (A) reference 1H spectrum of the N-terminal domain of Hsp90 and 4.20A (B) 
corresponding STD-NMR spectrum 
 
Figure S6.87: (A) reference 1H spectrum of the N-terminal domain of Hsp90 and 4.28 (B) 
corresponding STD-NMR spectrum 
 
 
 
Chapter Six Molecular modelling and STD NMR studies

 
Figure S6.88: (A) reference 1H spectrum of the N-terminal domain of Hsp90 and 4.29 (B) 
corresponding STD-NMR spectrum 
 
Figure S6.89: (A) reference 1H spectrum of the N-terminal domain of Hsp90 and 2.47 (B) 
corresponding STD-NMR spectrum 
 
 
